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Definition of Key Terms 
Acute renal failure 
Acute renal failure is defined as a sudden deterioration in renal 
function that results in the inability to excrete the products of 
metabolism, which produce a rise in blood urea and other nitrogen 
waste products (Smith, 1997). 
Automated peritoneal dialysis (APD) 
This involves the same principles as continuous ambulatory 
peritoneal dialysis . However an automated peritoneal dialysis 
machine performs the exchanges for the patient at night time, while 
the patient is sleeping. 
Arteriovenous (A V) Fistula 
An AV fistula is a permanent form of access to blood and consists 
of a subcutaneous anastomosis of an artery to an adjacent vein 
(Daugirdas et al., 2001). 
AV Graft 
An AV graft is an AV connection that can be made using a tube 
graft made from synthetic material (Daug irdas et al., 200 I) . 
Cbronic renal failure 
Chron ic renal failure is a result of a number of pathological 
processes causing irrevers ible damage to kidney t i ssue. There is a 
mass destruction of nephrons, so that the kidneys are unable to 
maintain fluid and electrolyte balance and excrete waste products 
from the body. A slow progressive kidney disease causes chronic 
renal failure over the course of many years . There may be an 
insidious onset of renal failure with the minimum of symptoms 
developing in the patient on the approach to end-stage renal failure 
(Smith 1997) . 
Continuous ambulatory peritoneal dialysis (CAPD) 
This procedure makes use of your body's own peritoneal membrane 
as a filter. Dialysis solution is placed in the peritoneal cavity 
through a permanent catheter that is surg ically placed, and the fluid 
is allowed to dwell, and then filter out , dra ining the body's waste 
products and excess fluid with it. This procedure also includes the 
processes of osmosis and diffusion across the peritoneal membrane. 
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Dialysis Outcomes Quality Iuitiatives (DOQI) Guideliues 
This is a set of guidelines, devised by the National Kidney 
Foundation for the treatment of renal failure and associated 
complications . 
End stage renal disease (ESRD) 
xviii 
ESRD is the stage of renal funct ion in which the kidney is no longer 
able to maintain the integrity of the internal environment of the 
organism. It involves irreversible kidney disease causing chronic 
abnormalities in the internal environment, and necessitates 
treatment with dialysis or kidney transplantation for survival (NRC , 
2002) . 
Glomerular Filtration Rate (GFR) 
The glomerular filtration rate is defined as the total amount of 
filtrate formed per minute by the kidneys (Marieb , 1998). 
Hemodialysis 
This procedure makes use of a hemodialysis machine , which pumps 
your blood through a dialyzer , which , via osmos is and d iffusion 
across the dialyzer, enables the removal of waste products and fluid 
from the body . 
Home dialysis 
Some patients may have access to a hemodialysis machine and have 
a family member who is trained to assist the patient in performing 
hemodia lysis at home. 
Permanent Catbeter 
A permanent catheter is a cuffed venous catheter. It is evolving into 
an alternative form of long te rm vascular access for patients in 
whom and arte ri ovenous access cannot be readily created (Daugirdas 
et al., 2001) . 
Pre-end stage renal disease (PERD) 
Pre-end stage renal disease is the time between the diagnosis of a 
kidney disease , and the time one beg ins renal replacement therapy 
or rec eives a transplant. This per iod may be br ief: only a few 
weeks , or it may be months or even years (NRC - Healthy Start, 
2002). 
© Central University of Technology, Free State
xix 
Renal Replacement Therapy (RRT) 
Renal replacement therapy/dialysis refers to the diffusion of solutes 
across a semi-permeable membrane down a concentration gradient. 
Dialysis removes fluid and waste products from the body, and i s 
performed on individuals suffering from renal failure. It includes 
peritoneal dialysis, hemodialysis and other forms of dialysis therapy 
(Daugirdas et al .. 2001). 
Re no p rotectio n 
Renoprotection is the use of dietary and pharmacological measures 
aimed at halting or at least slowing progress ion of renal failure 
(Jungers, 2002) . 
Temporary Catheter 
Temporary catheters are venous catheters that are commonly used 
for acute angioaccess (Daugirdas et al .. 2001). 
Slow continuous therapies 
S low continuous therapies are used in the treatment 'of critically ill 
patients with renal failure (Daugirdas et al .• 2001). 
Transplantation 
Pre - emptive transplantation occurs when an individual receives a 
donated kidney prior to the commencement of d ialysis. 
Living donor transplantation occurs when an individual receives a 
kidney from a compatible living donor. In the case of a cadaver, the 
patient receives a kidney from an individual who is declared brain 
dead and their family members agree to donate their organs/kidneys 
(NRC - Healthy Start, 2002). 
Uremic syndrome 
These changes arise when overall renal function IS less than 20- 25% 
of normal (Daugirdas et al .. 2001). 
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Summary 
End stage renal disease (ESRD) is a major health problem resulting 
in conside rably increased morbidity and mortality , in decreased 
qual i ty of life and in high costs from renal replacement therapy 
(RRT) . There are almost a m i llion people that owe their lives to 
dialys is and currently there is a 5 yea r survival rate of chronic renal 
failure (CRF) patients . Today opt imization of dialys i s must 
guarantee the full time restitution t o . society of a totally 
rehab i litated individual. This study a ims at investigating the 
indications for commencing RRT and the optima l timing for 
commencing the therapy , derived from comparative investigations , 
and incorporat ing factors affecting renal failure patients. It includes 
the benefits of screening high risk individua ls for renal d isease, and 
the benefits of managing factors affecting renal function to pro long 
the pretreatment phase . It also looks at the effectiveness and 
opt imal timing for commencing a pre-end stage renal disease 
(PESRD) program, and considers whether there is patient 
imp rovement in patients managed before development of renal 
failure . Finally the study aims at investigating a way to reduce the 
financial aspect related to treatment. 
The research was twofold. First ly it involved a screening of 100 
indiv iduals at tht: risk of chronic kidney disease (CKD) , whereby a 
serum creat in ine va lue was taken and the glomerular filtration rate 
(OFR) calculated . Secondly it incorporated a biochemical and 
clinical assessment of 95 CRF patients , a month prior to RRT , at 
commencement of RRT , at I month and 3 months after RRT. 
The screening revealed a mean creatin ine for males 128.45 flmollL 
and for females 108 .99 flmoll L. Twen ty-four percent (24%) of 
patien ts had a OF R of between 30 - 59 , 6% of patients had a OF R of 
between 15 29, and 3% of pat ients had a OFR of < 15 
ml / minlI.73m2. T his strongly ind icates the need to screen 
individua ls at risk for renal failure . The second part of the study 
revealed that at commencement t he mean OFR was 6.7 
ml / min lI .73m2, uremia , malnutrition, anemia , hyperparathyroid ism, 
hyperphosphatemia, and other electro lyte imbalances were present , 
all predisposing a patient to a poor clinical outcome , an inc rease in 
morbidity and mortal i ty, and a dec rease in the qual ity of life. F rom 
the investigation of patients commencing dialysis it was determined 
that the optimal timing for commenc ing RRT was at the first clin ical 
evidence of deterioration in the presence of uremia and / o r 
malnutrit ion despite medical in tervention . It was found that RR T 
should not be postponed until creatinine falls within mandated 
range , as postponement adversely affects the patient, and the 
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survival of dialysis patients depends on their condition at the time 
dialysis is first initiated. Postponing treatment was found to have 
adverse effects on patients commencing RRT, with an increase in 
the number of acute hemodialysis (AHD) sessions and increase in 
the number of access. Patients managed prior to commencement of 
RRT and patients commencing dialys is at a higher GFR experienced 
fewer complications , when compared to patients who commenced 
dialysis later. There is an improvement in patient outcome in 
patients managed prior to the commencement of RRT and it is 
beneficial to manage factors affecting renal function in order to 
prolong the pre-treatment phase . The PESRD educational program is 
an effective component in the management of kidney disease and 
initiating a PESRD program early in the course of kidney disease is 
advantageous to the patient. The financial costs related to renal 
replacement are extremely high, and can be reduced allowing more 
patients to be treated for the same amount of money. 
From the results obtained from the study it is clear that effective 
PESRD management and early commencement of RRT in dialysis 
patients leads to an improved qual it y of life, and a decline in 
complications experienced. 
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OpsolDlDing 
Eind stadium renale siekte (ESRS) is 'n groot gesondheidsprobleem 
wat lei tot ' n aansienlike vehoging in morbiditeit en mortaliteit, 
verlaagde lewenskwaliteit en hoe kostes van renale 
vervangingsterapie (RVT), Daar is bykans 'n miljoen individue wat 
hul lewens te danke het aan dialise en huidiglik is daar 'n 5 jaar 
oorlewing vir pasiente met chroniese renale versaking (CRV). 
Vandag moet die optimisering van dialise die voltydse restitusie van 
'n volle gerehabiliteerde individue aan die gemeenskap waarborg. 
Die doel van hierdie studie is die onde rsoek van d ie indikas ies v i r 
die aanvang van die terapie wat verkry is van vergelykende studies 
en die inkorporering van faktore wat renale versakingspasiente 
beinvloed. Dit sluit in die voordeel van die identifisering van hoe 
r isiko individue vir renale siektes en die voordeel van die bestuur 
van faktore wat renale funksies affekteer, wat die 
voorbehandelingsfase sal verleng. Dit kyk ook na die 
doeltreffendheid en optimale tydsberekening vir die aanvang van 'n 
pre-eind stadium renale siekte (PESRS) program, sowel as 
verbetering in pasiente wat behandel word voor die ontwikkeling 
van renale versaking . Laastens is die studie gemik daarop om 'n 
wyse te vind om die finansiele aspekte verwant aan behandeling te 
verminder . 
Die stud ie was tweevoud ig . Eerstens behels dit 'n sifting van 100 
indiv idue met 'n risko vir chroniese niersiekte (CNS) waarby 'n 
serum kreatinien waarde geneem is en die glomulere filtrasie tempo 
(OFT) bereken is. Tweedens behels dit 'n biochemiese en kl iniese 
bepaling van 95 CRY pas iente 'n maand voor RVT , tydens aanvang 
van behandeling, I maand en 3 maande later . 
D ie sifting het aangedui dat die gemiddeld vir die kreat in ien by 
mans 128.45 ~mol/L en by vroue 108 .99 ~mol/L i s . Vier en tw intig 
present (24%) van die pasiente het 'n OFT van tussen 30 - 59 , 6% 
het 'n OFT van tussen 15 - 29, en 3% het ' n OFT van < 15 
ml/m inll .73m2 . Dit beklemtoon die noodsaaklikheid om individue te 
identifiseer wat 'n r i siko loop om rena le versaking te ontwikkel. 
Die tweede deel van die studie het aangedui dat met die aanvang van 
RVT die gemiddelde OFT 6 .7 ml/min/l.73m 2 was. Uremia , 
wanvoeding, anaemia, hiperparat iroidisme , hiperfosfatemia en ander 
elektroliet wanbalanse was ook teenwoord ig en het aanleiding gegee 
tot ' n verhoging in morbiditeit en mortaliteit en 'n verlaging in 
lewenskwaliteit. Vanu it die waarnemings van pasiente wat dialise 
ondergaan het is vasgestel dat die optimale tyd vir die aanvang van 
RVT , die eerste kliniese aandu iding van agteruitgang In die 
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teenwoordigheid van uremIa en /of wanvoed ing is , ongeag medies 
inte r vens ie . Daar is gevind dat RVT n ie uitgestel moet word tot 
wanneer die kreat inien waardes daa l tot d ie voo rgestelde grens nie , 
omdat d ie vertraging nadelig is vir die pasiente. D ie ooriewing van 
d ial i se pasiente hang af van hul fisiese toestand tydens die eerste 
d ial i se. Met uitstel van die behandeling was gevind dat dit ' n 
nadelige uitwerking het op pas iente wat RV T ontvang. Daar was ' n 
toename in die getal akute hemodia l ise (AHD) sess ies . Pas iente wat 
behandel is voor die aanvang van RVT en pasiente wat dialise 
ontvang het met 'n hoer GFT, het minder komplikasies ervaar as 
pasiente wat dialise op 'n latere stadium ontvang het. ' n Verbeter ing 
in die uitkoms van pasiente wat behandel is voor die aanvang van 
RVT is waargeneem. Dit is voorde l ig om die faktore te beheer wat 
renale funksie affekteer om sodoende die voorbehandel ingsfase te 
verleng . Die PESRS opvoedingprogram is 'n effektiewe komponent 
in die verso rg ing van n iersiekte en d i e inis iering van 'n PESRS 
program vroeg i n die verloop van niersiekte i s tot voordeel van die 
pasie n te . Die finans ie l e koste verwant aan renale vervanging is 
besonders hoog en kan verminder wo rd deur meer pas iente toe te 
laat vir behandeling teen dieselfde koste . 
Uit die resultate wat verkry is vanuit d ie s t udie is dit du ide li k dat 
effekt iewe PESRS bestuur en die vroee aanvang van RVT in dial ise 
pas iente lei tot 'n verbetering in lewenskwa l iteit e n ' n vermindering 
in die komplikas ies wa t onde rvi nd word. 
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CHAPTER 1 
INTRODUCTION 
1.1. Gene ral background and problem statement. 
2 
Nephrology is a young medical spec ialty and its growth has been 
nurtured by major advancements in modern technology that have 
allowed the elucidat ion of the natu re of renal diseases , which in 
turn , has allowed improvements in the management of pat ients . 
The incidence of renal failure has been steadily growing over the 
past few years , and research has indicated it to be a world-wide 
public health problem. Wo r ldwide there a re approximately a million 
people that owe their lives to dialysis (Cameron , 1996) . 
Research by the National Kidney Foundation (2003) has revealed 
that more than 20 million Americans (one in nine adults) have 
chronic kidney disease . More than 20 million others are at increased 
risk . More than 378 ,000 Americans suffer from chronic kidne y 
failure and need an artificial kidney machine to stay alive. More 
than 50 ,000 patients are waiting for kidney transplants , but only 
about 14 ,000 will receive transplants this year because of a shortage 
of su itable organ donors 
(National Kidney Foundation; About Kidney Disease 2003) . 
Diseases of the kidney and ur inary tract remain a major cause of 
illness and death , not only in the United States , but world-wide . End 
stage renal disease is a major health problem resulting in 
considerably increased morbidity and mortality , and in decreased 
quality of life (Rossert el al . , 2002). 
The majority of individuals suffering from renal failure are depr ived 
of physical autonomy , robbed of satisfying work and interpersonal 
experiences , and often are forced to w ithdraw from their premorbid 
social sphere of functioning . The event shape of renal failure , as a 
part of the li fe line of the individual, IS both disruptive and 
destructive (Rossert el al. , 2002 ) . 
Furthermore , renal failure p resents an increasing challenge to the 
health care system owing to its increasing numbers , its marked 
degree of disability and its high consumption of health care 
resources. Kidney disease is one of the costl iest illnesses . A 
concerted effort by the government, the private sector , and medical 
volunteers is needed to ease its toll on society (Robinson , 2001). 
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In the past decades , various modalities through multidisciplinary 
efforts have been utilized in an attempt to prolong the life of people 
with end -stage solid organ failure . In the past few years , both 
treatments have increased both in scope and effectiveness , with a 
rising rate of success (Draft Document: Department of health: 
policy on organ transplantation and chronic renal dialysis, 2003). 
The clinical value of dialysis and transplantation for the 
prolongation of life in patients with otherwise fatal chronic uremIa 
has definitely been established (Bonomini et al., 1975). 
However, can the results of the dialysis and transplantation 
programs not be improved? Can the results be improved by a more 
appropriate starting time of both treatments? This is a problem to 
which the solution is still not clear. 
Currently there is a five year survival rate of chronic renal failure 
(CRF) patients, which is 20% lower than patients with malignancies 
(Hague , 2002) . Can this five year survival of CRF patients , not be 
improved? 
Karger and Basel (1975) have suggested that the optimization of 
dialysis can no longer have the gratifying significance of 
lengthen ing life and reinserting a patient into the restricted 
environment of the family, but rather must guarantee the full time 
restitution to society of a totally rehabilitated individual. 
In a healthcare system in which nephrologists and nurses are already 
scarce , and the costs of dialysis and transplants are extremely high , 
it is imperative to have patients who are better prepared to make 
important decisions about, and actively participate in, their care 
(Robinson , 2001). 
Delay in treatment and poor counseling affect rehabilitation both 
directly and as a result of medical compl ications . 
1.2. Justification of the stndy. 
A comparative investigation into the indications for renal 
replacement therapy, and the optimal timing for commencing the 
therapy will have a beneficial impact in an area that is characterized 
by poor clinical outcomes. It will provide an outline of the current 
status of renal failure patients commencing treatment , highlighting 
areas of failure, and most importantly, areas of improvement. 
Examining the areas of failure can attain optimization of treatment 
(Baillod & Moorhead, 1975). 
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Research into the indications and optimal timing for commencing 
renal rep lacement therapy will be of great va l ue to patients who are 
develop ing renal failure. It will ensure improved outcomes of 
patients , with an inc rease in patient well - being, a dec l ine in 
morbidity and mortality , and the best chance for survival in an area 
that is characterized by a poor outcome. It will also benefi t the 
health professionals caring for these individuals . 
Furthe rmore , the study will prove to be financially beneficial to the 
funders of renal therapy , by causing a decrease in hospitalizations , 
and a decline in complications like vascular access and acute 
hemodialysis. In addition it will be beneficial in the sense that it 
will stress the need for and indicate the importance of, early 
referral to ensure optimal timing for renal replacement therapy . 
Diagnos i s of pre-end stage renal disease in advance is i mperative 
for the optimal timing of commencement of treatment (Jungers , 
2002) . 
Establishing the psychological , nutritional , hematological 
abnormalities and electrolyte imbalances affecting renal patients 
can provide data leading to the establ i shment of optimal timing for 
commencement of renal replacement therapy. In addition, awa reness 
of the above factors and their implications can be taken into 
account , and these factors can , where possible , be treated by means 
of drug regimen or alterations in lifestyle , to cause an improvement 
in patient outcome and an improvement in the quality of life. 
Furthermore this study is unique as it investigates the ind ications 
and the current status of patients : a month prior to commencement 
of renal replacement therapy ; at commencement of renal 
replacement therapy , and three months after commencing renal 
replacement therapy . This is imperative , as stated by Baillod e/ af. 
(1975), s ince examining the areas of failure can attain optimization 
of therapy , and th is study aims in contributing to the optimization 
of treatment. Optimizing treatment results in a decrease In 
morbidity and mortality , as well as most importantly , an 
improvement in patient well-be ing. In add ition the study 
incorporates all aspects affecting renal failure patients , includ ing 
psychological, nutritiona l, he matological abnormalities and 
electrolyte imbalances, as well as the financial impact in the 
investigation of the indications for commencing renal replacement 
therapy and the optimal timing for commencing the therapy . 
© Central University of Technology, Free State
1.3. Aims and objectives of tbe study. 
Arising from the problem statement , 
incorporate both a primary and secondary 
the aims 
objectives. 
I) The primary objectives of the study a re: 
5 
of the study 
a) To investigate the indications for commencing acute and 
chronic renal replacement therapy. 
b) To investigate the guide l ines for the optimal time to 
commence chronic renal replacement therapy. 
The secondary objectives of the study are : 
a) To investigate the benefits of early screening of 
high-risk patients for developing chronic renal failure. 
b) To investigate the effectiveness of a pre-end stage renal 
disease (PESRD) educational program , as well as to provide a 
guideline for the optimal time to commence the PESRD 
program. 
c) To investigate the benefits of manag ing factors affecting renal 
function in order to prolong the pre- treatment phase . 
d) To investigate whether there is an improvement in patient 
outcome in patients who were managed before the development 
of renal failure . 
e) To investigate a way to reduce the financial costs related to 
the commencement of treatment and on-going treatment. 
© Central University of Technology, Free State
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2.1. INTRODUCTION 
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C urrently kidney failure is not nearly as common as a cause of death 
or medical problems as , for instance h eart and blood vessel disease, 
or cancers as a whole , which each cause more than 200 000 deaths a 
year in the UK alone (Cameron, 19 96). 
This figure may not seem lar ge for the whole country , but k idney 
failure is more common than a number of diseases which are well 
known to the public , for example muscular dystrophy and mUltiple 
sclerosis . 
The incidence of end stage renal disease (ESRD) I S rising (National 
Rena l Care, 200\). 
The process of renal degeneration is often slow and stormy as the 
patient reaches the end stage renal disease. 
All attempts to define the therapeutic guidelines for uremic patients 
have been complicated by the sheer number of faclors involved. 
As discussed by Cameron (\996) the kidneys regulate the 
composi ti on and volume of the fluid bathing the cells of the body. 
They excrete the waste end - products of the bod y' s chemical 
factories, and make a number of important messengers , which have 
effects outside as well as within the kidneys . Thus when kidneys 
fail , all of these important functions are compromised 
As the kidneys fail , all body systems eventually become involved. 
Normal body functions are drastically altered in ways that change a 
person's quality of life. Hardly an aspect of physical , socia l , or 
p s ychological performance is left untouched by this disease process 
(Lancaster , 1979) . 
2.2. ACUTE RENAL FAILURE 
Acute renal failure (ARF) is a temporary loss of the kidney's ability 
to excrete waste products and to regulate the body ' s e l ectrolytes 
( Cameron et al., 1976) . It is a serious condition and its mortality 
rate is still unacceptably high. The prognosis may vary with the 
cause and extent of renal failure. Deaths are much more common in 
ac ut e renal failure patients whose age exceeds 60 years 
© Central University of Technology, Free State
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(Smith, 1997). The outcome for each individual acute renal failure 
patient is often unpredictable and, despite new drugs and the 
availability of dialysis , around 5% of hospitalized patients will face 
a mortality rate of about 50% (Smith , 1997). 25% of all new 
intensive care unit (lCU) patients develop ARF and the mortality 
rate ranges from 50- 70%. Morta lit y is higher in patients who 
develop ARF in ICU, than tho se who are admitted to ICU for ARF. 
Infection is present in 50- 90% of patients and infection is the cause 
of death in 75% of patients, thereby clearly indicating the 
unacceptably high mortality rate of ARF patients. The co - morbid 
condition is however important to surv i va l (National Renal Care, 
2001). 
The causes of acute renal failure may be subdivided into three major 
groups, in which each category has a physiological location of the 
insult and includes pre-renal causes, renal causes and post-renal 
causes. ARF can be divided into two stages. The first stage, the 
oliguric phase may last from a few days to several weeks. As 
indicated by the name , in this period the urine output is very low. 
The second phase is the diuretic phase and begins as the oliguric 
phase subsides , after days or weeks. The transition is usually 
abrupt , taking one to three days before the large urine volumes 
found at this time are excreted . The diuresis usually lasts several 
weeks and on occasion may persist for a month or two. The length 
and severity of the diuretic phase depends on the severity of the 
damage to the renal tubules, and upon how much excess urea, salt 
and water have to be excreted. 
As can be seen in figure 2.1. the effects of acute renal failure are 
numerous and affect various body systems. They can pose a 
multitude of problems, and can also be life- threatening. 
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Figure 2.1. Effects of acute renal failure 
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C hronic renal failure (CRF) is a condition that occurs when the 
kidneys are progressively and irreversibly destroyed by disease 
(Cameron e/ al., 1976). This usually occurs over a pcriod of years. 
The kidney, unlike other organs such as the liver, cannot grow 
tissue after maturity. The most that occurs is an increase in the size 
of the remaIning nephrons, when others are removed or lost. 
Eve ntually all functions of every cell and tissue of the body are 
affected in severe kidney failure. 
C hronic renal failure is unfortunately one of the commonest renal 
conditions, and is a major cause of death. It has man y causes, but 
the patients suffer the same problems , even though they are 
suffe ring from a variety of diseases (Cameron et al., 1976). 
Many conditions can lead to chronic renal failure, but only a few 
are common and include glomerulonephritis: usually proliferative, 
so metimes membranous, chronic pyelonephritis, polycystic kidneys 
and essential hypertension. Other conditions, which are less 
com mon but may lead to chronic renal failure include; analgesics , 
gout, amyloidosis, "connective tissue" disease (systemic lupus 
erythematosus - SLE, polyarteritis), stones, other obstructions (e.g. 
retroperitoneal fibrosis, malignancy) , and renal tuberculosis. 
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2.3.1. The development of chronic renal failure 
The development of chronic renal failure is a slow insidious process 
and for the most part, it has been clearly indicated that the 
development of chronic renal failure is asymptomatic. The patient 
with kidney disease will often show a variety of non-specific sign 
and symptoms, which include nausea, anorexia, lethargy, edema, 
dyspnea and diminished urine output. However as the kidney disease 
progresses, so the symptoms begin to increase, resulting from the 
fluid and electrolyte abnormalities , disordered regulatory functions 
(anemia, hypertension, renal osteodystrophy, and metastatic 
calcification) and the accumulation of uremic toxins, which cause 
physiological changes and alter the functions of various organ 
systems. 
The most striking feature of the slow destruction of the kidneys is 
how little the patient notices until renal failure is very advanced, 
unless of course , the condition itself is painful or leads to symptoms 
(Cameron, 1996). A large amount of patients would not know that 
they are developing renal failure, and that the kidneys are in 
trouble , if they do not have routine medical examinations, whether 
they are for pre- employment, pre- life insurance or preoperative or 
any other reasons. By the time it produces symptoms there are very 
few kidney functions left , as one can survive fairly comfortably on 
only 10% of normal kidney function, although an observant person 
would reali ze that something is wrong. As a result patients are often 
misdiagnosed , until they develop complete renal failure and require 
acute dialysis. 
Research about renal disease has centered on the five stages of renal 
disease, as depicted in figure 2.2. 
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Figure 2.2 : Model of the course of chronic kidney disease (C KD) 
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Individuals suffering from an inherited renal disease , haematuria 
and / or proteinuria, arterial hypertension or cardiovascular disease , 
diabetes, recurrent urinary tract infections , unexplained anemia , 
exposure to certain drugs (e.g. non - steroidal anti - inflammatory 
drugs , antibiotics) or chemicals, as well as individuals older than 60 
years are all at the risk of developing renal failure. A patient 
s uffering from constipation, sleep disturbances, personality 
changes , dementia , itching and lethargy could also be at risk for 
renal failure. 
However , two of the leading caus e s of renal failur e today are 
hypertension and diabetes. 
Gorman and Noble (2004) discuss how doctors have never known so 
much about diabetes and yet diabetes is an epidemic that keeps on 
raging. Doctors have repeatedly been warned that the world is 
experiencing a diabetes epidemic. In 1985, around 30 million people 
worldwide had the disease . But today in Europe alone, 48 million 
people , and 7 . 8% of the population are living with it. And although 
Type 2 diabete s still tend s to strike people in their fifth or sixth 
decade , more children are getting it , a fact of grave concern to 
health officials. 
If we look at the South African statistics , estimates suggest that 
there are over 3 .4 million persons diagnosed with diabetes. The 
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current growth rate is about I I % per annum. In other words, there 
are approximately 375 000 cases every year. And to make matters 
worse, estimates suggest that there are another - I 000 000/ 
+ 1 000 000 persons with diabetes in South Africa who have not yet 
been diagnosed (Gorman & Noble , 2004). 
In addition Epidemiologists predict that by 2025 diabetes cases will 
more than double in Africa (Gorman & Noble, 2004). 
In the past decade scientists have learned about the most 
devastating complications of diabetes. Yet in some case the disease 
itself is almost entirely preventable. There are better techniques for 
monitoring diabetes, more effective drugs for treating it, and two 
major studies have shown that by making only modest changes in 
diet and exercise, people at high risk of Type 2 diabetes can stave 
off the disease for at least three years and perhaps a lot longer 
(Gorman & Noble, 2004) . 
A complex picture is emerging that is changing the way we think 
about what was already a complex disease. It turns out that patients 
are not as helpless against its ravages as we once thought, 
especially if they are warned at the disease's very earliest stages. 
Changes in lifestyle and diet can, in the vast majority of cases , 
make a big difference. The future for anyone with diabetes has 
never been brighter, provided he or she has the right treatments. 
But the consequences of inaction have never been more broadly 
devastating. Diabetes is the fourth main cause of death in developed 
countries. Furthermore, it is the leading cause of renal disease and 
end - stage renal failure, and therefore, renal failure is on the rise. 
Uncontrolled or poorly controlled high blood pressure is the second 
leading cause of chronic kidney failure in the U.S., which accounts 
for about 23% of U.S. cases. 
Kidney damage itself can cause hypertension. Hypertension further 
damages the kidney . The combination of the two assaults upon the 
kidneys sets up a vicious cycle and may lead to a rapid decline in 
renal function, and great rise in blood pressure, accelerated or 
malignant hypertension, often after many years of relatively slow 
deterioration (Cameron et ai., 1976). It is therefore important to 
decide whether the patient with high blood pressure has either a 
renal condition causing their hypertension, or renal damage 
resulting from it (Cameron et ai., 1976). 
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Research from the "Caring for Australians with renal impairment" 
(CARl) guidelines has indicated that early detection of patients with 
renal disease can slow the progression of patients to ESRD, and 
improve survival on renal replacement therapy (RRT). The presence 
of proteinuria and renal impairment should be routinely evaluated in 
patients at increased risk of renal failure. There is however , no 
evidence to support the screening of the general population for renal 
disease by urine dipstick, blood samp ling or other means, and this is 
further supported by the United States (U.S .) Preventative Services 
Task Force (2003). The Canadian Guide to Clinical Preventative 
Health Care (2003) states that there is fair evidence to exclude urine 
dip s tick screening for proteinuria from the periodic health 
examination of asymptomatic adults , yet there is good evidence to 
include urine dipstick screening for proteinuria in the periodic 
health examination of adults with diabetes mellitus. On the other 
hand , the National Kidney Foundation (NKF), Kidney early 
evaluation program (KEEP) , (2003) for high - risk patients states 
early evaluation should be considered for patients with diabetes , 
hypertension , and immediate relative s of patients with diabetes , 
hypertension, and renal disease (over 70% of patients screened had 
renal abnormalities). This IS further supported by the British 
Hypertension Soc i ety (2003), which recommends that all 
hypertensive patients should undergo urine analysis (Dipstick) and 
measurement of serum electrolytes, urea and creatinine . Furthermore 
the Austral ia and New Zealand Society of Nephrology (2003) 
consensus statements state "a periodic health exam that includes , 
urinalysis for proteinuria +/ - haematuria" should be available for 
Aboriginal and Torres Strait Islander patients. 
Since diseases of the kidney and urinary tract remain a major cause 
of illness and death, a concerted effort by the government, the 
private sector and medical volunteers are needed to ea se their toll 
on society (Robinson , 2001). 
2.3.2 . Factors affecting renal failure patients 
2.3 . 2 . 1. Residual renal function 
It has been suggested that residual renal function persists longer 
and at higher levels in peritoneal dialysis (PD) patients than those 
on hemodialysis (HD) and therefore plays an important role in the 
s uccess of PD. It has also been suggested that residual renal 
function contributes to salt and water removal and to cl earance of 
both small and medium - sized molecular weight solutes (Daugirdas 
e t al . , 2001). 
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However further research has noted that residual renal function 
might possibly have some biochemical reflections , but that it 
certainly does not modify the overall clinical results of dialysis 
(Bonomini et at. , 1975). 
2.3.2.2. Cardiovascular problems affecting renal failure patients 
Problems of the cardiovascular system related to chronic renal 
failure include the hypertensive heart disease , hyperkalemia, 
hypermagnesemia, hypocalcemia, myocardial calcification, 
cardiomyopathy, pericarditis, pericardial effusion, pericardial 
tamponade, arterial calcification, and hypertension (Daugirdas et 
at., 2001). 
The production of renin from the kidney is generally increased in 
kidney failure, which contributes to salt retention and the high 
blood pressure. This is because the tissues of the scarred kidneys 
are receiving too little blood. 
Hypertension is better controlled with continuous peritoneal dialysis 
than with hemodialysis ; patients on CAPO seldom requlfe 
antihypertensive drugs . In approximately 80% of hemodialysis 
patients, reducing body fluid via ultrafiltration can control 
hypertension. In the remaining 20%, antihypertensive drugs are 
required. 
Prognosis is better when post-dialysis blood pressure (BP) IS normal 
and if the patient does not smoke (Janssen - Cilag, 2001). 
2.3.2.3. Hematological problems affecting renal failure patients 
Effec ts of chronic renal failure on the hematological sys tem 
include: anemia , a defect in the quality of platelet s, an increased 
bleeding tendency, and a change in the physiology of red and white 
blood cells (Lancaster, 1983). 
C hronic renal patients usually display with a mild thrombocytopenia 
and a defect in quality of platelets. The results are a prolonged 
bleeding time , decreased platelet adhesiveness, and abnormal 
prothrombin consumption. Purpura may results from a minor injury 
and bleeding may occur from body orifices or mucous membranes 
(Daugirdas et at. , 2001). 
Anemia is characterized by a state of low hemoglobin (Hb) levels 
resulting in deficient transport and release of oxygen throughout the 
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body. It remains a leading cause of morbidity and mortality among 
patients with chronic kidney disease (CKD), (Richardson, 2002) . 
The development of cardiovascular disease (CVD) in CKD patients 
is a major contributory factor for a variety of reasons, including the 
fact that the heart compensates for the anemic condition by 
increasing the heart rate , left ventricular stroke volume, and thus 
cardiac output. 
Patients with chronic kidney disease are anemIc for a number of 
reasons, namely: 
I) Decreased red blood cells production caused by the diseased 
kidney. In a normal state, erythropoietin, or its precursor, i s 
produced by the kidney in response to hypoxia. This subs tance 
stimulates the bone marrow and increases red blood cell 
production. 
2) Decreased survival time of RBCs due to elevated uremIc toxins. 
3) Loss of blood through gastrointestinal bleeding. 
4) Loss of blood during hemodialysis from membrane rupture, 
hemolysis, and residual dialyzer blood loss. 
The hematocrit usually falls slowly over several months and 
stabilizes around 20%. One compensatory mechanism for the low 
hematocrit is an increase in the enzyme 2 ,3 -diphosphoglycerate 
(2,3 -DPG) , which causes the oxygen dissociation curve to the right 
and hemoglobin to liberate oxygen to tissues more readily 
(La ncaster , 1983). 
According to the DOQI guidelines (2003) anemia should be treated 
because anemia results in LVH, increase in RBC transfusions , and a 
decrease in the quality of life, decreased exercise tolerance and 
impaired cognitive functioning. 
Epo ietin alpha (recombinant human erythropoietin) is the principle 
treatment for the anemia of renal failure. Most iron - deficient 
patients are given supplemental iron. Because the absorption of oral 
iron is limited, many patients require iron dextran IV. 
In patients with chronic kidney disease sensitivity to recombinant 
human erythropoietin (r - HuEPO, epoetin) , is of clinical and 
economic importance. Effective treatment of renal anemia with EPO 
improves survival , decreases morbidity and increases quality of life 
(Richardson, 2002). 
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In a significant proportion of patients receiving epoietin, anemia 
persists despite adequate dosing, or high doses are required to 
achieve the desired hemoglobin level. This indicates a poor response 
to EPO, which not only has implications for clinical care , but also 
for the cost effectiveness of EPO treatment. 
Various factors influence EPO treatment, namely: gender, age, and 
concomitant conditions, route of administration , iron deficiency , 
length of time on dialysis and type of dialysis, dialysis adequacy, 
dialysis water quality and membrane biocompatibility , and dialysis 
fI ux . 
Inadequate response to EPO may result from the iron depletion, 
infection and / or inflammation, folate and / or vitamin B 12 deficiency, 
chronic blood loss, osteitis fibrosa (hyperparathyroidism), aluminum 
toxicity, hemoglobinopathies, multiple myeloma, malnutrition and 
hemolysis (Daugirdas et ai., 2001) . 
With regard to inflammation and infection, EPO response IS 
impaired by a variety of cytokines involved in inflammatory 
response . The infection/inflammation must be treated, since EPO 
therapy can only be stopped with chronic infection e .g. in TB and 
Hepatitis. 
Multiple blood transfusions can affect renal transplantation as 
patients can develop cytotoxic and agglutinating antibodies , and can 
therefore affect graft survival (Bonomini et ai., 1975). In addition 
blood transfusions result in the suppression of bone marrow 
production of red blood cells and the patient thus becomes 
transfusion - dependent to maintain his hemaocrit. Furthermore, there 
are the dangers of transfusion reactions and the transmission of 
diseases including hepatitis. Because of the problems related to 
blood transfusions , they are not given until the patient becomes 
symptomatic, showing dyspnea, fatigue, tachycardia, and 
palpitations. 
Leukocyte- poor blood and frozen blood is used to mItIgate this 
problem. According to Lancaster (1983) frozen blood is the 
preferred treatment as the recipient receives blood with greatly 
decreased antigenic properties, and fewer cytotoxic antibodies are 
formed. 
The mortality rate of patients with kidney disease is high because 
incidence of CVD is two times greater in these patients compared 
with the general population (Levin , 2001). For every Ig / dl decrease 
in Hb there is a 6% increase in LVH risk (Janssen - Cilag , 2001). 
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EPO may, however , affect the blood pressure (BP) of the patient and 
can cause a >lOmmHg increase in diastolic BP. Generally this is not 
a se rious problem and therefore the risks and benefits must be 
weig hed . This EPO induced hypertension can be prevented by a slow 
increase in Hb «2g/dl/month), a reduced EPO dose, fluid removal 
a nd volume regulation , effective dialysis, dietary management and 
the use of anti - h y pertensive drug therapy (up to 5 agent s). 
Despite the known benefits of treatment, anemia still remains 
com mon among CRF patients . Due to lack of awareness of the 
prevalence of anemia in the CRF population, there is a lack of 
scree ning for anemia and hence a lack of early intervention. 
Levi n (200 I) di sc usses the current evidence s upporting the need for 
early identification of anemia in patients with renal failure. To 
corroborate this, one study demonstrated that the incid e nce of LVH 
in C KD patient s prior to dial ys i s i s about 40 % , and has be e n 
repor ted to be as high as 74% in patients commencing dialysis . 
However , dialysis patients frequently have mor e than one 
manifestation of C VD, and include dysrhythmia , peripheral vasc ular 
disease, coronary artery disease, and angina pectoris and cardiac 
failure. 
Co mplet e prevention of anemia may minimi ze the development of 
LVH and / or other manifestations of CVD, and reduce the mortality 
rate in this patient population in the long term . 
2 .3 . 2.4. Pulmonary problems 
Pulmonary problems in chronic renal failure includ e pulmonary 
ede ma, pleuritic pain, pleural rub, pleural effusions , uremic 
pl euritis and a condition referred to as "uremic lung " or uremic 
pneumonitis . The sputum is tenacious , the cough reflex is depressed , 
and there is an increased susceptibility to infec tions beca us e of the 
pu lmonary macrophage activity in uremia. T he respiratory system 
attempts to compensate for the metabolic acidosis of renal failure 
by decreasing the r e spiratory rate to eliminate carbon dioxide, thus 
decreasing the body ' s carbonic acid concentration. 
Ure mic pneumonitis, which is one manifestation of fluid overload, 
usually di sa ppear s following fluid removal during two or three 
dialyses. Frequent chest X- ray s are necessary to detect changes in 
pneumonitis (Daugirdas e t ai . , 2001). 
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Fro m mouth to anus, the gastrointestinal system [s affected by 
uremia. It is not uncommon for uremic patients to suffer from 
sto matitis , fetor uremicus, esophagitis, gastritis, duodenal ulcers, 
nausea, vomiting, diarrhea, anorexia , lesions on the small and large 
bowel, and proctitis. The cause of these problems is elevated uremic 
toxins that cause inflammation and ulceration of the gastrointestinal 
mucosa. 
The metabolic consequences of chronic renal failure are numerous 
and include carbohydrate intolerance, hyperlipidemia, and protein 
metabolism. 
Ca uses of glucose intolerance in chronic renal failure are 
insens itivity of peripheral tissue to in su lin , delayed production of 
insulin by the pancreas , and an increased half- life of insulin. 
Insulin and glucose metabolism is improved, but does not 
com pletely normalize, after implementation of regular hemodialysis. 
Except in the nephrotic syndrome, serum cholesterol remains normal 
in renal failure. Because of increased production and decreased 
removal, serum triglycerides are elevated in uremia. The increased 
production of triglycerides is related to peripheral resistance to 
insulin and elevated ser um insulin, which cause an increased hepatic 
output of glycerides. Reduction in the activity of the enzyme, and 
lipoprotein lipase, also due to insulin resistance, contribute to the 
abnormality. The serum levels of triglycerides do not decrease after 
hemodialysis i s started. In fact, the condition often worsens, and 
patients who did not have elevated triglyceride s before the 
commen cement of hemodialysis will often develop elevated levels 
wi thin weeks after the treatments are implemented . The relationship 
between hyperlipoproteinemia, specifically type I Y, and 
arteriosclerotic cardiovascular disease is well docum en ted . Many 
uremic patients , especially those receiving hemodialysis, develop 
this heart and vascular disease and die from myocardial infarction. 
Because of a decrease in renal function the end-products of protein 
metabolism accumulate, as reflected b y an increase in blood urea 
nitrogen (BUN). The elevated BUN and other uremic to xi ns are 
responsible, in part, for the development of uremic syndrome with 
its various manifestations, as discussed earlier. 
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2.3.2.6. Endocrine problems 
Much controversial information has been published about abnormal 
endocrine functions in chronic renal failure. 
There are conflicting studies regarding the serum levels of growth 
hormone in chronic renal failure , most report an elevation of serum 
growth hormone (Lancaster , 1983). It is well known that children 
with chronic renal failure cease growth (Lancaster, 1983). Even 
though the serum level is elevated, there is a failure to respond to 
the growth hormone (Lancaster , 1983). 
In advanced renal failure infertility often occurs in both males and 
females. Amenorrhea and cessation of ovulation takes place in 
w o men . There is a decreased libido in both sexes , and men are 
us ually rendered impotent. This probably has a psychological as 
well as a pathological basis. Following implementation of dialysis , 
libido often improves in both sexes. As discussed by Lancaster, 
( 1983) the impact of chronic illness upon the patient's life is 
ex tensive. As the disease progresses, the patient experiences a 
narrowing of existence, mobility decreases, pain and di s comfort 
become common , and there are more and more treatment 
prescriptions with which to deal. A person's very identity is defined 
by an illness over which there is little control. Nowhere is the 
personal loss as profound as it is in the patient's inabilit y to live as 
a complete sexual being. 
E levated parathyroid hormone (PTH) levels are ubiquitous in 
patients with chronic renal failure. As renal function decreases , 
se rum calcium and vitamin D (calcitriol), hormone levels tend to 
decrease , while the serum phosphorus levels tend to increase. 
Parathyroid gland cellular proliferation and increased secretion of 
PTH initially compensate for these changes, delaying the appearance 
of frank hypocalcemia, hyperparathyroidism and hypovitaminosis D. 
Eventually the compensatory effect of an increased PTH level is 
o verwhelmed, and derangements in serum calcium, phosphorus and 
v itamin D become apparent. As the glomerular filtration rate (GFR) 
decreases, the circulating proportion of non - I.84 PTH fragments 
detected in iPTH assays increases from about 20 % in healthy 
individuals with normal renal function to about 50% in C RF patients 
on HD. Thus, with an 8- fold increase in total iPTH , as renal 
function diminishes, there is actually a 5- fold increases in 1- 84 
PTH and an 18 - fold increase in non 1- 84 PTH (Avram, 2001) . 
E ffective management of secondary hyperparathyroidi s m in the early 
stages of CRF is important to prevent the development of renal 
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The kidney is the site of the final production of active vitamin D. 
As it fails , so production of vitamin D falls away. This results in a 
failure of calcium absorption from the bowel and failure of normal 
remodeling of bone. The effects depend on whether the patient has 
stopped growing or not. If growth is still going on, then rickets 
develops with defective growth, bowed legs, and broadening of the 
wrists and ankles. If growth has stopped then osteomalacia 
develops. This is mainly noticeable by pain in the pelvis and hips 
(L ancaster, 1983) 
2 .3.2.7. Nutrition 
Acchiardo and Smith (2000) discuss that in spite of significantly 
higher doses of dialysis, the use of more biocompatible membranes, 
and higher hematocrits , malnutrition remain high in hemodialysis 
studies. 
Malnutrition is a widespread problems among hospital patients (40 -
50%) but it is especially so in the renal population (Acchiardo & 
Smith, 2000). Not only do the symptoms they experience interfere 
with appetite and dietary intake, but the severe dietary restrictions 
also contribute to their malnourished state. It has been proven that 
malnutrition is a strong predictor of poor clinical outcomes. A low 
s erum albumin is also a risk factor for cardiac disease in dialysis 
patients. In a study conducted by Acchiardo & Smith (2000), 
malnourished patients in both cohorts had more hospitalization per 
year per patient. The length of hospitalization was longer , and their 
mortality rate higher, than was observed in groups eating > 8g / kg / d . 
There are multiple markers of malnutrition that have been used as 
prognostic indicators of morbidity and mortality in dialysis patients . 
One of the most powerful is the serum albumin level as a measure of 
visceral protein (Acchiardo & Smith , 2000). 
Deterioration of nutritional status often begins early in th e course 
of chronic renal insufficiency (CRI), (Oosthuizen , 2002). As the 
GFR decreases, the state of nutrition may worsen. Nutrition declines 
when the CCr drops below 25 ml / min. 
Proteins in particular require higher levels of filtration and protein 
restriction should only be used in patients who are adequately 
nourished. It should never be restricted below 0.6 gram p e r kilogram 
of body weight, and must be adjusted for albumin losses in patients 
who are nephrotic. Dietary protein restriction helps prevent 
glomerular hypertension In experimental models of chronic renal 
disease. Patients who are on a low protein diet need to be monitored 
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by a qualified dietician, and should been seen on a regular basis. 
The urine urea nitrogen is generally a good indicator of protein 
intake , and can be used as a feedback tool. If serum albumin stores 
start to fall, then the diet needs to be adjusted. 
T he modification of diet in renal disease data together with 
meta-analysis of recent trials has shown that protein restriction can 
s low or retard the progression of renal disease 
( Acchiardo & Smith, 2000). 
However in accordance to Acchiardo and Smith (2000), Bonomini et 
al. (1975) states that most patients are on a low protein diet for 
many years before dialysis. It has been demonstrated that the longer 
the duration of the diet, the worse the systemic uremia , despite the 
initial slowing of the progression of renal disease (Bonomini et al., 
1975). 
Every patient with CRI or CRF should receive intensive nutritional 
counseling. The primary objectives of dietary intervention are: 
• To identify and treat of malnutrition early. 
• To provide a nutrition care plan this aims to meet the nutritional 
requirements. 
• To ensure acceptable anthropometric and biochemical parameters 
• To improve dietary compliance. 
(at present estimated at 25%-50%) 
• To improve quality of life . 
Survival is longest among patients who maintain a serum albumin 
> 3.5g / dL, sodium 3 to 4g and potassium 4g and fluid intake I to 
1.4L1day is typical in a 70kg adult. However the diet also needs to 
be practical , palatable , and acceptable to the patient. 
2 . 3.2.8. Neurological problems 
Nervous system changes occur in virtually all uremic patients. The 
signs and symptoms are numerous and vary according to the degree 
of uremia and the part of the nervous system affected: central , 
peripheral, or autonomic. Changes may occur in mental function, 
muscle function , behavior , sensory and motor nerves 
(Lancaster, 1983). 
Changes in mentation include shortened memory and attention span, 
lack of interest in the environment, confusion, stupor , coma , and 
convulsions. Electroencephalographic changes are indicative of a 
metabolic encepha lo pathy. Disturbances of cortical background 
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rhythm, and replacement of normal alpha waves by a slow irregular 
rhythm (Lancaster, 1983). 
Depending on the patient ' s premorbid personality , behavior changes 
may range from slight irritability to complete withdrawal. Other 
changes include psychosis, delusions , decreased or absent libido , 
agitation, and depression. As these symptoms are expressed, the 
patient becomes more and more difficult to manage for both his / her 
family and caregivers. Exacerbated by other manifestations of 
uremia, the patient ' s quality of life suffers . The patient uses his / her 
limited strength and resources to deal only with living on a day- to -
da y basis. Soon the patient realizes that his / her world has become 
narrow and restricted to managing only the chronic illness. 
A slowing of peripheral nerve conduction leads to peripheral 
neuropathy, manifested In symmetrical numbness and burning , 
beginning in the toes and spreading up the legs; the "restless leg" 
sy ndrome; foot drop; and the "burning- foot" syndrome. The 
s yndrome consists of painful cramps and crawling , prickling and 
itching sensations localized to the lower extremities and usually 
developing at night time. Movement, thus the name " restless legs" 
syndrome, often relieves the symptoms. If dialysis is instituted 
b e fore motor nerve dysfunction develops , these changes may slowly 
be reversed. Bilateral foot drop is the most common motor nerve 
abnormality of uremic neuropathy (Lancaster, 1983) . 
2.3.2.9. Psychology 
Renal failure can be a frightening and a bewildering time (Cameron , 
1996). Stress for the dialysis patient may be cau s ed by the 
termination of urination and reduced physical energy ; loss or change 
in se x ual function; changed appearance due to access surgery , 
peritoneal catheter, needle marks, bone disease, or other physical 
deterioration, and ultimately, the threat of death. Dialysis patients , 
along with their families, are constantly vulnerable to medical, 
social , and emotional crises . Depression is common in patients with 
end stage renal disease (ESRD), which is associated with increa s ed 
mortality. 
Dialysis permits at least a partial return to premorbid activity. How 
the patients and the treatment team cope affects quality of life and 
survival. Patients may resume their former interests and , if 
appropriate, return to gainful employment (Brundage, 1980). 
However , dialysis is often scheduled for the convenience of others , 
affects the patient's work or school schedule and leisure activities 
and employment may be precluded. 
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However, from the earliest days of hemodialysis, it was noted that 
patients go through a recognizable series of stages following the 
st art of treatment (Smith, 1997). These may overlap, or fluctuate , as 
with the stages of bereavement (Smith, 1997) , but can usually be 
id e ntified by both staff and the patients themselves. 
The first phase of emot ions of a chronic renal failure patient is 
euphoria and initia ll y includes a sense of relief, for several reasons . 
First, after months or even years of waiting in a kind of limbo, the 
hurdle of dialysis has been reached and cleared. Second, the patient 
may feel th e benefit of treatment immediately, especially if uremia 
was symptomatic, or if the patient was suffering from pulmonary 
edema . Third , the experience of hemodialysis is less traumatic than 
the patien t expects. This first phase may however , be influenced by 
the way dialysis was initiated, whether the patient was informed 
prior to the development of renal failure, or whether this was the 
first acknowledgement of renal insufficiency , as will be discussed 
later (Smith , 1997). 
The second emotional phase of a chronic renal failure patient is a 
depressive reaction, and it follows fairly quickly. The novelty of the 
treatment wears off; the limitations, frustrations and the time 
involved begin to take their toll, and the realization that this 
s ituation will continue indefinitely starts to sap the patient's 
re s erves of endurance. In addition, although the patient is no longer 
frankly uremic, the patient is aware that dialysis cannot make 
him / her feel fully well. Tiredness, lack of energy and enthusiasm 
for life , irritability , poor sleep and low grade depression make life 
on dialysis difficult to tolerate, especially for those who expected 
to feel 'miraculously' better. The partner and family are also likely 
to feel the strain , and relationships may suffer. The effort of trying 
to continue wi th work while under these pressures may seem to be 
too much. The patient doubts whether employment will be possible , 
and fears the financial and family consequences if work has to be 
abandoned. Those who had been full of determination not to let 
dialysis affect or interfere with their lives have to concede defeat: 
it is not possible to remain unaffected. This stage may last for 
weeks or months, and needs to be handled with tolerance and 
understanding by al l staff (Smith , 1997). 
The third emotional phase of a chronic renal failure patient IS 
realistic , and provided it goes according to plan , the patient 
gradually accepts the inevitable limitations, while making the most 
of the remaining possibilities. Hobbies, habits and roles at home 
may have to change. Alternative sources of satisfaction and 
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enjoyment need to be discovered and exploited , but all this takes 
time and may need to be actively encouraged by staff (Smith, 1997). 
It is not surprising that during this period of adjustment the patient 
may be low in mood, irritable , quick to take offense and so metimes 
be incompliant. The majority of patients do not find the dialysis 
itself a difficult ordeal , unless there are persistent problems with 
access, or cramps, or frequent problems with interdialytic weight 
gain. The factors likely to produce irritation are delays , especially 
caused by the machines not being ready, changes of schedule and 
the unpredictability of minor setbacks such as access problems. The 
time involved in the whole process becomes a central focus for 
many patients, who resent the amount of their life now dedicated to 
dialysis, in spite of the fact that it is the dialysis that is making 
their life possible at all. 
The age of the patient may also play a role in the patient 
com mencing dialysis. 
Smith (1997) discusses the psycholog ical issues affecting the young 
patient commencing renal replacement therapy. It is found that many 
young patients find it hard to make relationships with the opposite 
sex, feeling that they have little to offer a prospective partner . 
Smith (1997) states that middle- aged individuals usually have an 
established role and have achieved a number of their goals, such as 
marriage, family, a career and a home. From this basi s they are 
often, but not always, better able to adjust to limitations. For them 
there is the fear of losing what has been achieved , and being unable 
to carry out responsibilities to those who depend on them. Role 
changes within the family threaten the identity , pride and self image 
of the patient, who does not wish to become a burden or a liability. 
Reasonably fit elderly patients are in some ways the most satisfied 
group, (Smith , 1997,x , Weatlie et ai . , 1984; Auer, 1986). The 
attitude of many elderly patients is that they have already 'had a 
good life ' and have reached an age when death would not be 
unlikely in any case. They have not been cheated of a normal 
lifespan by their illness. To b e given the chance of a further few 
years due to dialysis is a bonus to those who still have an appetite 
for life . Those in their seventies and eighties probabl y do not want 
to pursue very strenuous activities, preferring a little gardening, 
cooking and the company of friends and family. Those who live 
alone and feel isolated regard the trips to the hospital for treatment 
as a welcome social activity. 
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Some dialysis patients act out their feelings, by non - compliance 
with diet and medication, by arriving late or missing dialysis or may 
become angry with the treatment team or home dialysis partner. 
However, many patients express their feelings and direct their 
energy in productive ways. They may return to work, resume former 
interests, or become lay counselors to fellow dialysis patients. 
The psychological treatment should incorporate psychological care 
duri ng all stages of the treatment , and should include co ncerns or 
difficulties about aspects of treatment, and integrate the treatment 
into daily lives. Psychological counseling for depression , behavior 
problems, and loss of adjustment issues benefits many dialysis 
patients and families. These services are available from nephrolog y 
socia l workers , psychologists, and psychiatrists. 
2.3.2.10. Reversible defects in chronic renal failure 
As discussed by Brest & Moyer (1967), chronic progressive renal 
disease is a slow proc ess, which relentlessly destroys renal 
su bstance , but remains relatively asymptomatic for many years. 
When the limits of renal reserve are reached , symptoms appear in 
swi ft succession, and the condition of the patient deteriorates 
rap idly , though there may be little actual acceleration of the rate of 
pathological destruction of the kidneys. The less kidney tissue that 
remains , the more difference a small increment in function makes to 
the patient. The extent of damage that is reversible is therefore 
tremendously important. 
The goal for the physician In the treatment of advanced renal 
disease should be to salvage every last bit of renal function; every 
last nephron. His goal should be to discover and to treat all 
reversible lesions , no matter how insignificant they appear , because, 
for a patient a small improvement In function may mean the 
difference between life and death. 
Reversible disorders of renal function can be of two types . In one 
the disease is self- limited; the damage will eventually resolve and a 
remi ssion takes place if the patient continues to live. The other type 
of reversible renal dysfunction may progress and even kill the 
patient if not discovered and actively treated. 
C ongestive heart failure, infection, obstruction, dehydration, salt 
de pletion, alkalosis and potassium depletion and hypercalcemia are 
all reversible defects of CRF. 
I 
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Although we cannot prevent the majority of individuals developing 
renal failure, we can treat them successfully by replacing their 
kidney function by either dialysis or transplantation. 
The overall aim of renal replacement programs are: (I) to achieve 
physical survival without medical complications; (2) to rehabilitee 
so that independence, ability to compete both physically and 
mentally, and social freedom are restored to former levels, and (3) 
to provide an organization able to meet treatment demands, maintain 
this service indefinitely and make it economically acceptable to the 
particular hospital, state and family (Baillod & Moorhead, 1975). 
Despite the relatively poor quality of life, the time spent on the 
procedures, and the failure to reverse many of the complications of 
uremia, regular hemodialysis and peritoneal dialysis provide an 
extraordinary successful palliation for end stage kidney failure. It is 
true that to some extent they merely prolong the problem, but most 
patients can attain useful survival in both human and economic 
terms. For some, it is the preferable treatment. The alternative 
treatment, transplantation, is undoubtedly more successful in terms 
of rehabilitation (Cameron, 1996). 
Dialysis is a relatively safe procedure that is used to alter the 
abnormalities of blood composition that result from renal failure . It 
is the differential diffusion of solute through a semipermeable 
membrane separating the solutions (Brundage , 1980). 
Research by Bonomini et al. (1975), has indicated that dialysis has 
the capacity to rehabilitate patients for working conditions, yet it 
does not have the capacity to rehabilitate the patients from uremia. 
If dialysis cannot be regarded as a valid method to cure or reverse 
systemic uremic manifestations, selected schedules indicate that it 
may be an acceptable method to slow their progression or even to 
prevent them, provided that treatment is started earlier. 
2.4.1. Hemodialysis 
Chronic hemodialysis (CHD) is defined as the process of attaching a 
patient to a hemodialysis (HD) machine for a period of 3 to 4 hours 
at a time, 2-3 times a week (NRC, 2003) . 
,/ 
./ 
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When uremic blood is exposed to dialysate, the flux rate of these 
solutes from the blood to the dialysate will initially be much greater 
than the back flux from the dialysate to the blood. In practice 
(duri ng dialysis) concentration equilibrium is prevented ; and the 
conce ntration gradient between blood and dialysate is maximized by 
continua lly refilling the dialysate compartment with fresh dialysate 
and replacing dialyzed blood with undialyzed blood. 
The vascular access is obtained by an arteriovenous (AY) shunt with 
prosthetic graft or an arteriovenous (AY) fistula between artery and 
vein or by a vascular catheter in a large central vein. The DOQ! 
guide lines (2003) recommend that the AY fistula be the first choice 
of access, then the AY graft and as a third choice the cuffed 
tunneled venous catheter. Therefore a pre-end stage renal disease 
patient's cephalic vein should be preserved for the creation of a 
fistu la. Prevention of vascular access complications significantly 
affects the quality of HD that can be de ivered; temporary catheters 
usually do not allow the blood flow r&quired to achieve optimal 
clearance. 
The advantages of HD incorporate the rapid correction of life 
threatening hyperkalemia or fluid overload and consistent 
clearances are achieved. On the other hand the disadvantages 
include the risk of hypotension and hypoxia in unstable patients 
(Nationa l Renal Care, 2001). 
2.4.2. Peritoneal dialysis 
Peritoneal dialysis (PD) is the method of RRT used by 
ap proximately 100 , 000 patients worldwide. The number of patients 
on PD has greatly increased because of its simplicity, convenience , 
and relatively lo w cost. 
For some patients PD may be the preferred mode of therapy. This is 
es pecially true In small children because of the problems in 
developing adequate blood access; in older patients with 
cardiovasc ular problems; in patients whose loss of a shunt site 
makes peritoneal dialysis a ' last resort' and in pati ents whose 
religious beliefs prevent the use of blood transfusions. 
PD involves the transport of solutes and water across a "membrane " 
that separates two - fluid - containing compartments. These two 
compartments are (a) the blood in the peritoneal capillaries, which , 
in renal failure, contain an excess of urea , creatinine, potassium and 
so forth, and (b) the dialysis solution in the peritoneal cavity, which 
typically contains sodium , chloride and lactate and i s rendered 
! 
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hyperosmolar by the inclusion of high concentration of g lu cose. The 
peritoneal membrane that acts as a "dialyz er" is actually a f 
heteroporous , heterogeneous, semipermeable membrane with a 
relatively com pl ex anatomy and physiology. 
PD access IS through the peritoneal catheter, which can be 
subdivided into acute and chronic catheters. The most commonly 
used PD catheter is the Tenckhoff catheter. 
PD is subdivided into Conti nu ous ambulatory peritoneal dialysis 
(C. A .P .D) and Automated peritoneal dialysis (A.P.D). 
CAPD typically involves four 2.0- 2.SL exchanges daily. 
PD is, however contraindicated in patients with malnutrition, unless 
aggressive measures to correct malnut ri tion are instituted. Asc it es is 
also contraindicated In PD patie '2-ts because patients have a 
predisposition to become severely malnourished ; if there are 
extensive abdominal adhesions; from a previous operation , as it may 
interfere w ith catheter function. PD is contraindicated in patients 
with an upper limb amputation because if such patients do not have 
a helper, they are incapable of doing PD. Furthermore, ostomies can 
pose a major hazard being contamination of the PD catheter and 
peritoneum. PD is also contraindica ted in patients with chronic 
obstructive pulmonary diseases because a swollen abdomina l may 
aggravate the respiratory insufficiency. Furthermore , marked 
proteinuria can contraindicate PD to prevent malnutrition. It seems 
logical to place patients with a daily proteinuria of > IOg on HD, at 
least until the proteinuria decreases as the GFR falls. There are, 
however, no study supporting this assumption , In addition, 
conditions such as sclerosing peritonitis , severe inflammatory bowel 
disease , acute diverticulitis , active ischemic bowel disease, or 
abdominal abscesses are absolute contraindications for PD . Severe 
ps ychiatr i c illness , severe dementia, or even mental retardation are 
al so contraindications for PD . 
APD on the other hand ranges from anything between three and ten 
dwel l s, and is delivered nightly using an automated cycler. In the 
daytime the patient usually carries a dwe ll , wh i ch is drained each 
night before cycling recommences ; this is referred to as continuous 
cycling peritoneal dialysis (CCPD). Alternatively the patient is left 
"dry" during the day, and this is termed nocturnal intermittent 
peritoneal dialysis (NIPD) , (Daugirdas e l ai . , 2001) . 
In this section, automated peritoneal dialysis (APD) refers to the 
us e of a cycler for various regimens , including NIPD, CCPD, tidal 
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peritoneal dialysis (NTPD or CTPD), and intermittent peritoneal 
dialysis (IPD) twice or thrice weekly, which is not recommended 
because satisfactory clearances are seldom achieved with this 
modality (CARl guidelines, 2003). 
2.4 . 3. Dialysis adequacy 
According to the Dialysis Outcomes Quality Initiatives (DOQI) 
guidelines, (2003) every effort should be made to ensure that 
patients receive adequate renal replacement therapy (RRT). 
For hemodialysis, the DOQI guidelines , 
minimum Kt / V of 1 .2 or a urea reduction 
There are four variables that determine the 
(2003) recommend a 
ratio (URR) of 65%. 
actual delivered Kt / V 
namely, the clearance of a hemodialyzer; treatment duration, and the 
flows of blood and dialysate. Accurate measurement of the change 
in blood urea nitrogen (BUN) con \ entration that results from a 
hemodialysis treatment can only be made when blood samples are 
collected properly. 
PET (peritoneal equilibration test) is used to determine the 
adequacy of peritoneal dialysis. Equilibration ratios are measured in 
a standardized PET that involves a 2L 2.5% dextrose dwell with 
dialysate samples taken at 0, 2, and 4 hours and a plasma sample at 
2 hours. A PET is also used to measure net fluid removal and the 
ratio of dialysate glucose at 4 hours to dialysate glucose at time 
zero. Patients are classified principally on the basis of their 4-hour 
D I P Cr into one of the categories: high; high-average; low - average 
and low - transporters (Daugirdas et ai., 2001). The PET is useful 
because it guides prescription of PD and it helps to predict the 
particular complication that a given patient will be prone to develop 
(Daugirdas et ai., 2001). 
2 . 4.4. Transplantation 
Prolonged life by transplanting healthy organs into diseased bodies 
IS a wondrous event. For patients who have experienced 
transplantation, it is truly a miracle (Lancaster, 1979). 
Everywhere in the world there is a relative shortage of donor 
kidneys from the recently dead, and waiting lists for kidney 
transplants become longer and longer every year (Cameron, 1996). 
A kidney from a close relative is probably the most successful 
treatment of all, but raises problems of whether someone who is fit 
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and well should have an ' unnecessary' operation, as far as s / he IS 
concerned which carries some risk (Cameron, 1996). 
However according to Legrain et al. (1975) transplantation, when 
the recipient is an 'ideal' candidate (i . e. between 10 and 50 years , 
free of visceral lesions , without special risk of recurrence of the 
primary renal disease , well - matched with the donor) is the best 
form of treatment and should be carried out as rapidly as 
possible. Dialysis in this group is only a method of preparation for 
grafting and can be avoided if transplantation is adequately planned 
when creatinine clearance is about 10ml/min. 
On the other hand, complications from immunosuppression can lead 
to catastrophy in patients previou)sly well equilibrated in dialysis. 
Alexandre's study (1975) conclu de d that, to select among patients 
those who should be good candidates for transplantation , the main 
criteria to take into account are the following: 
I) Age: On the one hand children are very good candidates for 
transplantation. On the other hand, patients who are 45 - 54 years 
of age do less well in transplantation , but they also do less well 
in dialysis. Over 55 years of age, there is no doubt that the 
patients are best treated by home dialysis. Patients transplanted 
at this age show a high mortality rate, especially during the first 
year post - transplant. One year patient survival after 
transplantation is only 54% against 89% for patients in dialysis 
at home and 78% for patients dialyzed in the hospital. 
2) The original disease is of great importance: certain types of 
glomerulonephritis do recur with great frequency, namely some 
types of focal glomerulonephritis and also some malignant 
glomerulonephritis with extracapillary proliferation. It must be 
noted that even when original disease does recur in a first 
transplant , a second graft is not automatically contraindicated. 
The decision , in this case, depends essentially on the rapidity of 
recurrence. Malfunctions of the urinary tract may need corrective 
operations prior to transplantation. Although satisfactory results 
are obtained , it is clear that the risks involved in these cases are 
increased . Metabolic congenital diseases may be a 
contraindication, such as oxalosis , or may on the contrary, offer 
a way to cure the enzymatic deficiency. 
3) Associated diseases among the presence of infection must be 
thoroughly controlled. Sepsis is responsible for the majority of 
deaths after transplantation, and these sites of infection must be 
eradicated. 
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4) Preimmunization is another important factor to take into account, 
since it influences very much the possibility of finding a 
compatible graft and also the outcome of the transplant. 
However , the demand for donor organs has outstripped the supply in 
both the public and private health sectors . When one of these vital 
organs fails , death is inevitable, except in the case of kidney failure 
where an alternative exists to prolong life, i.e. maintenance dialysis 
(Draft Document: Department of Health: Policy on organ 
transplantation and chronic renal dialysis, 2003). 
What is often forgotten is the fact that the p~ tients who are waiting 
for a cadaver transplant may develop seri \)us complications that 
hinder the success of a future transplant, or they may even become 
definitely untransplantable. 
Shortage of organs is one of the most senous threats facing the 
organ transplant systems . As an example, more patients are 
accepted onto the transplant program particularly renal 
transplantation, but only a small proportion receives transplants as a 
result of the shortage of donor organs. The highest percentage 
remain in dialysis for many years. In most cases, a patient can wait 
for a match for more than two years, but unfortunately, this 
increasing demand for dialysis constantly exceeds provision. 
The contributing factors to the poor organ procurement system in 
South Africa is the lack of willingness to donate organs in our 
c ommunity , which can in turn be attributed to lack of knowledge, 
cultural beliefs etc. In addition there is a shortage of personnel 
working in organ procurement and the lack of training of personnel 
in the skills needed to approach donor families with sensitivity In 
order to obtain consent for organ donation. Furthermore, there is an 
unwillingness in medical personnel to refer potential donors to 
transplant units. 
There is a great need to improve this situation for better healthcare 
delivery in our country. The low donor rate in South Africa could, 
to a large extent , be improved by addressing the deficiencies as 
outlined above. Non-governmental organizations involved in renal 
transplant and dialysis, such as the Organ Donor Foundation in 
South Africa , contribute to the public awareness of organ donation 
and transplantation. Education programs should be encouraged to 
put more emphasis on the management of some of the causal 
diseases that lead to renal failure, such as diabetes (Draft 
Document: Department of Health: Policy on organ transplantation 
and chronic renal dialysis, 2003) . 
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As the success of transplantation as a treatment for organ failure 
increases, it is equally important that highest standards be \ 
maintained within the accepted legal , moral and ethical guidelines. 
2.4.5. Comparisons among treatment modalities 
Hemodialysis, CAPO, and transplantat ion should be seen everywhere 
as fully integrated approaches to end-stage kidney failure, rather 
than competing treatments . 
PO and HO are equally preferred in diabetics , in CV disease, in 
polycystic disease and in scleroderma. 
In diabetics, PO offers the option of painless and probably more 
physiologic intraperitoneal administration of insulin . Registry data 
have concluded that, even in diabetics , PO offers a survival benefit, 
but this benefit is smaller than in non - diabetics . United States 
Renal Oata System (USROS) data suggest that diabetics younger 
than 50 years have a survival benefit on PO, while those older than 
50 years had some survival benefit on HO. 
With regard to CV disease fewer patients on PO experience severe 
cardiac arrhythmias. 
Polycystic kidney disease patients do equally well on either PO or 
HO. However, if the cyst-filled kidneys are very large and occupy 
the entire abdomen, PO may be uncomfortable. 
Both scleroderma (involvement of the skin) and other structures of 
the abdominal wall could restrict the distensibility of the abdomen 
during PO. On the other hand, with HO there can be difficulty in 
maintaining homeostasis after constructing the fistula or the graft, 
or following the insertion of a central vein catheter . 
PO is not preferred but may be selected with added adjustments in 
large body size and/or obesity; with a history of diverticulosis or 
d i verticulitis; with the presence of severe backache or hernias; with 
multiple abdominal surgery; with poor manual dexterity or with 
blindness. 
According to the CARl guidelines (2003) patients should be offered 
APO rather than CAPO for the following clinical indication: 
1) High transporter status particularly associated with suboptimal 
ultrafiltration. 
2) Inadequate small solute clearances obtained on CAPO. 
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3) Psychological reasons incl uding 
facilitation 
employment consideration, 
of the care of elderly or school attendance, or 
debilitated patients. 
1) Physicians should be aware that peritonitis rates are lower with 
2) 
3) 
APD than CAPD. 
Patients 
function 
Patients 
are less 
residual 
and physicians should ~ aware that residual renal 
may decline more rapidly on APD compared with CAPD. 
with low peritoneal membrane transport characteristics 
well suited to APD, particularly in the setting of poor 
renal function . 
The British Renal Association (BRA) guidelines (2003) state that 
APD should be available as clinically indicated (high transport 
status of the peritoneum, impaired filtration and psychosocial 
reasons forming 20 - 25% of the total CAPD population) and not 
constrained by financial considerations. The Canadian Society of 
Nephrology (CSN) guidelines (2003) state that patients who are high 
transpor ters and who are having fluid overload problems on CAPD 
should be considered for transfer to APD. 
To choose between dialysis and transplantation, for the patients who 
may be transplanted, is to choose between remaining in a condition 
of sickness, although it can be very satisfactory, and to try to get 
out of sickness at a slightly higher risk (Alexander, 1975). 
It is difficult to compare two different treatments of chronic renal 
insufficiency . One involves a lifetime that depends on an artificial 
kidney and is not able to eliminate all symptoms of chronic uremia 
(especially anemia), while the other can lead to a nearly normal life 
with the absence of all consequences of renal insufficiency, but with 
the continuous dangers of rejection crisis and of the side- effects of 
immunosuppressive therapy (Dutz et ai., 1975). 
For a patient who understands the pitfalls of both treatments, the 
decision to take will be, to a certain extent, a reflection of his 
personality (Alexander, 1975). 
According to Alexander (1975) there IS no doubt that a well 
functioning kidney transplant in a patient who suffers no 
complications from the immunosuppressive therapy offers the best 
treatment for chronic renal insufficiency. 
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As described by Daugirdas et al. (2001) renal replacement therapy 
s hould be implemented under the following conditions: 
A . In patients with laboratory evidence of impaired renal function 
(e.g. , creatinine clearance < 20-25mLlminll. 73m 2 ) 
I. Symptoms known to be associated with uremia: 
a) Nausea , vomiting , impaired nutrition because of poor 
appetite, other gastrointestinal symptoms , including 
gastritis with hemorrhage, ileus, and colitis with or 
without hemorrhage . 
b) Altered mental status (e.g., lethargy, somnolence, 
malaise, stupor, coma, or delirium) or signs of uremic 
encephalopathy (asterixis, tremor, multifocal 
myoclonus, sei z ures) 
c) Pericarditis (high risk of hemorrhage and / or 
tamponade) - urgent indication. 
d) Bleeding diathesis associated with uremic platelet 
dysfunction (urgent indication, although this may 
respond to increasing hematocrit to > 30%). 
2. Refractory or progressive fluid overload 
3. Uncontrollable hyperkalemia 
4 . Severe metabolic acidosis, especially In an oliguric 
patient. 
B. Steady worsening of renal function , with blood ur e a nitrogen 
exceeding 25-36mmol / L or measured (urine collection) creatinine 
clearance <15 - 20 mllmin (ideally factored by l.73m 2 body surface 
area). 
Dialysis is initiated prophylactically in patients with acute renal 
failure. In the absence of any clinical manifestations of uremia and 
with acceptable serum levels of potassium and bicarbonate, acute 
dialysis does not necessarily have to be performed when the serum 
urea nitrogen level or creatinine clearance crosses these boundaries. 
On the other hand , in patients with decreased urea generation due to 
poor nutrition or to liver disease, manifestations of the uremic 
syndrome may appear when the serum urea nitrogen level is well 
below 18 mmol / L or lower. 
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Less common indications for dialysis therapy include, drug 
intoxication (hemoperfusion for certain drugs), hypothermia , 
hyperc alcemia , hyperuricelT' la- and metabolic alkalo s i s, which 
requires a special dialysis solution. 
Trea tment options for acute renal failure include hemodialysis, 
peritoneal dialysis and slow continuous procedures. 
2.5.2 . Chronic renal fa ilure 
The survival of end - stage renal disease patients on dialysis depends 
to a large extent on their condition at the time of dialysi s is first 
initiated. 
The dialysis outcomes quality initiatives (DOQI) guidelines, (2003) 
s uggest that dialysis should be started at a creatinine clearance o f 
9- 14mL per minute per 1 . 73m 2 in all patients , irrespective of their 
diabetic status , or earlier if their protein intake is less than 0.8g per 
kg per day, or if they are uremic. The rationale for this approach is 
t hat ultimate survival on dialysis depends greatly on nutritional 
status and serum albumin status at the time dialysis is initiated. 
Pat ients s tarted early on dialysis (at higher creatinine clearance 
levels) have higher serum a lbumin levels. Furthermore, s pontaneou s 
protein intake begins to fall early in chronic renal insufficienc y 
(w hen creatinine clearance is still above 25mL per minute). 
Whereas, according to the caring for Australians with renal 
impairment (CARl) g uidelin es (2003) the criteria for s tarting renal 
replacement therapy include the following : 
1) Co mmence dialysis at first indication of malnutrition s uspected 
to be due to uremia and unresponsive to dietary int erve ntion or 
correction of other reversible causes . 
2) Monitor normali z ed protein catabolic rate (nPCR) quarterly by 
mea s uring 24-hour urea excretion from a GFR of 15 - 20 
mllmin / 1.73m 2, and monthl y from GFR < IOmllmin ll.73 m 2 
3) Use of "absolute indications" for dialysi s Initiation is a 
historical concept , which is no longer valid, and their presenc e 
suggests delayed Initiation. However, in some patients with 
comorbid conditions dialysis may be indicated for these reasons 
even when GFR is greater than I Oml / min ll. 73m 2 (T raditional 
absolute indicators include pericarditis , fluid overload and 
hyperten s ion poorly responsive to non - dialytic treatment , 
advanced uremic encephalopathy and / or neuropathy , s ignificant 
bleeding diathesis , severe nausea and vomiting). 
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4) Similarly, traditional ' relative indications' may not be useful 
because they are largel Su bjective , depend on patient perception 
and acceptance, and may be due to intercurrent diseases. 
(Traditional relative indications include anoreXIa; profound 
fatigue and weakness; impaired cognition, memory and attention 
span; severe pruritus; depression, and poor interpersonal 
relationships). 
The BRA guidelines (2003) provide no recommendations as to the 
indications for commencing renal replacement therapy. 
The CSN guidelines (2003) state that dialysis should commence In 
patients with clinical evidence of uremia or malnutrition (including 
nPNA < O.Sg / kg / d (or 0.9g / kg / d if nephrotic). 
Whereas the National Institute of Health (NIH) recommends the 
initiation of hemodialysis or peritoneal dialysis training when GFR 
(mean urea and creatinine clearance) is below 10cc / min (1Scc / min 
in diabetics) or earlier when albumin is < 4, or when nPNA is 
O.Sgm/kg/day. In addition, it is recommended that hemodialysis 
begins as an outpatient with functioning AV access, or begins with 
peritoneal dialysis training, with a functioning PD catheter. Ideally 
the hematocrit equals 36%, serum albumin 4gm / dL, and diastolic 
blood pressure < SOmmHg or lower. 
In the United States, the decision to start chronic dialysis is 
monitored by the US Health Care Finance Administration (HCFA) 
and regional peer reVIew organizations (networks). Medicare 
reimbursement IS contingent on meeting a federally approved 
creatinine clearance criterion of less than 10mL per minute for non -
diabetics, or less than ISmL per minute for diabetics (not adjusted 
for body size). If the patient's clearance does not meet these 
benchmarks, then the treating physician must justify the decision to 
start dialysis to the regional network. If the justification is rejected, 
then payment for dialysis is not approved (Daugirdas et al., 2001). 
There are, however, problems with such criteria, in that they are 
limited to clearance measures that occur in patients with renal 
impairment who have problems with fluid overload , hyperkalemia , 
or "failure to thrive" that are out of proportion to their creatinine 
clearance. This may include older patients and patients with a 
cognItIve impairment, as they may be poorly compliant with taking 
high-dose diuretics or potassium-lowering agents . Patients with 
advanced cardiac disease and borderline creatinine clearances may 
have trouble with refractory fluid retention. Such patients may 
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appear frequentl y in emergency facilities with pulmonary edema, 
hyperka lemia and worsening a zote mia (Daugirdas et al., 2001). 
Delay in initiation of dialysis for such patients until their creatinine 
clearances fall into the mandated range may have an adverse effect 
on their long- term survival (Daugirdas et al., 2001). 
According to a study conducted by Bonomini et al. (1975) a late 
dialysis starting time, i.e. when residual CCr is below I Oml / min (2 -
4ml / min in the majority of cases) may be associated with a 
significant survival rate . In survivors, however , systemic uremic 
cha nges are not reversed , but progress year after year. These 
patients may be rehabilitated for working, but not cured from 
sys temic uremic manifestations. Whereas an early dialysis starting 
time, i .e. residual CCr above 10ml / min, is associated with 
remarkable differences in both basic values and progression rate of 
c linical and subclinical uremic changes. Impairment in several 
parameters is le ss evident, and even after several years of treatment 
may still remain moderate. In addition, it was found that early 
dialysis starting time is likely to be of greater value in dialysis 
versus cadaver transplantation , when a long waiting tim e for surgery 
is expected. 
Treatment options for chronic renal failure include: hemodialysis , 
peritoneal dialysis and transplantation, as previously discussed. 
2 . 5. 3. Excluding patients from dialysis. 
Are there any patients who should be routinely excluded from 
dialysis for chronic renal failure (Daugirdas et al., 200 I)? 
According to Cameron et al . (1976), at the moment only a small 
proportion of patients reaching terminal renal failure are offered 
renal replacement therapies. Although facilities for both regular 
dialysis and renal transplantation have expanded and are expanding 
rapidly, it is likely that the demand will always exceed the supply 
of available dialysis places and renal transplantation. Frequently the 
doctors and nurses are faced with the disappointing situation of a 
patient for whom no treatment is available, although s/ he could 
definitely benefit from it. 
The selection of patients for dia lysis or transplant programs is a 
controversial subject since it places upon the doctor the burdensome 
problem of who should be treated and who should be allowed to die. 
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At first it was suggested that impartial bodies of lay and medical 
people could select patients for dialysis and transplant programs 
after considering all the problems of personality and social worth 
offered by the candidates. This has, perhaps fortunately , proved 
impossible to practice. Patients rarely present themselves in a state 
in which assessment is possible, along with several others so that a 
choice may be made. 
Many units have now adopted the attitude 'first come, first served' 
providing that certain medical criteria are satisfied. Some of the 
factors the doctor may take into cons ideration in selecting patients , 
are whether there is a medical reason why the patient should not be 
accepted, or should be given a lower priority, such as presence of a 
systemic disease affecting not only the kidneys but other organs , or 
coincident disease, particularly of the cardiovascular system. There 
is also the question of whether the patient is too old or too young? 
In the United Kingdom, there continues to be an age cut - off above 
which federal support of dialysis is not available. In the United 
States and elsewhere, the fastest growing age group needing dialysis 
is the "oldest old" (patients older than 80 years old). Access 
placement in this group is not particularly difficult, and cuffed 
venous catheters have been used with success in difficult cases. 
Time constraints aren't a prohlem and these patients often arrive 
eager for their treatments. Transportation is often available from 
assisted - living providers, retirement community staff, or municipal 
programs . A high rate of compliance with all aspects of treatment 
often offsets a higher prevalence of comorbid conditions in 
achieving a good outcome. As a result, many elderly patients placed 
on dialysis continue to enjoy a good quality of life and benefit from 
documented improvement in a variety of health outcome measures 
(Daugirdas e t ai. , 2001). 
Patients with advanced disease in an organ system other than the 
kidneys, or those with malignancy , have sometimes been excluded 
from dialysis (e.g. advanced liver disease). Futility is an ethical 
principle, on which one can make a reasonable decision not to 
initiate dialysis. On the other hand , some such patients may achieve 
good quality of life and "remission" of failure in the other organ 
system with the fluid removal, electrolyte balance and improved 
nutrItIon provided by the multidisciplinary support available 
through ESRD management. 
In South Africa the government nephrology department has strict 
rules regarding admittance to the dialysis program. These strict 
criteria are kept due to the reason that there is a tremendous 
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shortage of dialysis machines and s taff in the health system , which 
makes it impossible to run a chronic dialysis program if patient 
compliance is not maintained . Should the patient be admitted for the 
program there are certain criteria to which they need to adhere: 
Firstly , there are a limited number of HD slots available , and 
therefore all patients accepted onto the program are only accepted 
o n condition that they accept peritoneal dialysis as the first option 
o f dialysis. They will only be accepted for HD if there is a medical 
contra - indication for PD. 
Secondly, if the patient is accepted for CAPD, and for any reason 
s l he they can no longer continue s l he will be tran s ferred to HD 
provided there is s pace available . 
Defaulting treatment on more than three occasions , or for a period 
of more than 2 weeks without notice will result in the patient's 
withdrawal from the program . Examples of warnings include the 
failure to return for treatment on the prescribed day without an 
adequate reason or explanation , failure to come for an insertion of 
Tenckhoff catheter or creation of vascular access , persistent fluid 
overload without a medical reason for overloading , and not adhering 
to prescribed medication. 
2 . 6. OPTIMIZING RENAL REPLACEMENT THERAPY 
2.6.1. Pre-end stage renal failure (Pre-ESRD) 
Pre - ESRD is defined a s the time between the diagnosis of a kidney 
disease, until the time one begins renal replacement therap y or 
receives a transplant. This period may be brief as in a few weeks or 
it may be months or even years (NR C - Healthy Start , 2002) . 
Early diagnosis is the key to prevention of renal failure , offering 
the potential for both disease- specific and non - specific 
intervention s to slow disease progression. 
According to Legrain e t al. (1975), the pro s pectiv e treatment of 
end- stage renal failure , and that it should actuall y start at the 
earliest possible stage of renal disease. 
Having nephrological advice as soon as any sign of renal disease is 
detected enables an establishment of an accurate diagnosis, and 
thereby allows for preventive intervention at a stage when renal 
disease may respond to aetiological therapy. 
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However, in contrast the Merck Manual of diagnosis and therapy 
(2003), which states that ideally patient assessment should begin 
when progressive, irreversible renal disease is present but before 
dialysis or transplantation is needed. Patients can have their 
psychosocial strengths and weaknesses assessed in a non-crisis 
atmosphere, participate in the choice therapy, and have vascular 
access created early, allowing time for maturation. 
It has also been noted that in addition to the cardioprotective and 
renoprotective strategies, optimal treatment includes the prevention 
of metabolic disorders, the prevention of malnutrition , the 
preservation of quality of life and adequate preparation for renal 
replacement therapy. As described by Lancaster, (1979) there is 
hardly an aspect of physical, social, or psychological performance 
that is left untouched by this disease process. 
Only early, regular management by a dedicated nephrological team, 
in close cooperation with other involved physicians, may give the 
patient her / his best chance of avoiding, or at least substantially 
delaying, end- stage renal disease and preventing or at least 
attenuating , uremic complication. Late referral of patients unfairly 
deprives them of such benefits. Moreover, as indicated later in the 
study, there is considerable extra cost for the health care system. 
Various studies have indicated that pre-end stage renal disease 
programs can prevent , or at least slow, the progression of renal 
failure if implemented early in the course of renal disea se (Rossert 
et al., 2002; Jungers, 2002). To slow the progression of kidney 
failure, to prevent the consequences of chronic kidney disease and 
to decrease cardiovascular mortality associated with CKD, it is 
crucial to detect patients with CKD early and to optimize their care 
(Rossert & Wauters , 2002). 
Many patients with potentially serious yet reversible renal disease 
are not referred until substantial irreversible scarring has occurred. 
According to the CARl guidelines adequate preparation for dialysis 
and transplantation (or both) requires at least 12 months of frequent 
contact with a renal team. As indicated in the table below (table 
2.1) this would demonstrate that in accordance to the CARl 
guidelines , a patient with a serum creatinine of 220-343 should be 
monitored and have frequent contact with a renal team to ensure the 
patient is adequately prepared for renal replacement therapy. 
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Table 2.1: Serum Creatinine and percentage of kidney function 
in relation to time before commencement of treatment. 
~ 35% 26 % - 35% 15% - 25% <15% 
Kidney Kidney Kidney Kidney 
function function function function 
> 18 months 12 - 18 months 6 - 11 months 0- 6 months 
Serum Serum Serum Serum 
Creatinine Creatinine Creatinine Creatinine 
< 220 220 - 343 352 - 434 > 440 
In recent years , several studies have shown that the care of patients 
with progressive CKD can be improved. According to the CARl 
guidelines (2003) early detection of patients with renal disease can 
slow progression of patients ESRD and improve survival on RRT. 
Furthermore, as indicated in the figure 
disease renoprotection programs are 
progression of chronic renal failure . 
Kidney Disease Renoprotection Programs 
below (figure 2.3), kidney 
aimed at preventing the 
Chronic Kidney Disease 
ESRD 
Preparing people 
Prevent Progression 
Kidney disease renoprotection 
programmes 
Initiator I Injury 
Protein le~e. Proteinuria 
Locate People at risk 
Diabetes, Hypertension, Elderly, HIV 
(Katz. 2003) 
F igure 2 .3: Hierarchal representat ion of chronic renal failure 
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The presence of proteinuria and renal impairment should be 
routinely evaluated in patients at increased risk of renal failure. 
2.6.2. Pre-End Stage Renal Disease Education program 
In a healthcare system in which nephrologists and nurses are already 
scarce, and the costs of dialysis and transplants are extremely high, 
having patients who are better prepared to make important decisions 
about, and actively participate in, their care is imperative 
(Robinson, 200 I). 
A pre-end stage renal disease program can prevent, or at least slow, 
the progression of renal failure by ensuring tight blood pressure 
control; the use of angiotensin II inhibitory drugs; statins; calcium 
and iron supplements and phosphate binders; vitamin 
supplementation; timely use of recombinant erythropoietin; dietary 
counseling; preservation of nutritional status assessed by serum 
albumin levels, and in-time creation of access to parts of the 
integrated therapeutic strategy to be offered to the pre-dialysis CRI 
patient. 
Research has highlighted the importance of planning rehabilitation 
programs, focusing on the areas of dysfunction emerging from 
assessment (Robinson, 2001). The therapies required incorporate 
various members of the healthcare team and include a specialist 
physician, a nephrologist, a dietician, a social worker and members 
of renal care. The phases may extend over a long period of time 
(Robinson, 200 I). 
It has been clearly indicated in various literatures that the success 
of a pre-dialysis program depends on timeous referral and patient 
preparation (Rossert & Wauters, 2002). Ultimately a PESRD 
program should slow or retard kidney disease; enable a smooth 
transition to dialysis or a transplant; it should reduce dialysis 
morbidity and mortality through better health, and provide the 
patient with the best chance for permanent access for renal 
replacement therapy (NRC-Healthy Start, 2003) . 
Unfortunately, only approximately a half of the patients who enter 
renal replacement programs are followed up in a pre-dialysis clinic 
during the decline of their renal functions towards end stage . The 
remaining patients show acute signs of end stage renal failure 
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(ESRF) , or acute signs of chronic renal failure , previously under 
diagnosed , which progress rapidly to end stage renal disease. 
Patients who have had time to adjust, over a period of months or 
even years, to the point that dialysis and/ or transplantation will 
become necessary, seem to adjust more smoothly to the treatment 
(Smith, 1997). 
It is known that kidney disease education leads to increased 
participation by patients in their own care . That is , it can result in a 
d ecline in morbidity and mortality ; can lower the cost of care for 
the patient, facility, and government, and that it lowers the stress 
rate for both patients and their families (Robinson , 2001). 
Thus, the educational intervention both reduces the healthcare risk 
to the patient and lowers the associated healthcare cost. It has been 
recently reported that the benefit of an early education, PESRD 
program is that it allows the patient to make an informed decision , 
while it increases the likelihood of continued emp loyment, and 
improves in the placement of access for the initiation of dialysis. 
2.6.3. Optimizing timing for referral of patients 
Despite all efforts to alert the medical community about its multiple 
detrimental effects , late nephrological referral of renal patients s till 
remains a frequent problem in all countries (Jungers, 2002) . 
Clinical studies have used many different definitions of what 
constitutes "an early referra l" . 
According to the canng for Australians with renal impairment 
(CARl) guidelines (2003) patients with GFR < 30ml / minll.73m2 are 
at high risk of progressive deterioration in renal function and 
should be referred to a nephrology service for specialist 
management of renal failure . To prevent progressive renal disease , 
early referral should be considered for patients at higher GFR but 
with declining renal function or c lini cal features to suggest that 
residual renal function may decline rapidly, including patients that 
are hypertensive , proteinuric ( > lg / 24 hours) , or have a significant 
co - morbid illness. 
According to the British renal association (BRA) guidelines (2003) 
all patients who have progressive renal insufficiency and a plasma 
creatinine >150umo1lL and /or a rapidly rising creatlntne 
concentration should be referred to a nephrologist for assessment 
and follow - up. 
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According to the Canadian society of nephrology (CSN) guidelines 
(2003) early referral to nephrologists of patients with elevated 
creatinine levels is expected to lead to better health care outcomes 
and lower costs for both the patients and the health care system. 
Medical staff should refer patients with a creatinine clearance of < 
30ml / min / m2 to a nephrologist for opinion regarding management of 
renal failure. All patients with newly discovered renal insufficiency 
(as evidenced by serum creatinine elevated to a level above the 
upper limit of the normal range of that laboratory, adjusted for age 
and height in children) must undergo investigations to determine the 
potential reversibility of the disease, to evaluate the prognosis and 
to optimize the planning of care. All patients with an established, 
progressive increase in serum creatinine level should be followed up 
by a nephrologist. 
The National Institute of Health (NIH) consensus conference on 
morbidity and mortality (2003) associated with dialysis states that 
pre-dialysis referral to a renal team , consisting of a nephrologist , a 
dietician, a nurse, a social worker, and a mental health professional, 
allows time to establish a working relationship, to acquaint the 
patient with the various modes of renal replacement therapy, and to 
provide information on dialysis access, nutritional modification, 
avoi dance of potential nephrotoxic drugs , and potential financial 
support for ,ervices. It is essential to InItIate the medical 
interventions, discussed below, to reduce mortality and morbidity as 
soon as possible . Referral of a patient to a renal team should occur 
when the serum creatinine has increased to 1.5 mg / dL in women and 
2.0 mg/dL in men. 
2.6.4. Management of PESRD patients 
In 1993 the NIH looked at measures by which early intervention in 
pre -d ialysis patients could be used to reduce the morbidity and 
mortality of this population. The consensus concluded that anemia, 
acidosis, hypertension , malnutrition , renal osteodystrophy, lipid 
abnormalities and metabolic acidosis were present prior to the onset 
of dialysis, and in addition, smoking and poor glycemic control 
influenced morbidity and mortality. 
A survey conducted by Robinson (200 I) showed an overwhelming 
willingness by patients to be involved in their healthcare and to be 
active participants in the decision-making process. 
As described by Lancaster and Pierce (1979) the goals of 
conservative management of chronic renal failure are to preserve 
renal function , postpone or eliminate the need for definite treatment 
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(dialysis or transplantation), improve body chemistries, reverse 
organ system alterations where possible, and provide comfort and an 
improved quality of life. 
This will include management of patient's diet and medications, the 
relief of uremic symptoms, the treatment of infection , alterations in 
body chemistries, alterations in organ systems and teaching the 
patient to live within the limitations imposed by her / his disease. 
Should a stage transpire in which treatment is inevitable, a PESRD 
program can contribute to enabling a smooth transition to dialysis 
or transplantation; avoid emergency dialysis; avoid the need for 
hospitalization; allow the patient to participate in the choice of 
treatment; provide the patient with the best chance for permanent 
access; reduce dialysis morbidity and mortality through better 
health and assist with the social and psychological welfare. 
Jungers (2002) discusses the various effects on patients who are 
referred late to a nephrologist. This decreases benefits , especially 
of the renoprotective and cardioprotective strategies that constitute 
the basis of optimal therapy of chronic renal insufficiency (CRl) 
patients. Renoprotection includes the use of dietary and 
pharmacological measures aimed at halting or at least slowing 
progression of renal failure, and it is currently considered a 
fundamental goal in the treatmcnt of CRI patients. It is however 
noted that it can only be effective if implemented from the early 
stag e of renal failure. Ca rdioprotection has only recently emerged 
as another fundamental goal in the treatment of chronic renal failure 
in the pre-dial ys is stage (Jungers, 2002). According to Jungers 
(2002) risk factors for accelerated atherosclerosis, left ventricular 
hypertrophy and myocardial fibrosis are the main causes of 
cardiovascular disease in uremic patients. It develops from an early 
stage in CRl and therefore cardioprotective therapy should be 
implemented as early as possible in the course of renal failure to 
prevent the development of cardiovascular disease and reduce the 
excess cardiovascular morbid - mortality that affects uremic patients. 
PESRD patients should undergo continuous monitoring. According 
to the CARl guidelines (2003), patients with chronic renal failure 
shou ld have regular estimation of the glomerular filtration rate 
performed , and should be clinically reviewed every three months 
from a value of 30mllminll.73m2 and monthly from a GFR < 
IOmllminll.73m2 The BRA guidelines (2003) state that patients 
with progressi ve renal insufficiency need careful follow - up and 
monitoring in an attempt to slow the progression of renal failure 
when possible . No recommendation is made about how often patient 
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status should be reviewed. The CSN guidelines (2003) recommend 
renal function should be measured at least every three months. One 
should measure renal function using a valid estimate of GFR 
corrected to a body surface area of 1.73m2 . The recommended 
method is the mean of urea and creatinine clearance. Adequate 
preparation for dialysis or transplantation (or both) requires 
relatively frequent contact with a renal care team. 
However, no interval for follow - up should be set in stone. As part 
of a multi-disciplinary approach to patients with renal impairment, 
follow - up needs to be tailored carefully to individual patient 
requirements. 
T he success of interventions to delay the progression of renal 
disease depends heavily on close monitoring of the patient's status. 
Patients with renal impairment require regular review, in order to 
monitor the rate of renal disease progression; perform and optimize 
appropriate interventions, and allow for the timely initiation of 
RRT. In addition, the rate of decline in renal function patients 
appears to be slowed in patients benefiting from a close follow - up 
(CARl guidelines, 2003). 
Correction of any superimposed reversible factors that contribute to 
a decreased GFR can restore a level of renal function compatible 
with a more conservative approach to care , and delay the need for 
dialysis. Progression to ESRD is therefore delayed to the extent that 
initiation of RRT may also be delayed. There IS also some 
experimental evidence that superimposed renal Injury may 
contribute to the accelerated progression of chronic renal disease, 
through nephron loss and fibrosis (CARl guidel ines, 2003). 
According to the CARl guidelines (2003) early efforts should be 
made to identify and , where possible, correct pre - renal and 
post- renal insults, to prevent irreversible injury and delay the need 
for dialysis. Exposure to nephrotoxic agents should be avoided 
where possible in patients with renal disease. Where contrast 
exposure cannot be avoided, the risk of renal injury can be reduced 
by pre - hydration, acetyl cysteine, using lower doses of contrast and 
using non - ionizing contrast. 
Pre - renal insults 
Patients with renal impairment require close attention to their 
volume status , especially in the setting of superimposed illness. 
Such patients rely heavily on renal prostaglandin production to 
maintain glomerular filtration pressure via efferent arteriolar 
vasoconstriction. This reliance can be exacerbated by states of 
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reduced flow in which maximal efferent vasoconstriction means that 
sma ll changes in renal perfusion pressure are directly translated into 
changes in glomerular filtration rate (loss of so - called renal 
auto - regulation). 
Co mmon pre - renal insults include: intra - vascular hypo vo lemia (e.g . 
vomiting, diarrhea , salt restriction, and excessive diuresis); low 
card iac output , and systemic vasodilatation (e.g . sepsis , drugs , 
cirrhos is). Drugs that impair auto-regulation of GFR 
(no n- steroidal anti-inflammatory drugs, COX - 2 , A CE I , AT1RA) 
shoul d therefore be used with caution. 
Post - renal insults 
Obstructive uropathy is a common cause of renal impairment. It is 
estim ated that acquired obstruction is responsible for 3 to 5% of 
new cases of end stage renal disease in patients over the age of 65, 
due (most often) to prostatic disease in men. Co rrection of 
obs truction uropathy results in a reduction in serum creatinine in 
some but not all patients. It is clear that complete o r prolonged 
partial urinary tract obstruction can lead to tubular atrophy, and 
eventually , irrev e r s ible renal injury . 
Common acquired causes of renal obstruction include 
nep hrolithiasis; bladder outlet obstruction (prostatic hypertrophy , 
ca ncer) diabetic cytopathy; neurogenic bladder ; papillary necrosis ; 
cervical cancer; urethral strictures, and anti-cholinergic therapy. 
There is some evidence that the earlier ob st ructiv e uropathy is 
corre cted, the more likely GFR will improve following relief of the 
obstruction. 
Ne phrotoxin s 
Many patients with chronic renal failure continue to be pre s cribed 
n e phrotoxic drugs. Much of thi s exposure is unnec essa ry . Co mmon 
culprits include NSAIDs , CO X- 2 and aminoglycoside a ntibiotic s. In 
the patient with underlying renal failure , in whom the rate of 
progression may have accelerated, early recognItI o n of drug 
n ephrotoxicity and cessation of the offending agent can help avoid 
addit ional irreversible renal injury. 
Rad i ocon tras t- a gen ts 
Pre - existing 
development 
incidence of 
renal impairment is a major ri s k factor for the 
of radio -co ntrast - induced acute tubular necro s is . The 
a ri s e in the plasma creatinine concentration of more 
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than 50 % above baseline or more than 88umoi/L is 4 to 11 % in 
mild to moderate renal insufficiency alone (plasma creatinine 
between 132 to 352umoIlL). This risk is increased to above 40 % in 
more advanced renal dysfunction , severe heart failure , concurrent 
administration of nephrotoxic drugs or volume depletion, the 
presence of diabetes mellitus or multiple contrast studies within a 
72 hour period. Although this injury is usually reversible, in 
patients with advanced renal disease, baseline renal function may 
not be restored . 
Where possible, patient s with renal impairment should avoid the use 
of imaging studies that involve contrast and in particular, multiple 
studies performed in rapid succession. Where intravenous contrast 
forms an indispensable tool to management, low-osmolality, 
non-ionic or gadolinium-based contrast media may be less 
nephrotoxic in patients with renal failure. Lower contrast doses may 
also be less nephrotoxic. Volume-depletion or non-steroidal anti-
inflammatory drugs , both of which can increase renal 
vasoconstriction, should be avoided n patients undergoing contrast 
procedures . 
2.6.5 . The optimal time to commence renal replacement 
therapy 
Examining the areas of failure can attain optimization of treatment. 
Fig . 2.4. shows the interactions between the failures of three basic 
aims . Delay in treatment; poor counseling; technical problems , and 
drudgery are major causes of treatment failure because they directly 
impede each aim (Baillod & Moorhead, 1975). 
Delay in treatment 
and poor }----_+_~ 
counseling 
Medical 
Expensive use of 
hospital facilities and 
staff 
Technical 
problems and 
drudgery 
Fig . 2.4 .The interaction of failure to ach ieve i nitial aims 
(Baillod et al ., 1975) . 
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'Failure to thrive' is difficult to reverse when patients have been 
kept in their low clearance phase for long periods , during which 
time calorie intake gradually decreases, blood pressure control 
becomes increasingly difficult and anemia becomes more profound. 
The time taken to replace body weight and muscle mass closely 
approximates the duration of the patient's inability to work and 
commencement of effective dialysis. 
Baillod and Moorhead (1975) state that failure to start treatment 
early is due not only to inability to recognize the problems 
associated with renal disease and the inadequate facilities , but to 
delayed referral by medical colleagues . 
Delay in treatment and poor counseling affect rehabilitation both 
directly and as a result of medical complications. Mental and 
physical rehabilitation are independent. The three major factors 
influencing mental rehabilitation are physical health, loss of 
creditability at work and within the family, and the lowering of 
standards and expectations of life. A negative approach by medical 
staff reduces the patient's hope and initiative. 
A comparison conducted by Dr . D. Campbell (Table 2.2) clearly 
indicated the advantages of early referral of patients. Patients that 
were referred late suffered more major complications and had a 
higher mortality rate as opposed to those referred early. 
Table 2.2: A comparison of patients referred early and those 
referred late. 
Earl referral of atients Late referral of atients 
lications 
died on initial admission 
(Campbell, 2003) 
The quality of life depends the on efficiency of treatment. Low 
physical and mental status escalates technical errors into serious 
medical complications. Varying degrees of morbidity and 
occasionally mortality still result from unreliable blood access 
(Baillod & Moorhead, 1975). 
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Bonomini et al. (1975) have determined that the 5 year survival rate 
was 70% in patient who commenced renal replacement therapy 'late' 
(Ccr under 10 ml / minll.73m 2 ) and 96.3% In patients who 
commenced renal replacement therapy early (Ccr over 10 
ml / min / l.73m 2 ). 
Baillod and Moorhead (1975) have determined that optimal dialysis 
requires adaptation or tailoring of the treatment to the particular 
needs of each patient. Their experience defines optimization of 
dialysis as a willingness on the part of the center to adapt to the 
patients' needs using as much technical ingenuity as necessary to 
motivate the patient to demand of them and himself the ability to 
lead a normal life so that he can be successfully reassimilated into 
his community. It is only by attaining these aims that the efforts of 
the patient and the staff, and the financial cost to the state can be 
justified . 
2.7. FINANCIAL ASPECTS OF RENAL REPLACEMENT 
THERAPY AND RELATED COSTS 
Every health care system also has a financial-economic co nponent. 
This component incorporates the ways in which financial and 
economic matters , are organized and regulated. This component 
actually includes the entire spectrum of methods and mechanisms by 
which the payment and remuneration take place: payment and 
remuneration of service providers by the consumers , the 
remuneration of care providers or personnel, the recovery of costs 
by the clientele and service providers, as well as the financing of 
services and the ownership or shareholding of facilities (Van 
Rensburg et al. , 1992). 
2.7.1 HeaIthcare in South Africa 
According to Neels Barendrecht, chief executive officer of Mx 
Health, speaking recently on the future of the private industry 
(Bhengu, 2002), there are still too many people who do not have 
access to the most basic health care services in a country renowned 
for the worlds first successful heart transplant. 
According to Kgosi Letlape (2002) the Chairperson of the national 
council of the South African Medical Association, general 
healthcare in South Africa is in a crisis. All sectors of healthcare 
are experiencing a crisis, particularly the private healthcare sector 
(Personal Finance, 2002). 
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However , according to Shaun Matisonn (2002), Principle officer of 
Discovery Health Medical Scheme, funding of healthcare is a 
universal problem that all countries around the world are trying to 
solve, the problems vary from country to country. In South Africa 
the problems are exaggerated by a shortage of medical specialties, 
the rising costs of imported medical technology, the high prevalence 
of HIV/AIDS and an onerous regulatory framework for the funding 
of private healthcare. Matisonn (2002) says: "This exaggeration of 
the funding problem is well evidenced in the local marketplace by 
the significant market consolidation and large- scale series of 
interim medical scheme contribution increases. Interim contribution 
increases are a clear indication of individual medical scheme 
financial pressure (Personal Finance, 2002). 
2.7.2. Financial aspects of renal replacement therapy and related 
costs 
Providing treatment for everyone is both a technical and a financial 
problem. Offering everyone the best treatment remains a difficult 
medical decision. CRF patients' medical expenses are extremely 
high and incorporate not only RRT but also medications and the 
rehabilitation of the patient. The cost of medications needs to be 
addressed in the context of the total cost of health care of kidney 
patients in the long term. 
As discussed, with regard to late referral, there is a considerable 
amount of wastage of medical resources, both direct and indirect 
over-costs . However, the costs and labour- intensive therapeutic 
programs to alleviate the long- term personal suffering of patients 
suffering from renal failure can be justified on humanitarian 
grounds alone. The motivation for funds to finance these labour 
intensive services can, however be problematic. This is especially 
the case for the majority of individuals suffering from renal failure 
in not only the public but also the private sector. 
Today renal replacement therapy is provided in both the public and 
private sector. 
However in these healthcare systems the costs of dialysis and 
transplantation are extremely high for the funders (Robinson , 2001). 
Maintenance costs become very high, which places a heavy burden 
on national resources. The observation of the current situation 
suggests that the cost that is incurred per patient through dialysis 
could be dramatically reduced if more donor organs could be made 
available . Alternatively, the cost per patient treated for end stage 
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renal failure could drop, allowing for more patients to be treated 
better with the same amount of money. 
2.7.3. Private sector 
APproximately eight years ago, individuals suffering from renal 
failure were routinely referred to State Hospitals. At that point, the 
policy was skewed in favor of acute-care for the minority. 
However a new government came into power and a policy change 
took place. Renal Care benefits slowly became part of the private 
health care agenda while state resources were focused on primary 
care. 
Barendrecht (2002) chief executive officer of Mx Health said that 
there are currently only 7,5 million beneficiaries of private 
healthcare, and added the fact that the healthcare funding market 
has become increasingly competitive and discerning, which has not 
helped the industry outreach, because healthcare cover has become 
one of the greatest cost burdens for the consumer. He said that with 
the contribution rates of most medical aid schemes having doubled 
over the past three years, members had to make do with cheaper 
healthcare plans. Others were forced out of the private healthcare 
system altogether. He concluded by saying that it was essential that 
a balance be maintained between advocating patient interests, which 
included quality, affordability and accessibility of heaIthcare, and 
the allocation of scarce resources (Personal Finance, 2002). 
The registrar and chief executive of the Council for Medical 
Schemes, Patrick Masobe (2002) has expressed concern about the 
large increase in non-healthcare costs incurred by medical aid 
schemes . Non-heaIthcare costs are the portion of medical scheme 
premiums that are not spent directly on heaIthcare, and include 
items such as administration fees, broker commissions, marketing 
and payment to trustees. Masobe said that there was a widening gap 
between contributions made by the members and the claims, which 
suggested that the increasing costs of medical schemes were not 
necessary financing medical benefits. 
Letlape (2002) says, 'your heaIthcare is worth more in your hands 
than it is in a fund'. Medical schemes are becoming glorified 
hospital plans with limited cover. Dealing with one's scheme has 
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become an administrative nightmare for members and healthcare 
providers. The average person can buy more healthcare on their own 
than through a medical scheme. 
Patients are concerned about how they will afford the expenses 
associated with being hospitalized. Many patients run into trouble 
because they thought they were covered by a scheme and later 
discover that their bills are not paid, says Letlape (2002). 
However Patrick Masobe (2002) says that medical schemes In South 
Africa are in good shape overall, although there are areas of 
concern. 
2.7.4. Government sector 
Shortages of equipment as basic as needle kits, X - ray films and 
surgical threads are crippling patient care at Tygerberg and Groote 
Schuur Hospitals . Every weekend trauma ward patient s die because 
resources are limited. Frustrated doctors, say that the deaths of 
consumables mark a 'critical point' in the deterioration of 
healthcare. It means they have to decide which patients to neglect 
and which to treat. As a result of shortages, patients were becoming 
more ill and some die (Smetherham, 2002). 
The number of patients who have hope of returning to normal health 
is progressively increasing. As expected , this has increased the 
government's responsibility to provide this kind of service , together 
with the accompanying increasing costs. 
"At the same time, these advances in medical technology and 
therapeutics have placed an increasing financial burden on societies. 
E ven developed countries are not able to provide a comprehensive 
public health care service using state of the art methods for all 
citizens. The challenge, therefore is to maximise health gain per 
unit of expenditure, within acceptable ethical and moral criteria, 
and taking the local issues into account. A potential area of conflict 
may exist between health care funders (medical aids and 
government) trying to limit costs, and doctors trying to provide the 
best for an individual patient., This policy is an attempt to resolve 
these issues with the best interest of all the patients in the Republic 
of South Africa as the primary goal" (Department of health: Policy 
on organ transplantation and chronic renal dialysi s : Draft 
Document , 2003). 
" The greatest barriers to equitable access to chronic renal dialysis 
and transplantation are those related to the historic inequalities, and 
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poor socio-economic status. Lack of access to transport and 
telecommunications in rural areas and informal settlements, as well 
as unemployment and lack of social support systems have all 
prevented equitable access to these services in the past. The 
provision of dialysis services in smaller communities is woefully 
lacking. This problem needs urgently to be addressed, both by the 
provision of funding to establish adequately sized dialysis programs 
in smaller communities, as well as to provide health care staffing 
with personnel who are adequately trained to deal with the se 
patients . Local regional hospitals should also establish organ 
procurement programs in conjunction with regional transplant 
ce nters" (Department of health: Policy on organ transplantation and 
chro nic renal dialysis: Draft Document, 2003). 
"The progressIve decrease In funding for academic and state 
hospitals has led to a decrease in number of pat i ents who are 
offe red these specialized services. The lack of funding has resulted 
in the decrease in the number of solid organ transplants being 
performed in the government hospitals that serve the majority of the 
population. Transplantation in the private sec tor has increased 
significantly in the last few years, but the medical Insurance 
companies are finding it increasingly difficult to fund the large 
costs of transplantation in the private sector, thus tran sp lantation is 
increasingly seen to benefit only the rich. These barriers have 
denied access to people who could qualify for acceptance onto 
chronic renal dialy s is and all forms of organ transplantation" 
(Department of health: Policy on organ transplantation and chronic 
renal dialysis Draft Document, 2003). 
"T he Department of Health supports transplantation as an essential 
com ponent of the end stage organ failure. The focus is presently on 
the following organs: kidneys, lungs, heart, liver , bone marrow and 
cornea. The procedures are quite unique in that they are totally 
reliant on human tissue and organ donation. However, the demand 
for donor organs has outstripped the supply in both the public and 
private health sectors. When one of these vital organs fails, death is 
inevitable, except In th e case of kidney failure In which an 
alternative exists to prolong life, i.e. maintenanc e dialysis" 
(Department of health: Policy on organ transplantation and chronic 
renal dialysis Draft Document, 2003). 
"S hortage of organs is one of the most serious threats facing organ 
transplant systems . As an example, more patients are accepted onto 
the transplant program particularly renal transplantation , but only a 
small proportion receives transplants as a result of the shortage of 
donor organs. The highest percentage remains in dialysis for many 
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ye ars. In most cases, a patient can wait for a match for more than 
two years , but unfortunately, this increasing demand for dialysis 
co nstantly exceeds provision. Maintenance costs become very high , 
which places a heavy burden on national resources . Observation of 
the current situation suggests that the cost that is incurred per 
patient through dialysis could be dramatically reduced if more donor 
organs could be made available. Alternatively, the cost per patient 
tr eated for end-stage renal failure could drop, allowing for more 
patients to be treated better with the same amount of money" 
(Department of health: Po l icy on organ transplantation and chronic 
re nal dialysis Draft Document, 2003). 
2. 7.5. The public/private relationship: 
According to Shaun Matisonn (2002) Principle officer of Discovery 
Health Medical Scheme: 
o The government provides some of the subsidy for the safety 
net. 
o The government insures those who cannot help themselves. 
o The government enforces laws and administers applicable 
subsides. 
o The private sector provides insurance for thos e who can help 
themselves, perhaps with some subsidy for tho s e unable to 
pay. 
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CHAPTER 3 
METHODS OF INVESTIGATION 
3. 1. RESEARCH DESIGN 
The research design is twofold, as it incorporates both quantitative 
and qualitative research designs . 
3.1.1. Quantitative, non-experimental design 
Within the quantitative, non-experimental design, there was no 
manipulation of the independent variables, nor was the setting 
controlled. The study was carried out in its natural setting, the renal 
unit and hospital, and the phenomena were observed as they 
occurred. The major purpose of this research design was to explain 
the relationship between the variables. It enabled the generation of 
knowledge in a situation in wh ich it would have been difficult, 
unethical or impossible to employ an experimental result. 
a) Survey study 
In order to investigate the benefits of early screening of high-risk 
patients for deve loping chron ic renal failure, the first part of the 
study includes a simple survey that was conducted , and this survey 
takes into consideration the investigation of the indications for 
commencing renal replacement therapies (2.5.1-2.5.2). 
This survey incorporates a screening of a hundred volunteers 
(n = 100) at risk for renal failure (Appe nd ix B) , over a one-year 
period. For research purposes, this group was classified as group A . 
Group A (n = 100) were all volunteers and the procedure and results 
were explained to each ind ivid ual who took part in the screening 
(Appendix A, consent form). 
A 5ml blood sample was taken in a yellow top tube, and a creatinine 
value was determined from the laboratory. Ampath and Lancet 
laboratories were used . Thereafter the GFR was determined , via a 
calculated formula (Appendix G) and if applicable , the individual 
was classified into a stage of renal failure (Appendix C) . All results 
were explained to the patient and patients with abnormal results 
were referred to their consulting doctors for further investigation. 
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b) Epidemiological research 
Epidemiological research was conducted and non-experimental 
designs were used. A further hundred patients (n = 100), who had 
commenced renal replacement therapy were evaluated over a three 
month period from the commencement of treatment, and where 
results were available a month prior to commencement of treatment. 
This constituted the second part of the study. This second part of 
the study aims at investigating the optimal timing for commencing 
renal replacement therapy. 
For research purposes the second group of 100 renal patients was 
classified as group B. 
It included an evaluation of a biochemical and clinical assessment, 
(Appendix E) as well as a psychosocial assessment (Appendix D) . 
Furthermore it included a nutritional assessment, and the subjective 
global assessment (Appendix F) . 
The patients were selected via the required criteria (3.2.3 - 3.2.4) 
and were followed over a period of three months and a month pnor 
to commencement , where the patients were being treated for their 
renal insufficiency , to determine possible outcomes and their 
quality of life. From the hundred patients (n = 100) who \y ~ re 
selected , five patients withdrew from the study and were classified 
as drop-outs. This left ninety-five patients (n = 9S) participating in 
the study (group B). 
Descriptive studies were used and incorporated into the description 
of patterns of renal disease and the determination of mortality and 
morbidity. 
c) Ex post facto design 
The analysis and guidelines for the indications for commencing 
renal replacement therapy were derived from descriptive 
comparative investigations incorporating factors affecting renal 
failure patients (S.I). 
A prospective study was conducted, and the descriptive correlation 
method-ex post facto design-was employed to investigate and 
compare the relationships between results obtained from the 
procedures employed from the ninety-five patients (n = 9S) taking 
part (group B), excluding the five patients who withdrew from the 
study . Thereafter the ninety-five patients, (n = 9S) were subdivided 
into three groups. These three categories consisted of the following: 
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I) Acute renal fai lure patients, who were not diagnosed or educated 
prior to the development of acute renal failure. 
2) Chronic renal failure patients who were aware of their renal 
insufficiency prior to the commencement of treatment but were 
not managed by PESRD program. 
3) Chronic renal failure patients who were informed and educated 
regarding their renal insufficiency and who participated in a 
PESRD program. 
The original ninety-five patients (group 8) were once again 
sub di vided into various stages based on their glomerular filtration 
rate (GFR) (Table 3.1.). 
Table 3.1: Stages of glomerular filtration rate. 
Glomerular filtration 
(ml/minll.73m2) 
rate Stage 
0-5 
2 6 - 10 
3 I I - I 5 
4 16 - 20 
The advantage of this method was that it enabled the present 
researcher to determine the relationship between the variables, and 
to explore possible predications that could be made . 
One of the problems that arises when the correlation method is used 
is that extraneous (third) variables could mediate and influence the 
variables being studied and their relationship. Potential extraneous 
variables that could exert an influence on the study will be 
incorporated into the study as factors affecting the renal failure 
patients. In addition, several findings will be incorporated in the 
determination of the indications and optimal timing for commencing 
renal replacement therapy , and the decision will therefore not be 
based on one individual factor. 
3.1.2 Qualitative research designs 
Qualitative methods were used in the early stages of the project, 
when trying to clarify important issues to be investigated , and 
included open-minded observation of the delivery of care and 
careful interviewing of the staff and patients involved. 
An evaluation research design was used in conjunction with other 
research designs in the determination of both primary and secondary 
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objectives (1.3). A formative evaluation was employed to 
investigate the effectiveness of a PESRD program, as well as to 
investigate whether there is an improvement in patients who were 
managed before the development of renal failure. 
Patients with chronic renal failure can be managed in a variety of 
ways: hemodialysis, peritoneal dialysis and transplantation . Each of 
these treatments makes use of different resources, and has differing 
benefits for the patients. In addition, patients may move between 
these treatment modalities when, for example, donor kidneys 
become available, or when kidney grafts are rejected. It is not easy 
to decide how best to use health care resources to meet the current 
need. Therefore, with the above taken into account, the 
investigation in decreasing the financial aspect related to treatment 
was focused on possible reduction of cost, due to improvement in 
management and unnecessary use of resources like catheters. 
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Table 3.2: Summary of research designs used. 
Research design Purpose of study 
Quantitative research 
designs 
Survey study • To investigate the benefits of 
screening high·risk patients for 
developing CRF. 
(Group A ; n = 100) 
Epidemiological research • Investigatio n of 95 renal patients to 
design set guidelines for the optimal 
timing for commencing renal 
replacement therapy. 
(Group B; n = 95) 
• To include the description of 
patterns of renal disease and the 
determ ination of mortal ity and 
morbidity. 
(Group B; n = 95) 
Ex post facto design • To set gu ide lines for commencing 
renal replacement therapy derived 
from descriptiv.c comparati ve 
investigations. 
(Group B; n = 95) 
Qualitative research 
designs 
Evaluation research • To investigate the effectiveness of 
design a PESRD education program. 
(Group B ; n = 95) 
• To investigate the benefits of 
patients being managed prIor to 
commencement of RRT. 
(Group B; n = 95) 
Operational research • Within renal failure there are many 
possible courses of action, and this 
was taken into account In the 
investigation of the optimal timing 
for commencing renal replacement 
therapy. 
(Group B; n = 95) 
© Central University of Technology, Free State
65 
3.2. RESEARCH POPULATION 
3.2.1. Number of subjects 
A total of 195 patients were involved in the study. 
Two separate research study populations were used. Firstly one 
hundred individuals (n = 100) were used in the screening of 
individuals at risk for the development of renal failure (3 .2.3 , p.67) 
and were classified as group A 
A second separate group of one hundred patients (n = 100) was used 
(3.2.4. p68). However five patients withdrew from the study and 
were therefore classified as drop- outs, leaving ninety-five patients, 
used for evaluation. These ninety-five patients (n = 95) who were 
classified as group B . 
a) Group A 
Group A included individuals taking part in the screening. All 
hundred individuals (n = 100) took part on a vo luntary basis 
(Appendix A, consent form). The test and procedure w.as explained 
to the individual, and the individual had the opportunity to ask any 
question regarding the procedure. These individu a ls were weighed 
against the inclusion (section 3.2.3) and exclusion criteria , (section 
3.2.4) prior to being included in the study. 
The individuals who volunteered for the screening, where 
interviewed on an informal basis with regard to their medical 
hist ory, and, where applicable , their admission diagnosis with the 
doctor concerned (or the hospital) was noted. 
b) Group B 
Group B , included ninety·five patients (n = 95) who had developed 
renal failure. These patients were weighed against the inclusion 
(section 3.2 .3.) and exclusion criteria (section 3.2.4) prior to 
selection for participation in the research. The nature of the 
research was described and discussed with the patient , who was then 
required to sign a consent form (Appendix A). 
The psychosocial assessment (Appendix D) and the nutritional 
assessment (Appendix F) were conducted at commencement of renal 
replacement therapy (RRT). A biochemical and clinical assessment 
(Appendix E) was conducted over a three month period, from the 
date of commencement. An additional biochemical and clinical 
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assessment (Appendix E) was conducted one month prior to 
commencement of RRT from patients who were managed or treated a 
month prior to commencement of RRT. 
3.2.2. Research locations 
a) Group A patients 
The screening included patients from the various general 
practitioners and hospitals: 
• Benoni Medicross 
• Dalview Clinic 
• Linmed Hospital 
• Sunward Park Hospital 
b) Group B patients 
The following units and patients provided their consent to conduct 
research, and were therefore included : 
From Gauteng: 
In the private sector: 
• National Renal Care - Benoni Medicross 
• National Renal Care - Sunninghill Hospital 
• National Renal Care - Milpark Hospital 
• National Renal Care - Garden City Clinic 
• National Renal Care - Jacaranda 
• Morningside Clinic 
In the government sector: 
• 1.G. Strydom Hospital 
• Chris Hani Baragwananth Hospital 
• Pretoria Academic Hospital 
From the Free State 
In the private sector 
• National Renal Care - Rosepark 
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In the provincial sector 
• Pellonomi Hospital 
• Universitas Hospital 
3.2.3. Inclusion Criteria 
a) Group A patients 
Group A incorporated patients taking part in the screening of 
individuals at risk for the development of renal failure, and weighed 
them against the following inclusion criteria : 
• Individuals with diabetes. 
• Individuals with arterial hypertension and/or cardiovascular 
disease. 
• Individuals with a family history of kidney disease. 
• Individuals with recurrent urinary tract infection . 
• Individuals with continuous exposure to certain drugs (NSAID 
or antibiotics) . 
• Individuals with a medical history of renal related problems. 
• Any population group. 
• Between 18-80 years of age. 
• Males and females . 
• Patients who provide their consent. 
b) Group B patients 
Group B incorporated patients who had developed renal failure and 
were evaluated over a three month period. 
• Renal failure patients. 
• Diabetic patients who display signs of renal disease. 
• Hypertensive patients who display signs of renal disease. 
• Receive treatment in Gauteng or the Free State region . 
• Any population group. 
• Between 18-80 years of age. 
• Males and females. 
• Patients who provide their consent. 
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3.2.4. Exclusion criteria 
a) Group A patients 
• Individuals who do not provide their consent. 
• Individuals who are not at risk for the development of renal 
failure (Appendix B). 
• Pregnant women. 
b) Group 8 patients 
• Individuals who do not provide their consent. 
• Patients who develop acute renal failure that does not lead to 
chronic renal failure because of regained renal function. 
• Pregnant women. 
3.2.5. Justification for inclusion and exclusion criteria 
a) Group A patients 
The inclusion criteria 
developing renal failure 
while excluding those 
sc reen ing. 
enabled all individuals at the risk of 
(Appendix B) to participate in the study , 
who did not want to take part in the 
Furthermore the risk criteria for the development of renal failure 
formed part of both the inclusion and exclusion criteria eliminating 
those who are not classified as at risk to avoid mass screening, 
which has not yet been proven viable . 
In addition any population group 
to mInImize possible bias on 
demography. 
b) Group 8 patients 
within South Africa was included 
the bases of population and 
The inclusion criteria incorporated all chronic renal failure patients 
from any population group from the Gauteng and the Free State 
regions . These two regions were used as patients could be seen in 
patient consultation . 
Due to the exclusion criteria , all patients were eliminated if they 
developed acute renal failure, but regained renal function and 
therefore , were not identified as chronic renal failure patients. 
Patient may develop acute renal failure due to a variety of reasons, 
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but usually not as a result of chronic renal disease , and therefore 
their kidneys may begin to function again. Pregnant women were 
excluded from the study. 
Patients in Group B were selected from the Gauteng and Free State 
regions. Both the private and government sector was used in order 
to achieve a diverse group of patients participating in the study. 
Furthermore, any population group from South Africa was included 
to minimize possible bias on the bases of population and 
demography. 
3.2.6. Subject Identification 
The patients (n = 195) included in the study were identified by a 
numerical value, which incorporated the first three letters of their 
surname, followed by two numbers. These were determined through 
a computer database allocation, which was then followed by a slash 
and a number 1- 100 that was based on the number of the patient in 
the study , e .g. GooOIII. For publication the last number only was 
published. This was performed to protect the patient ' s identity. 
3.2.7. Withdrawal criteria 
, 
Any patient (n = 195) in the study could have withdrawn at their 
own free will at any time during the duration of the study without 
anything being held against them or experiencing any consequences, 
and their treatment would have commenced as usual. 
Five patients (n = 5) from group B withdrew from the study , and 
were classified as drop- outs. 
3.2.8. Pre-study clinical evaluation 
All group A patients (n = 100) were screened to determine their at 
risk criteria either by a doctor, a clinical technologist , or a nurse , 
either in the doctor ' s consulting room , or within the hospital. 
All group B patients (n = 95) were screened to determine their renal 
function either by a doctor, a clinical technologist or a nurse, either 
in the doctor ' s consulting room, or in the renal unit within the 
ho s pita I. 
The patient and his / her data were then weighed against the inclusion 
(section 3.2.3.) and exclusion criteria (section 3.2.4.). The nature of 
the research was described and discussed with the patient , who was 
then required to sign a consent form (Appendix A). If the patient 
provided consent , the blood test was preformed in group A patients 
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and an evaluation and assessment was conducted in Group B 
patients. 
3.2.9. Drop-outs 
Any patient who withdrew from the study was not replaced and was 
classified as a drop-out. 
Five patients from group B withdrew from the study and were 
therefore not replaced, and were classifie d as drop - outs . 
3.3. FINANCIAL IMPLICATIONS 
The financial implications of this study were minimal , as no new 
apparatus needed to be bought. Instruments and apparatus used in 
the study were already available from the renal units and hospitals 
used in the study . 
The creatinine blood test performed on the individuals (group A) 
was paid for by the individuals themselve s o r from the relevant 
medical aid. 
The blood samples used in the study from group B patients were 
from routine bloods performed on the patient during his/her hospital 
stay , or in the renal unit under request from his / her physician . No 
new or extra blood samples were taken from the patients for use in 
this study. 
3.4. SAFETY VARIABLES 
The research project was very safe . There were no adverse effects 
resulting from the research study . 
Furthermore there were no adverse effects from the blood tests that 
were performed, since they were not done for the sole purpo se of 
the research project. 
3.5. PREMATURE DISCONTINUATION OF THE STUDY 
It was at no time necessary to discontinue the study prematurely . 
Throughout the duration of the stud y, neither the researcher nor the 
study leaders felt that any unethical procedures were employed, or 
the patients ' confidential ity compromised . 
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3.6. CONFIDENTIALITY 
The confidentiality of this research study was of utmost importance . 
Throughout the duration of the research , the patients ' identities 
could not be made known to any person, other than those, to whom 
the patient had provided hislher consent. 
3.7. ETHICS COMMITTEE 
The study protocol and the informed consent form , which was used 
in the study , were submitted to the Ethical Committee of the 
University of the Free State. 
The Ethical Committee of the University of the Free State , approved 
the study and provided the following ETOVS number : 108 /03. 
3.8 . QUESTIONNAIRE 
3.8.1. Consent form 
An explanation of the study, as well as the procedures and 
implications of the study were explained to all the patients 
(n = 195) . 
Thereafter the patients participating in the study, (n = 195) were 
required to give their consent prior to participation in the study , as 
this was required for ethical and confidential reasons (Appendix A) . 
Furthermore the patients were provided with an opportunity to ask 
any question regarding the study prior to its commencement, as well 
as throughout the duration of the study . 
3.8.2. Patient psychosocial assessment (Group B patients only) 
The patients (n = 95) , were interviewed and all participants 
participating in the study completed the psychosocial assessment. 
(Appendix D). 
The first part of the questionnaire incorporated demographic and 
situational variables. The demographic variables included factors 
such as age , sex, race, employment , and habits such as drinking and 
smoking. Additionally, situational information regarding patient 
participation in activities such as sports or recreational activities 
was incorporated . 
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Following the demographic and situational variables was the 
question of religion. This was incorporated since certain religious 
beliefs may influence or playa role not only in the patient's life but 
his /her choice of treatment. Jehovah's witnesses for example , do not 
believe in blood transfusions and therefore would be inclined to 
peritoneal dialysis rather than hemodialysis because of a smaller 
predisposition to blood loss. 
Thereafter the family and patient medical history was evaluated. 
This allowed for acknowledgement (if any) of any previous medical 
problems that predisposed the patient to the development of renal 
failure and / or contributed to the patient being at risk for chronic 
kidney disease. 
The abovementioned questions included the development of renal 
impairment , the treatment of renal failure and the management of 
the patient's disease. This was incorporated in order to obtain the 
patient's perspective, feelings, emotions and levels of understanding 
and education with regard to his / her disease. 
Patients completing the questionnaire were no t forced to answer any 
of the questions that they didn ' t want to answer, or felt 
uncomfortable answering. Questions that were not answered were 
included in the results section, as a frequency missing. 
3.S.3. Patient clinical and biochemical assessment 
(Group B patients only) 
A clinical and biochemical assessment (Appendix E) was preformed 
on all group B patients (n = 95). 
The assessment incorporated the diagnosis, modes of therapy , 
vascular access , and a biochemical and clinical assessment. The 
assessments were carried out at the date of commencement of renal 
replacement therapy, after one month of treatment and three months 
thereafter. 
The clinical assessment incorporated the subjective global 
assessment (SGA), which was used to indicate nutritional status 
(Appendix F) , and was performed at the commencement of renal 
replacement therapy. 
The biochemical assessment incorporated various blood results as 
discussed below (3.11-3.12). The patient's GFR (Glomerular 
Filtration Rate) was also calculated according to standard formula 
where a formula measurement was unavailable (Appendix G) . 
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The diagnosis and the indications for 
therapy were studied and noted 
concomitant renal-related problems. 
commencing renal replacement 
and considered with other 
3.9. METHOD OF DATA COLLECTION AND DATA ANALYSIS 
The researcher conducted did all manual procedure . 
./ All the data of patients was collected from the renal units 
involved, or the doctors consulting rooms and/or the 
associated laboratory . 
./ All the GFRs were calculated according to the procedure 
explained in 3.14 . 
./ All the data was counterbalanced against the inclusion and 
exclusion criteria (3.2 .3-3.2.4) and was assessed manually. All 
the data that met the exclusion criteria (3.2.4) was deleted . 
./ All the data was printed out for manual analysis . 
./ The researcher manually counted the total amounts of each 
variable . 
3 . 10. APPARATUS 
A mecer, pentium 4 computer already in use in the unit , with the 
GFR formula on it, was used to determine the patient ' s glomerular 
filtration rate. 
A one decimal tan ita (HD - 308) electronic scale was used to 
determine the patient's weight. 
A Critikon, dinamap, blood pressure monitor (and vital signs 
monitor) was used to determine the patient's blood pressure . 
Both the scale and the blood pressure monitor were already In use In 
the un its , and were used because all are standard ized. 
3 . 11. LABORATORY ANALYSIS (GROUP B PATIENTS) 
5ml blood samples were drawn monthly from each patient over a 
three month period from the date of commencement of treatment. 
Where the patient was managed or treated a month prior to 
commencement, 5ml blood samples were collected and lab analyses 
we re p erfo rm ed. 
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The laboratory analysis was performed by Ampath, Lancet, and the 
government hospital laboratories, and included the following 
analyze: 
Sodium 
Potassium 
Ch loride 
C02 
Urea 
Creatinine 
Magnesium 
Phosphate 
Albumin 
Calcium (total) 
Cho lestero I 
Iron studies: 
Iron 
Transferrin 
Ferritin 
% Saturation 
Hemoglobin 
Hematocrit 
Parathyroid 
hormone 
3.12. METHODOLOGY AND CLINICAL SIGNIFICANCE OF 
LABORATORY ANALYSIS 
(Group B patients only, except for creatinine, which was used in 
group A and group B patients) 
3.12.1. SODIUM 
Performed by 
Ampath, Lancet laboratories, Pathcare . 
Specimen 
Freshly drawn serum or plasma is the specimen of cho ice . A yellow 
top SST tube is used. 
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Clinical significance 
Sodium measurements are used in the diagnosis and treatment of 
aldosteronism, diabetes insipidus, adrenal hypertension, Addison ' s 
disease, dehydration, inappropriate antidiuretic hormone secretion, 
or other diseases involving electrolyte imbalance . Furthermore, they 
are used in the management of renal failure patients , as they are 
characterized by electrolyte imbalances , including sodium 
imbalances , which may require treatment if they indicate 
hyponatremia or hypernatremia. 
Methodology 
Ensure the tubes are correctly filled and inverted six times to ensure 
the mixing of clot activator with blood. 
The Synchron CX5 system determines sodium by measuring sodium 
ion activity in the solution . 
To measure sodium concentrations a precise volume of sample is 
mixed with a buffered solution. The ratio used is one part sample to 
20 parts reagent. High molar strength buffer is employed to 
establish a constant ionic strength. This serves to set a constant 
activity coefficient for the electrode. With constant activity 
established, the electrode is calibrated to concentration values. 
Sensitivity 
The test is accurate provided quality control measures and 
calibration procedures are followed. 
Limitations 
If plasma is the sample of choice , the following anticoagulants are 
found to be compatible with this method: 
• Ammonium heparin 
• Lithium heparin 
• Sodium heparin 
The following anticoagulants are incompatible : 
• Potassium oxalate / Sodium Fluoride 
• Sodium citrate 
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A sodium heparin tube less than one-half full may result in a falsely 
elevated sodium value . 
3.12 .2 . POTASSIUM 
Performed by 
Ampath , Lancet laboratories , Path care . 
Specimen 
Freshly drawn serum or plasma is the specimen of choice. A yellow 
top SST tube is used . 
Clinical significance 
Potass ium measurements are used in the diagnos·is and treatment of 
hypokalemia, hyperkalemia, renal failure , Addison's disease or 
diseases involving electrolyte imbalance. 
Methodology 
Ensure the tubes are correctly filled and inverted six times to ensure 
mixing of clot activator with blood . 
The Synchron CX5 system determines potassium IOn concentration 
by measuring electrolyte activity in the solution. 
To measure potassium concentrations , a precise volume of sample is 
mixed with a buffered solution . The rat io used is one part sample to 
20 parts reagent. A high molar strength buffer is employed to 
establish a constant ionic strength. This serves to set a constant 
activity coefficient for the electrode . With constant activity 
established , the electrode is calibrated to concentration values. 
Sensitivity 
This test is very accurate, i f quality control measures and 
calibration of the machine are carried out accordingly . 
Limitations 
If plasma is taken , the following anticoagulants are compat ible : 
• Ammonium heparin 
• Lithium heparin 
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• Potassium oxalate / Sodium fluoride 
• Sodium heparin 
The following anticoagulants are found to be incompatible: 
• Sodium citrate 
• EDTA 
3.12.3. CHLORIDE 
Performed by 
Ampath , Lancet laboratories, Pathcare . 
Specimen 
Freshly drawn serum or plasma IS the specImen of choice . A yellow 
top SST tube is used . 
Clinical significance 
Chloride measurements are used in the diagnosis and treatment of 
electrolyte and metabolic disorders such as cystic fibrosis and 
diabetic acidosis . 
Methodology 
Ensure the tubes are correctly filled and inverted six times to ensure 
mixing of clot activator with blood . 
Synchron CX Delta systems determine chloride IOn concentration by 
measuring chloride ion activ ity in the solution . 
To measure chloride concentrations, a precise volume of the sample 
is mixed with a buffered solution . The ratio used is one part sample 
to 20 parts reagent. High molar strength buffer is employed to 
establish a constant ionic strength. This serves to set a constant 
activity coefficient for the electrode. With constant activity 
established the electrode is calibrated to concentration values . 
Sensitivity 
The test is very accurate if quality control measures and calibration 
of the machine are carr ied out accordingly . 
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Limitations 
If plasma is taken , the following anticoagulants are compatible: 
• Ammonium heparin 
• Lithium heparin 
• Potassium oxalate/Sodium fluoride 
• Sodium heparin 
The following anticoagulants are found to be incompatible : ~ 
• Sodium citrate 
• EDTA 
3.12.4. Carbon Dioxide (COd 
Perfo rm ed by 
Ampath, Lancet laboratories , Pathcare. 
Specimen 
Freshly drawn serum or plasma is the specimen of choice. The 
specimen is taken in a yellow top SST tube. 
Clinical significance 
Carbon dioxide measurements are used in the diagnosis and 
treatment of numerous potentially serious disorders associated with 
changes in body acid-base balance . Carbon d io xide measurements 
are used in the management of renal failure patients as they provide 
an indication of the acid-base balance , which is disrupted in renal 
failure patients. 
Metbodology 
Ensure the tubes are correctly filled and tubes should be inverted 
six times to ensure mixing of clot activator with blood. 
The SYNCHRON CX5 system determines total carbon dioxide by 
measuring the rate of pH change as carbon d ioxide ions diffuse 
across a membrane. 
To measure carbon dioxide concentrations , a precise sample volume 
69 microliters is mixed with a buffered solution. The rat io used is 
one part sample to 20 parts reagent. The solution is acidified by the 
© Central University of Technology, Free State
79 
addition of C02 acid reagent. The electrode (in conjunction with a 
reference electrode) used for carbon dioxide determination is 
actually a pH electrode with the tip covered by a silicone rubber 
membrane . When carbon dioxide is released from the sample in the 
flow cell, it diffuses through the membrane and lowers the pH of a 
bicarbonate solution between the membrane and the tip of the 
electrode. 
-
The electrode measures the CO 2 by a differential pH rate of change . 
When the sample solution is mixed with acid, all forms of C02 are 
converted in to their gaseous form. 
A proportional amount of liberated gas diffuses through the 
membrane lowering the pH of the bicarbonate solution located 
between the membrane and the face of the electrode . The rate of the 
pH change is directly proportional to the carbon dioxide in the 
sample. 
Sensitivity 
The proper operation of the SYNCHRON CX exhibits accurate 
values. 
Limitations 
If plasma is the sample of choice, the following anticoagulants are 
found to be compatible with the method: 
• Ammonium heparin 
• Lithium heparin 
• Sodium heparin 
• Potassium Oxalate / Sodium Fluoride 
The following anticoagulants were found to be incompatible with 
this method: 
• EDTA 
• Sodium Citrate 
3.12.5. UREA 
Performed by 
Ampath, Lancet laboratories, Pathcare. 
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Specimen 
Freshly drawn serum or plasma is the specimen of choice. A yellow 
top SST tube is used . 
Clinical significance 
Urea nitrogen measurements are used in the diagnosis and treatment 
of certain renal and metabolic diseases. 
Methodology 
Ensure the tubes are correctly filled and inverted six times to ensure 
mixing of clot activator with blood . 
Urea reagent is used to measure the urea concentration by an 
enzymatic rate method. In the reaction , urea is hydrolyzed by urease 
to ammonia and carbon dioxide. Glutamate dehydrogenase (GLDH) 
catalyzes the condensation of ammonia and A-ketoglutamate with 
the concomitant oxidation of reduced B-nicotinamide adenine 
dinucleotide (NADH) to B-nicotinamide adenine dinucleotide 
(NAD). 
The Synchron ex system automatically proportions the appropriate 
sample and reagent volumes into a cuvette. The ratio used is one 
part sample to 100 parts reagent. The system monitors the change in 
absorbance at 340 nanometers. This change in absorbance is directly 
proportional to the concentration of urea in the sample and is used 
by the Synchron ex system to calculate and express the urea 
concentration. 
Sensitivity 
The test is very accurate , if quality control measures and calibration 
of the machine is carried out accordingly. 
Limitations 
If plasma is taken , the following anticoagulants are compatible : 
• Ammonium heparin 
• EDTA 
• Lithium heparin 
• Potassium oxalate / Sodium fluoride 
• Sodium hepar in 
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The following anticoagulants are found to be incompatible : 
• Sodium citrate 
The following interferences have been noted: 
• Fluoride is a known inhibitor of urease activ i ty and will 
decrease the reaction rate of this reagent 
• The presence of ammonium ions in anticoagulants may 
produce falsely elevated results 
• Lipemic samples >3+ should be ultra - centrifuged and the 
analysis preformed on the infranate . 
A maximum limit of two hours from the time of collection is 
recommended . 
3 . 12.6. CREATININE (Group A and Group B pat ients) 
Performed by 
Ampath , Lancet laboratories, Pathcare. 
Specimen 
Freshly drawn serum or plasma IS the specimen of choice . A yellow 
top SST tube is used. 
Clinical significance 
Creatinine measurements are used in the diagnosis and treatment of 
renal diseases , in mon itoring renal dialysis , and as a calculation 
basis for measuring other urine analys i s . 
Methodology 
Ensure the tubes are correctly f i lled and inverted S I X times to ensure 
mixing of clot activator with blood . 
Creatin ine reagent is used to measure the creatinine concentration 
by a modified rate Jaffe ' method . In the reaction , creatinine 
combines with picrate in an alkaline solution to form a creatinine-
picrate complex . 
The Synchron CX system automatically proportions the appropriate 
sample and reagent volumes into the cuvette. The ra tio used is one 
part to II parts reagent for serum . The system monitors the change 
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in absorbance at 520 nanometers. This change in absorbance is 
directly proportional to the concentration of creatinine in the 
sample and is used by the Synchron CX system to calculate and 
express creatin ine concentration. 
Sensitivity 
The method is very accurate , provided that the sample is handled 
correctly and the machine is regularly calibrated. 
Limitations 
The following anticoagulants are compatible with this method: 
• Ammonium heparin 
• EDTA 
• Lithium heparin 
• Potassium oxalate / Sodium fluoride 
• Sodium citrate 
• Sodium heparin. 
3.12.7. PHOSPHATE 
Performed by 
Ampath, Lancet laboratories, Pathcare. 
Specimen 
Freshly drawn serum or plasma is the specimen of choice. A yellow 
top SST tube is used. 
Clinical significance 
Hypophosphatemia is predominantly associated with malnutrition 
and patients receiving hyperalimentation may have low phosphate 
levels . Severe hypophosphatemia can cause respiratory muscle 
weakness and alterations in hemoglobin oxygen affinity. 
Hyperphosphatemia can be associated with a decline In renal 
function . 
Methodology 
Ensure the tubes are correctly filled and inverted six times to ensure 
mixing of clot activator with blood . 
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The Synchron CX5 system determines the phosphate Ion 
concentration. 
To measure phosphate concentration , a precise sample volume IS 
mixed with a buffered solution. 
Sensitivity 
The test is very accurate, if quality control measures and calibration 
of machine the is carried out accordingly. 
Limitations 
If plasma is taken, the following anticoagulants are compatible : 
• Ammonium heparin 
• Lithium heparin 
• Potassium oxalate/Sodium fluoride 
• Sodium heparin 
The following anticoagulants are found to be incompatible : 
• Sodium citrate 
• EDTA 
3.12.8. MAGNESIUM (Mg) 
Performed by 
Ampath, Lancet laboratories , Pathcare. 
Specimen 
Freshly drawn serum or plasma is the specimen of choice. A yellow 
top SST tube is used. 
Clinical significance 
Determination of magnesium is useful in assessing several diseases 
and conditions. High Mg is associated with uremia, dehydration, 
diabetic acidosis, Addison ' s disease and the increased medicinal 
intake of Mg . Low Mg is associated w i th malabsorption syndrome, 
acute pancreatitis , hypoparathyriodism , chronic alcholism and 
delirium tremens, chronic glomerulonephritis, aldosteronism, 
digitalis · intoxication and protracted I.V. feeding. 
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Methodology 
Ensure the tubes are correctly filled and inverted six times to ensure 
mixing of clot activator with blood . 
Magnesium reagent i s used to measure the magnesium concentration 
by a timed end-point method . In the reaction magnesium mixes with 
calmagite to form a stable chromogen. The product is formed 
rapidly giving reproducible results with a minimum of interferences. 
The Synchron ex system automatically proportions the appropriate 
sample and reagent volumes into a cuvette . The ratio used is one 
part sample to 103 parts reagent. The system monitors the change in 
absorbance at 520 nanometers . The change in absorbance is directly 
proportional to the concentration of magnesium in the sample , and 
is used by the Synchron ex system to calculate and express the 
magnesium concentration . 
Sensitivity 
\ 
The test is very accurate. 
Limitations 
The following anticoagulants are compatible with this method: 
• Ammonium heparin 
• L ithium heparin 
• Sodium heparin. 
The following anticoagulants are incompatible with this method : 
• EDT A 
• Potassium oxalate/Sodium fluoride 
• Sodium citrate 
3 .12.9. ALBUMIN 
Performed by 
Ampath, Lancet laboratories , Pathcare. 
Specimen 
Freshly drawn serum IS used to determine the albumin. A yellow top 
SST tube is used . 
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Clinical significance 
Albumin measurements are used in the diagnosis and treatment of 
numerous diseases involving the liver and /or kidneys. 
Methodology 
Ensure the tubes are correctly filled and tubes inverted six times to 
ensure mixing of clot activator with blood. 
Albumin reagent is used to measure albumin concentration by a 
timed endpoint. In the reaction, albumin mixes with bromcresol 
purple (BCP) to form a coloured product. 
The SYNCHRON CX system (Beckman) automatically proportions 
the appropriate sample and reagent volumes into the cuvette. The 
ratio used is one part sample to 100 parts reagent. The system 
monitors the change in absorbance at 600 nanometers. This change 
in absorbance is directly proportional to the concentration of 
albumin in the sample and is used by the SYNCHRON CX system to 
calculate and express albumin concentration. 
Sensitivity 
The acceptability and accuracy is determined through the quality 
control measures and successful calibration . The test is accurate if 
correct measures are employed. 
Limitations 
The following anticoagulants are compatible with this method: 
• Ammonium heparin 
• Lithium heparin 
• Sodium heparin. 
• EDTA 
The following anticoagulants are incompatible with this method: 
• Potassium oxalate / Sodium fluoride 
• Sodium citrate 
There are several interferences 
• Hemoglobin may interfere with this methodology 
© Central University of Technology, Free State
86 
• Lipemic samples >3+ should be ultra-centrifuged and the 
analysis performed on the infranate . 
3.12.10. CALCIUM 
Performed by 
Ampath , Lancet laboratories Path care. 
Specimen 
Freshly drawn serum is used to determine the calcium concentration . 
A yellow top SST tube is used. 
Clinical significance 
Calcium measurements are used in the diagnosis and treatment of 
parathyroid disease, a variety of bone diseases, chronic renal 
disease and tetany. 
Methodology 
Ensure the tubes are correctly filled and inverted six times to ensure 
mixing of clot activator with blood. 
Calcium reagent is used to measure calcium concentration by a 
timed endpoint method. [n the reaction, calcium combines with 
Arsenazo I I I a bluish - purple colour product. 
The Synchron CX system automatically proportions the appropriate 
sample and reagent volumes into the cuvette . The ratio used is one 
part sample to 100 parts reagent. The system monitors the change in 
absorbance at 650 nanometers. This change is directly proportional 
to the concentration of calcium in the sample and is used by the 
Synchron CX system to calculate and express calcium concentration. 
Sensitivity 
The acceptability and accuracy is determined through the quality 
control measures and successful calibration. The test is accurate if 
correct measures are employed. 
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Limitations 
The following anticoagulants are compatible with this method: 
• Ammonium heparin 
• Lithium heparin 
• Sodium heparin 
The following are found to interfere with this method: 
• Samples containing EDTA , fluoride, oxalate or citrate should 
not be used. 
• Magnesium at a level less than Smg/ dL will not produce a 
significance bias 
• Positive or negative interference may be obtained from 
patients diagnosed as having plasma cell dyscrasias and 
lymphoreticular malignancies associated with abnormal 
immunoglobulin synthesis, such as multiple myeloma, 
Waldenstroms macroglobulinemia , or heavy chain disease. 
• Lipemic samples should be ultra-centrifuged and the analysis 
performed on the infranate. 
3 . 12.11. IRON STUDIES 
Performed by 
Ampath , Lancet laboratories, Pathcare. 
Specimen 
Freshly drawn serum or heparinized- plasma is the specimen of 
choice. A yellow top SST tube or a blue SST tube is used for 
collection. 
Clinical significance 
Alterations in iron and total iron binding capacity levels result from 
changes in iron intake , absorption , storage , and release mechanisms. 
Such changes are indicative of a wide range of dysfunctions 
including anemia, nephrosis, cirrhosis and hepatitis . Both iron and 
total iron binding capacity measurements are important for 
definitive diagnosis because they are interrelated. 
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Methodology 
Ensure the tubes are correctly filled and inverted SIX times to ensure 
mixing of clot activator with blood . 
Iron reagent is used to measure the iron concentration by a timed -
end point method . In the reaction, iron is released from transferrin 
by acetic acid and is reduced to the ferrous state by hydroxylamine 
and thioglycolate. The ferrous ion is immediately complexed with 
the FerroZine Iron reagent. 
The Synchron ex system automatically proport ions the appropriate 
sample and reagent volumes into a cuvette . The ratio used is one 
part sample to 8 parts reagent. The system monitors the change in 
absorbance at 560 nanometers . This change in absorbance is directly 
proportional to the concentration of iron in the sample , and is used 
by the Synchron ex system to calculate and express the Iron 
concentration. 
Sensitivity 
The acceptability and accuracy is determined through the quality 
control measures and successful calibration. The test is accurate if 
correct measures are employed. 
Limitations 
If plasma is the sample , the following anticoagulants are found to 
be compatible with these methods : 
• Lithium heparin 
• Sodium heparin 
• Ammonium heparin 
Interferences 
• EDT A, sodium citrate and potassium oxalate are known to 
interfere with this method 
• Use d isposable lab ware whenever possible . 
• Ingestion of oral contraceptives will elevate iron or total Iron-
binding values. 
• Iron-dextran administration can cause elevations In total 
serum iron with this methodology. 
• Lipemic samples > 3+ should be ultra-centrifuged and the 
analysis preformed on the int ranate . 
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A maximum limit of two hours from the time of collection is 
recommended for use as a sample. 
3.12.12. HEMOGLOBIN 
Performed by 
Ampath, Lancet laboratories , Pathcare. 
Specimen 
Freshly drawn serum is used to determ ine the hemoglobin . A purple 
top EDTA tube is used for the determinat ion of hemoglobin. 
Clinical significance 
Determination of the hemoglobin is used in the diagnosis and 
management of anemia and heart failure. 
Methodology 
Ensure the tubes are correctly filled and tubes should be inverted 
six times to prevent clotting. 
The blood is added to the hemoglobin reagent (containing cyanide) 
in the test tube. The solution is mixed and allowed to stand for 5 
minutes. The absorbance is measured via the spectrophotometer at a 
wavelength of 546nm. The hemoglobin concentration IS then 
measured via the following formulae: 
Hemoglobin concentration (g /dl) = Absorbance x 36.77. 
Sensitivity 
The acceptability and accuracy is determined through the quality 
control measures and successful calibration. The test is accurate if 
correct measures are employed. 
Limitations 
• Caution should be exercised with patients with hemolytic 
anemia , because of the shortened life of erythrocytes, and 
patients with iron deficiency anemia because it can lead to an 
increased erythrocyte mass . 
• Samples containing citrate should not be used. 
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3.12.13. HEMATOCRIT 
Performed by 
Ampath , Lancet laboratories , Pathcare . 
Specimen 
Freshly d r awn serum is used to determine the hematocrit. A purple 
top EDTA tube is used for the determination of hematocrit. 
Clinical significance 
When who le blood is centrifuged, the red blood cells become packed 
at the bottom of the tube , leaving the plasma at the top . The ratio of 
packed red blood cells to the total blood volume is called the 
hematocrit. 
Determination of the hematocr it is used In the diagnosis and 
management of anemia . 
Metbodology 
Ensure the tubes are correctly filled and inverted six times to 
prevent clotting . 
Th e sealed capillary tube is placed into the centrifuge . After 
centrifugation the capillary tube is placed into the hematocrit reader 
to obtain a hematocrit value. 
Sensitivity 
The acceptability and accuracy is determ ined through the quality 
control meas u res and successful ca l ibrat ion. The test is accurate if 
correct measures are employed . 
Lim i tations 
• Samples containing citrate should not be used. 
3.12.14. PARATHYROID HORMONE (PTH) 
Performed by 
Ampath , Lancet laborator ies , Pathcare . 
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Specimen 
Freshly drawn serum is used to determine the parathyroid hormone. 
A purple top , EDTA tube is used for the determination of the 
parathyroid hormone. 
Clinical significance 
Elevated parathyroid hormone levels may indicate 
response in order to regulate electrolyte balance. 
elevated parathyroid hormone levels may indicate 
hyperparathyroidism in chronic renal failure patients . 
Methodology 
Ensure the tubes are correctly filled . 
Sensitivity 
an adaptive 
Furthermore 
secondary 
The acceptability and accuracy is determined through the quality 
control measures and successful calibration. The test is accurate if 
correct measures are employed. 
Limitations 
• Samples containing citrate should not be used. 
3.13. SUBJECTIVE GLOBAL ASSESSMENT (SGA) 
(APPENDIX F) 
Performed by 
A registered clinical technologist or nurse . 
Clinical significance 
The subjective global assessment is a clinical technique used for 
assessing the nutritional status of a patient based on features of the 
patient's history and physical examination (Oosthuizen , 2002) . 
Methodology 
The SGA is performed on the patients at the commencement of renal 
replacement therapy. 
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A four item , seven point scale was used: 
I) Weight change 
2) Dietary intake 
3) Gastro-intestinal symptoms 
4) Physical exam ination 
3.14.1. SGA rating: 
1) Weigbt cbange 
Weight loss: 
• 
• 
• 
< 5%: considered small-insignificant. 
10%: potentially significant. 
> 10%: definitely significant. 
The pattern of weight loss is also important. 
2) Dietary intake 
• Classified as normal and abnormal 
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• 
• 
If abnormal ask further questions as indicated on SGA card. 
Ask patient for a description of a typical breakfast, lunch etc. 
to gather more info. 
3) Gastro-intestinal symptoms 
• Symptoms have persisted for 2 weeks 
• Diarrhea and occasional vomiting lasting only a few days are 
not considered significant (but can be noted for future 
referral) 
4) Pbysical Examination 
• Loss of subcutaneous fat. Check shoulders, triceps , chest and 
hands for loss of fullness or loose fitting skin (note that the 
latter may appear in older persons who are not malnourished). 
• Scoring: Normal = 0 
3.14. GLOMERULAR FILTRATION RATE (APPENDIX F) 
Pe rfo rm ed by 
A registered clinical technologist or nurse 
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Clinical significance 
Used in the determination of kidney function . 
Methodology 
The patient ' s GFR (Glomerular Filtration Rate) is calculated 
according to standard formulae , where a formulae measurement is 
unavailable (Appendix G). 
The equation is derived from the data obtained from the MDRD 
study (DOQI , 2002). GFR is measured by creatinine and 
incorporates factors of gender, race and age. 
3.15. DETERMINATION OF FINANCIAL IMPL I CATIONS 
Performed by 
A registered clinical technologist. 
Methodology 
The costs involved in renal replacement therapy , hospital fees , and 
fees for blood tests were all analyzed and were obtained from 
various private practices . T hey were put together to provide an 
estimation of the fees involved in this life - saving treatment. 
3.16. STATISTICAL ANALYSIS 
A statistical analyst from the department of statistics , University of 
Pretoria , was consulted for assistance with the processing of th e 
data. 
The variables used within the study were subjected to a series of 
statistical analyses. However, the variables were mostly described 
by frequencies and percentages. 
ANOVA was used as a means to compare the d iffe rent var iables. 
Duncan ' s multiple range tests were used to determine the level of 
significance among the variables . 
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3.17. GOOD CLINICAL PRACTICE I QUALITY ASSURANCE 
All clinical work conducted under this research project was 
subjected to the good clinical practice guidelines (Principles of ICH 
OCP). 
The declaration of Helsinki's basic principle number 3 states that 
research should be conducted only by scientifically qualified 
persons (World Medical Association Declaration of Helsinki, 2002). 
Therefore , the whole research project was compiled by a registered 
Clinical Technologist (Registered with the Health Professional 
Council of South Africa, number KT 0008087) under the supervision 
of two qualified study leaders. 
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CHAPTER 4 
RESULTS 
4.1. SCREENING OF INDIVIDUALS AT RISK OF DEVELOPING 
RENAL FAILURE. 
(Partt; n=100; group A) 
4. 1.1. RESPONDENT'S CHARACTERISTICS OF THE 
SCREENING 
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Consideration of basic demographic data (gender, age and race) Is 
important, as it is a requirement in the determination of the GFR 
rate . Creatinine varies between males and females , as well as 
between in the different ages and races, and was therefore taken 
into consideration. 
49% of individuals (n=IOO) who took part in the screening (group 
A) were males, and 51% were females. The majority of the subjects 
were white. White subjects comprised 89% of the sample, with only 
9% black subjects and 2% indian subjects. 
As indicated below, (figure 4.1) the majority of individuals who 
took part were above 61 years of age (30%). Another 22% were 
between the ages 41 and 50. A further 20% of the individuals were 
between 51 and 60 years of age. 16 % were between the ages 31 and 
40 . An additional 10% were between 21 and 30 years old. A final 
2% fall into the 18-20 years of age category. 
30 
25 
Percentage 20 
(%) 15 
of patienta 
10 
5 
o 
above 
Age ( years) 
Figure: 4.1. Graphic representation of the age of individuals 
taking part in the screening (Group A) . 
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4.1.2 MEDICAL HISTORY AND DIAGNOSIS OF RESPONDENTS 
As can be seen below (fig. 4.2) 34% of the individuals screened are 
diabetic. 32% have arterial hypertension, and a further 8% have both 
diabetes and hypertension. An additional 1 % has a family history of 
kidney disease and another 1 % has recurrent urinary tract 
infections. 2% were exposed to certain drugs or chemicals and 22% 
have a medical history of renal related problems . 
n= 100 
32% 
• Diabetes 
Arterial hypertension I 
cardiovascular disease 
C Diabetes and 
hypertension 
III Family history of kidney 
disease 
• Recurrent urinary tract 
infections 
• Exposure to certain 
drugs or chemicals 
• Medical history of renal 
related problems 
Figure: 4.2. Graphic representation of the risk factors of 
individuals screened. 
On admission the patients displayed a variety of conditions. 
Although these were not necessarily renal related, the medical 
history is of great importance, as their history is what placed them 
at risk for the development of renal failure (table 4.1). 
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In addition to the risk factors displayed by the individuals, their 
admission conditions included the following (Table 4.1) : 
Table: 4.1. Admission conditions of patients in the sample 
(n=100) 
Frequency Percentage 
Anemia 2 2.00 
Bronchoscope 1 1.00 
Bronchospasm 1 1.00 
Chest pain 3 3.00 
Cholecystomy 1 1.00 
Chronic obstructive 1 1.00 
pulmonary disease 
Colitis 2 2.00 
Congestive cardiac 1 1.00 
failure 
Diabetes 26 26 .00 
Diabetes & Hypertension 8 8.00 
Diabetic I septic wound 1 1.00 
Functional endoscopic 1 1.00 
sinus surgery 
Gastrosco py-biopsie 1 1.00 
G lomerulonep_h ritis 1 1.00 
Good pastures syndrome 1 1.00 
Haematemesis 1 1.00 
Hematuria 1 1.00 
Hem icolectomy/previous 1 1.00 
kidney problems 
Hydronephrosis 1 1.00 
Hypertension 19 19.00 
Hypertension & renal 1 1.00 
caliculi 
Hypertension/ch ronic 1 1.00 
renal failure 
Hypertension, Analgesic 1 1.00 
nephropathy 
HYPoQlycaemia 3 3.00 
Muscular spasm-back 1 1.00 
Myocardial infarction & 1 1.00 
Hypertension 
Nephritis 1 1.00 
Nephrotic syndrome 1 1 .00 
Pancreatitis 1 1.00 
Peptic ulcer 1 1.00 
Pneumonia 1 1.00 
Polycystic kidneys 2 2.00 
Previous ARF 1 1.00 
Pylenephritis 4 4.00 
Renal Calculi 1 1.00 
Renal Failure 3 3 .00 
Renal TB 1 1 .00 
Renal cyst 1 1.00 
© Central University of Technology, Free State
101 
4.1.3. RESULTS OBTAINED FROM THE SCREENING OF 
PATIENTS AT RISK OF DEVELOPING RENAL FAILURE 
(PART 1; GROUP A) 
4.1.3.1. Creatinine 
A creatinine value was taken and used as a measurement. Creatinine 
is used in the diagnosis and treatment of renal d iseases, in 
monitoring renal dialysis, and as a calculation basis for measuring 
other urine analysis. 
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Figure .4.3. Graphic representation of the serum creatinine of 
patients screened (n = 100). 
I 
Figure .4.3. Indicates the serum creatinine of the hundred patients' 
that were screened for kidney disease (Group A). The pink squares 
represent the serum creatinine of females and the blue diamond 
shapes represent the serum creatinine of males (fig . 4.3). 
The normal serum creatinine for males is between 80 and Il5l!molll, 
and for females the normal creatinine is between 53 and 971!molll. 
From the study the mean creatinine for both male and female 
participates was 118.521!molll. The mean creatinine for the male 
participants was 128.451!mol/l and for females it was 108.991!molll. 
18% of males showed an elevated creatinine and 9% showed a low 
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creatin Ine value . 18% of females had an elevated creatin ine and 4% 
had a low creatinine value (fig.4.3). 
4 . 1.3.2. The glomerular filtration rate (GFR) 
From the 100 volunteers that took part in the screening, 36% had a 
glomerular filtrat ion rate (GFR) of between 60 and 
89mllmin / 1.73m 2. A further 31% had a GFR of greater than 
90ml / minll .73m 2. An additional 24% showed a GFR of between 30 
and 59 ml / minll.73m 2, and 6% presented with a GFR of between 15 
and 29ml /minll.73m 2. A final 3% had a GFR of less than 
15 m 11m inll .73m 2 (fig . 4.4) . 
6% 3% 
36% 
!I >90 
!l OO - 89 
030-59 
D 15 - 29 
• <15 
Figure 4 . 4 : The GFR (ml/min/1.73m2) frequency - i ndividuals a t 
risk (Group A; n = 100) 
As depicted above 31 % of the patients screened showed a GFR of 
greater than 90ml / minll.73m 2, and may have a normal GFR (120-
125ml / minll .73m 2 ) . However , it must be acknowledged that despite 
their current values they still have a predisposit ion to chronic 
kidney disease and should continue to be monitored to prevent 
progression . 
Co-morbid conditions need to be managed . 
36% of patients displayed a mild decrease in GFR (60 - 89 
ml / minll .73m2) (fig. 4.4) and , as according to the model of the 
course of chronic kidney disease (CKD) , the progression should be 
estimated , and if possible , further progression prevented (fig. 2.2). 
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A further 24% of individuals showed a moderate decrease in GFR 
(30-59ml /minll .73m 2 ) (fig.4.4) and , based on the model of the 
course of chronic kidney disease (fig. 2 .2), the complications 
experienced should be evaluated and treated . 
6% of patients showed a severe decrease in GFR (15 - 30 
ml / minll.73m2) (fig. 4.4) and should be prepared for renal 
replacement therapy (fig. 2.2). 
An additional 3% of patients with a GFR <15mll min/1.73m2 
(fig.4 .4) should already be on dialysis or be transplanted (fig.2.2). 
Although several individuals were aware of a previous kidney 
problem, very few individuals who participated in the screening 
realized that there was a possibility that renal replacement therapy 
could become a means of survival. Many, in fact , never knew that 
they had a decreased renal function or even that they were at risk 
for the development of kidney disease. 
Not one of the patients screened had seen a nephrologist and only 
24% of patients were being treated for renal related conditions. 
4.1.4. RELATIONSHIP BETWEEN THE GFR AND CREATININE 
As indicated in the graph the glomerular filtration rate and the 
serum creatinine have an inverse relationship (fig. 4.5). 
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Figure ,4.5 . Graphic representation of the relationship between 
the glomerular filtration rate (GFR) and the 
creatinine, 
104 
4.2. EVALUATION OF CRF PATIENTS FOR THE 
DETERMINA TION OF THE OPTIMAL TIMING OF 
COMMENCING RENAL REPLACEMENT THERAPY. 
(Part 2; Group B, patients; n = 95) 
From the one hundred patients who were diagnosed with chronic 
renal failure , who fell within the criteria and were selected , five 
patients withdrew from the study , were classified as drop outs , and 
were not replaced (n = 95). 
4.2.1. PATIENT CHARACTERISTICS 
Consideration of bas ic demographic data (gender , age and race) was 
important, as it could influence the results in both the biochemical 
analysis and clinical assessment. Demographic data was therefore 
taken into cons ideration . 
The majority of patients in the sample were ma les (69.47%) and the 
minority females (30.53%). 
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Figure .4.6. Graphic representation of the age versus race 
distribution of chronic renal failure patients in the 
sample (group B; n = 95) . 
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The majority of the patients were black patients , who made up 
50.53% of the sample, while on ly 35 .79% were wh ite patients and 
13.68% were Indian patients (fig. 4.6.). 
The majority of the patients in the sample (23.16%) are between 20 
and 30 years old. Another 22 . 11 % of patients fall between the ages 
of 31 and 40. A further 20% of the sample falls between 51 - 60 years 
of age. 16.84% are between the ages of 41 and 50. An additional 
14.74% are above 61 years of age . A final 3.16% fall into the 18 - 20 
age category (fig.4.6). 
From the renal units represented in the sample (3.2 .2) , the majority 
of patients receiving renal replacement therapy (RRT) belongs to 
the private sector and comprises 56%. A further 44% of patients In 
the sample receive treatment from the government sector . 
Both private and government sector patients were used in the study 
to achieve a diverse group of patients, and to achieve results from 
both units to provide a better overview of the renal population as a 
whole. 
4.2.2. AETIOLOGY OF CHRONIC RENAL DISEASE IN THE 
SAMPLE 
The main cause of kidney disease in patients in the sample is 
hypertension . This grove comprises 41.05%. The second leading 
cause is diabetic nephropathy , a cause affecting 14.74%. Patients 
with both hypertension and diabetic nephropathy constitute 9.47% 
© Central University of Technology, Free State
106 
of the sample. Other causes include: nephritis (6.31 %); 
glomerulonephritis (5.26%); analgesic nephropathy (3 . 16%); 
polycystic kidney disease (3.16%) ; chronic interstitial nephritis 
(2.11%); congenital abnormalities (2.11%); Lupus nephritis 
(2.11 %); Wegeners granulomatosis (2.11 %); benign nephrosclerosis 
(1.05%); glomerulosclerosis (1.05%); Vesico- urethra reflux 
(1.05%); Systemic lupus erythematosus (1.05%). A further 4.21% of 
patients in the sample have an unknown aetiology (table 4.2). 
Table 4.2: Aetiology of chronic renal disease in the sample 
(n = 95) 
i" req ll e n c) Pe rce n tage 
Analgesic 3 3 . 16 
nephropathy 
Benign 1 1.05 
n ephro sc Ie ros i s 
Chronic interstitial 2 2.1 1 
nephritis 
Congenital 2 2.1 1 
abnormalities 
Diabetic 14 14 .74 
nephropathy 
Diabetic 9 9.47 
nephropathy & 
Hypertension 
Glo merul on eph ri ti s 5 5.26 
Glo me rul 0 sci erosi s I 1. 0 5 
Hypertension 39 41. 05 
N eph ri ti s 6 6.31 
Polycystic kidney 3 3.16 
disease 
Unknown etiology 4 4.21 
Vesico-urethra I 1.05 
Reflux 
SLE' 3 3.16 
Wegeners 2 2 . 11 
gran u lomato s is 
·1 SLE - Systemic lupus erythematosus 
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In studying the aetiology of chronic renal disease (table 4.2), it 
became apparent once again that the two leading causes of rena l 
failure were in fact hypertension and diabetes. 
4.2.3. PATIENT PSYCHOSOCIAL ASSESSMENT 
(APPENDIX D) 
The patients (group B ; n = 95) completing the psychosocial 
assessment were not required to fill ou t the questions that they did 
not want to , and were simply classified as frequency missing within 
analysis when questions were left unanswered .. 
The frequency missing within this study will therefore be defined as 
individuals who did not answer the question . 
4.2.3.1. Chronic renal failure patients' lifestyle. 
14% 
. Full-time 
• Part - time 
o Self-employed 
o Unemployed 
III Retired 
n=95 
Figure .4 .7. Graphic representation of the employment status 
of chronic renal failure patients (n=95). 
As indicated (fig.4.7) the largest percentage of patients represented 
in the sample are unemployed. These patients account for 41 %, 
followed by 32% of patients who are employed full - time. A further 
14% of patients are retired, and 8% are employed part- time. An 
additional 5% of patients are self-employed (fig.4 .7 . ). 
With respect to the employment of patients, it was found that the 
majority (41%) of patients were unemployed (fig.4 .7 . ) . However, 
when taking into consideration all forms of employment , including 
full - time , part- time , and self-employment, 45% of patients are 
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employed and a further 14% are retired (fig.4.7.). Despite the fact 
that these patients are afflicted by chronic disease, these 
unemployment statistics are lower in relation to the employment 
sector of South Africa, which (according to the University of 
Stellenbosch) calculated that 44% of the labor force in the year 
2000 would be unemployed, provided there was a growth rate of 
3.1 % per annum , and unemployment would continue to increase 
(Van Rensburg e/ al., 1992). This clearly indicates that patients 
with chron ic renal failure can and do maintain an active role in 
society, and the economic sector, and can return to gainful 
employment after diagnosis. 
I ~ yes l 
I!!I No 
n=95 
Figure .4.8 . Grapbic representation of tbe percentage of 
patients taking part in activities (n=95). 
The majority: 78% of patients do not take part in activities and only 
22% of patients do take part in activities (fig.4.8). The frequency 
missing was 2, which shows that two patients in the sample did not 
answer the question within the psychosocial assessment (fig .4.8). 
As discussed by Lancaster (1979) hardly an aspect of physical, 
social, or psychological performance is left untouched by this 
disease process, which is clearly indicated by the majority of 
patients not participating in activities. These activities include 
sports, hobbies , and actIvIties in organizations. This lack of 
part ici pat ion by renal patients can be due to numerous factors, 
which range from their dialysis schedule, to the psychological 
factors and other medical conditions affecting them. However, 
where possib le, these factors should be addressed to provide the 
patient with the opportunities to return to a normal sphere of 
functioning . As discussed by Karger and Basel (1975) optimization 
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of dialysis can no longer have the gratifying significance of 
lengthening life and reinserting a patient in the restricted 
environment of the family , but rather must guarantee the full time 
restitution to society of a totally rehabilitated individual. 
With consideration of the patient's religion, it was determined that 
the larger percentage (92%) of patients are religious, and a smaller 
percentage of patients are not religious (8%). The type of religion 
and belief may influence the treatment for various reasons , 
including the choice of treatment. On the other hand the 
development of chronic renal failure may also affect religious 
beliefs and the patient's relationship with God. Religion can also 
provide support for the patient. 
It was further determined that 63% of patients classified their 
relationship with God as good, 28% of patients classified their 
relationship as close and an additional 7% classified it as distant. 
2% of patients did not have any religious beliefs. Seven patients did 
not give a response to the question. 
Patients with a distant or no relationship with their God, when 
asked whether they had a religion, said no. 
In consideration of the patient's lifestyle, it was determined that the 
majority of patient's (98%) did not smoke cigarettes , whereas the 
minority (2%) did smoke. 
Smoking is associated with more severe proteinuria and renal failure 
progression in patients with renal disease . The clinical evidence for 
this association is stronger for diabetic patients than for non -
diabetic patients. Although cessation of smoking retards the 
progression of renal failure in patients with diabetic renal disease , 
this is not the case in patients with non-diabetic renal disease 
(CARl guidelines, 2003). 
It was further determined in the consideration of the patient's 
lifestyle that the larger percentage (88%) of patients did not drink 
alcohol and the smaller percentage (12%) did drink alcohol. The 
amount or frequency of alcohol use was not determined , nor whether 
alcohol abuse was apparent. 
However, clinical observations suggest that alcohol intoxication is 
often associated with the occurrence of negative life events, and 
circumstances that precipitate alcohol abuse are those in which 
people ordinarily attempt to avoid or escape self awareness (Snyder 
& Forsyth , 1991). 
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It was additionally determined that 99% of patients did not have 
other habits, whereas I % of patients did have other drug related 
problems . Drug abuse, like alcohol abuse, predominantly results 
from an attempt to avoid or escape self- awareness , and may be 
associated with negat ive l ife events . 
4.2 .3.2. Patients' immediate family history 
The patients' immediate family history was taken into consideration 
as it is an important component. Many conditions may be inherited , 
such as renal conditions, or diabetes. 
Consideration of the immediate family history indicated that 58% of 
patients' immediate family did not suffer from hypertension and 
42% of them did suffer from hypertension. 76% suffered from heart 
conditions whereas 24% of patient ' s immediate family did suffer 
from heart conditions. 76% suffered from diabetes whereas 24% of 
the patients' immediate family did not suffer from diabetes . The 
majority of patients ' immediate family (80%) did not suffer from 
renal conditions , whereas the minority of patients' immediate family 
(20%)did suffer from renal related conditions. 
4.2.3.3. Patient's previous hospitalizations 
ICNO I 
I!!IYes 
n=95 
Figure .4.9. Grapbic representation of patient's previous 
bospitalizations (n=95). 
The larger percentage of patients (67%) was previously hospitalized 
and a smaller percentage of patients ' (33%) were not hospita lized 
prior to commencement of renal replacement therapy (fig.4 .9). 
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As can be seen above , the major i ty of patients (67%) have 
previously received prior medical treatment , not necessarily renal 
related . As depicted in the screening, their admission diagnosis may 
in fact vary. However , previous med ical history is of vital 
importance (fig.4 .9). 
The question arises: could the patient's renal insufficiency not have 
been detected earlier and perhaps managed better? Could the patient 
not have been educated w ith regard to his /her high r isk of kidney 
d isease , and been encouraged to take responsibility in conjunction 
with his/her medical team, to monitor his /her condition and slow its 
progression. 
4.2.3 .4. Preparation and knowledge of the patient. 
The preparation of the patient for chronic RRT and the knowledge 
of the patient regarding chronic kidney failure , were investigated . 
The results are displayed in table below (table 4.3). 
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Table 4.3. Preparation and knowledge of the patient (n=95) 
Number Question Yes No YeslNo Frequency 
Frequency % Frequency % Frequency % missing 
1 Patients prepared prior to commencement ofRR T. 17 18 77 82 0 0 I 
2 Patients informed prior to commencement ofRRT. 34 36 59 63 1 1 I 
Patients' rena1 impairment managed prior to 
3 commencement ofRRT. 23 24 71 76 0 0 1 
Patients who were part of a support group prior to 
4 commencement ofRRT. 6 6 89 94 0 0 0 
Patients educated regarding kidney disease prior to 
5 commencement ofRRT. 23 24 71 76 I 
Patients who would have liked to participate in a 
6 PESRD program. 81 92 7 8 7 
7 Patients who are aware of the cause of renal failure 58 61 37 39 0 
8 Patients' knowledge with regard to fluid intake. 87 97 3 3 5 
Patients' knowledge with regard to anemia 
9 management. 59 66 31 34 5 
10 Patients' knowledge with regard to diet. 84 95 4 5 7 
Patients' knowledge with regard to the complications 
11 of renal failure. 63 70 27 30 5 
Patients' knowledge with regard to the handling of 
12 complications. 56 62 34 38 5 
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With regard to whether the patients were prepared prior to 
commencement of RRT , it was found that the minority of patients 
(18%) were prepared prior to commencement of therapy, whereas the 
majority (82%) of patients were not prepared for therapy. One 
patient did not provide a response to the question (table 4.3). 
When patients were asked whether they were informed prior to 
commencement of RRT, it was found that the majority (63%) of 
patients was not informed prior to commencement of RRT , and 36% 
of patients were informed prior to therapy. A further I % of patients 
were informed, but felt that they were not adequately informed and 
therefore answered both yes and no. One patient did not respond to 
the question (table 4.3) . 
As to whether the patient ' s renal impairment was managed prior to 
commencement of RRT , it was determined that the majority (76%) 
of patients' renal impairment was not managed prior to 
commencement, and only 24% of patients with renal impairment 
were managed prior to commencement of renal replacement therapy . 
One patient did not respond to the question (table 4 .3). 
With regard to whether the patient took part in a support group prior 
to commencement of RRT , it was found that the larger portion 
(94%) of patients did not take part in a support group , and only a 
small portion of patients (6%) did take part in a support group prior 
to commencement of therapy (table 4 .3) . 
It was concluded that the majority of patients (76%) were not 
educated regarding kidney disease and only 24% of patients were 
educated regarding kidney disease prior to commencement of 
therapy. One patient did not answer the question (table 4.3). 
However when the patients were asked whether they would have 
liked to participate in a PESRD program , it was found that 92% of 
patients would have liked to participate in a PESRD program and 
only 8% of patients did not want to participate in a PESRD . Seven 
patients did not respond to this question (table 4.3). 
Furthermore, it was concluded that the majority of patients (61 %) 
were aware of the cause of their renal failure , whereas the minority 
(39%) were unaware of the cause of their renal failure 
(table 4.3) . 
In conclusion with regard to table 4 . 3, 36% of patients were 
informed regarding their condition prior to the commencement of 
therapy and yet only 24% of patients ' renal impairment was 
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managed prior to commencement of therapy, and only 18% of 
patients were prepared for renal replacement therapy. 
Seventy-six percent (76%) of patients were not educated regarding 
kidney disease prior to the commencement of RRT and only 6% of 
patients participated in support groups. A further 39% of patients 
were still not aware of the cause of their renal failure after 
commencing RRT. 
Yet the majority (92%) of patients would have liked to participate 
in a PESRD program, so therefore question arises: why are we not 
(when possible) providing the patients with this option? Why are we 
blindfolding our patients to reality? 
As indicated the majority of patients did not have the benefit of a 
PESRD program , nor did they benefit from cardioprotective and 
renoprotective strategies. 
Thereafter the patients ' knowledge with regard to the management 
of their kidney disease was considered, with respect to fluid intake , 
anemia management , diet, the complications involved in renal 
failure and the management thereof. 
It was found that 97% of patients are aware of how to manage their 
fluid intake, and a further 3% of patients are unaware of how their 
fluid should be managed. Five patients did not respond to the 
question (table 4.3). 
The majority (66%) of patients were aware of anemia and tho: 
treatment thereof. However, 34% of patients did not understand 
their anemia and the treatment thereof. Five patients did not answer 
the question (table 4 .3) . 
The majority of patients (95%) were aware of how to manage their 
diet, whereas the minority (5%) of patients was not aware of to how 
manage their diet. Seven patients did not respond to the question 
(table 4.3). 
The majority (70%) of patients was aware of the complications 
associated with renal disease and a further 30% did not know what 
the complications of renal failure were. Five patients did not answer 
the question (table 4.3) . 
Sixty-two (62%) of patients were aware of how the complications of 
renal disease are managed, whereas 38% did not know how the 
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complications of renal failure are managed. Five patient s did not 
answer the question (table 4.3). 
Even though (as indicated in table 4.3) the majority of patients are 
aware of how to manage their kidney disease with respect to fluid 
intake , anemia management , diet , complications of renal failure, and 
handling thereof, there is still a m inor ity who are not aware of how 
to manage their kidney disease. 
Particularly in this stage of renal fa i lure patients should be aware of 
how to manage their kidney disease , as educating the patient can 
have a direct impact on patient compliance and well being , and even 
morbidity and mortality. In addition , as according to Robinson 
(200 I), kidney disease education lowers the cost of care for the 
patient, facility and government, and it lowers stress for both 
patients and famil ies. 
4.2 .3 .5 . Patients' perspective of their disease 
According to Lancaster (1979) there is hardly an aspect of physical , 
social or psychological performance that is left untouched by the 
disease process. The results that follow look at the patients ' 
perspectives of their disease . 
I-Nol ~ 
n=95 
Figure .4.10. Grapbic representation of the patients' 
Perspectives as to tbe serionsness of tbeir 
renal failure (n=95) . 
The majority (68%) of patients felt that their renal failure was a 
serious disease and a further 32% of patients felt it was not serious. 
Two patients did not respond to the question (fig. 4.10) . 
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As previously described by Cameron (1996) , renal failure can be a 
frightening and bewildering time. The majority of patients perceive 
renal fai l ure as a serious condition (fig. 4 . 10). It is a condition that 
is life threatening and it entails dependency on dialysis or 
transplantation as a means of survival. 
1% 
1% 
III No 
• Sometimes 
o Yes 
OYes/No 
n=95 
Figure .4.11. Grapbic representation of tbe restriction tbat 
renal failure imposes (n=95). 
As indicated in figure 4.11, 55 % of patients felt their life was 
restricted by renal failure . A further 42% felt that having renal 
failure did not restrict their life and I % felt that renal fail ure 
restricted their life only sometimes. An additional I % of patients 
felt that renal failure restric ted certain aspects of their life and 
other aspects of their life where unaffected. Three patients did not 
respond to the question (fig. 4.11). 
The majority of individua l s suffering from renal failure are deprived 
of physical autonomy , robbed of satisfying work and interpersonal 
experiences , and often forced to withdraw from their pre-morbid 
social sphere of functioning. Renal failure can be seen as a major 
restriction, as indicated by the majority of individuals. On the other 
hand , as indicated by some, it can become apart of life , instead of a 
restriction. 
According to Karger and Basel (1975), optimization of dialysis can 
no longer have the gratifying significance of lengthening life and 
reinserting a patient into the restricted environment of the family. 
Yet the majority of patients within the study felt that they are 
restricted. Therefore, in reference to Karger and Basel, their 
dialysis is not optimal. 
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Dialysis should rather guarantee the full-time restitution to society 
of a totally rehabilated individual, which has not yet occurred for 
the patients taking part in the study. 
4.2.3.6. Patients' acceptance of chronic renal failure 
1% 
44% o Acceptance 
I!I Denial 
iii Bargaining 
n=95 
Figure 4.12. Graphic representation of the phases of acceptance 
at commencement of RRT (n=95) 
The majority of patients (55%) were in a phase of denial at the 
beginning of RRT, and a further 44 % of patients were in a phase of 
acceptance . The minority of patients (I %) were in the bargaining 
phase at commencement of RRT. An additional eight patients did not 
respond to the question (fig. 4.12). 
It must be remembered that the phase of acceptance may be 
influenced by the way dialysis was initiated: whether the patient 
was informed prior to development, or whether this was their first 
acknowledgement of renal insufficiency. This will be taken into 
consideration and discussed further on. 
4.2.3.7. Effect of chronic kidney disease on the family 
The effect that chronic kidney disease has on the patients' family 
was investigated. The results are displayed in table 4.4. 
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Table 4.4: The effect of chronic kidney disease on the family 
Number Question Yes No Sometimes Frequency 
Frequency % Frequency % Frequency % mlssmg 
I Support system of the patient. 84 92 6 7 I 1 4 
2 Families affected by the kidney disease. 31 33 64 67 0 
3 Additional pressure placed on family by kidney disease. 15 16 80 84 
4 Patients' families worried about the kidney disease. 44 46 51 54 
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The majority (92%) of patients had s upport from family and friends, 
whereas 7% did not have a support system. A further 1 % felt they 
had support but only sometimes. Four patients did not respond to the 
question (table 4 .4) . 
S upport from family and friends is vital and , as indicated, the 
majority of individuals are fortunate enough to have this component 
in their lives, as the disease itself affects not only the patients , but 
the family and friends are also affected in some way or another. 
As indicated in the table (table 4.4) , 67% of patients felt that their 
renal failure had no direct effect on their family, whereas 33% of 
patients felt that it did have an effect on their family. 
The majority , 84% of patients felt that their kidney disease did not 
place any additional pressure on their family, whereas a further 16% 
of patients felt that their kidney disease placed additional pres s ure 
on their family's lives (table 4.4) . 
According to the patients 54% of their families 
about their condition, whereas 46% of patients 
families are worried about their disease (table 4.4). 
are not worried 
feel that their 
The dialysis patients along with their families are constantly 
vulnerable to medical , social and emotional CrIses . Various 
literatures have indicated that renal failure affects not only the 
patient, but also the family , and it may place strain on the family . 
However, surprisingly the majority of patients felt that their kidney 
disease had no direct affect on their family, and did not place 
additional pressure on the family, nor were the families worried 
about their kidney disease as indicated in the results (table 4 .4) . 
lt must be acknowledged that this was the patient's perspective and 
not in fact the family and therefore may not be a true reflection on 
the impact of the disease on the family. 
4.2.3.8. Patients informed regarding treatment 
An investigation of whether or not the patients were informed 
regarding the various treatment modalities was conducted. The 
results are displayed in the table below (table 4 .5). 
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Table 4.5: Patients informed regarding treatment 
Only 
Number Question Yes No afterwards Frequency 
Frequency % Frequency % Frequency % mlssmg 
1 Patients informed regarding different treatment modalities. 71 79 18 20 I I 5 
2 Choice of treatment. 55 61 35 39 5 
3 Patients' satisfaction with treatment. 83 93 6 7 6 
Number Question Yes No Do not know Frequency! 
Frequency % Frequency % missing 
4 Number of patients on the transplant list. 47 55 38 44 I I 9 
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As displayed in table 4.5, the majority of patients (79%) felt that 
they were informed about the various treatment regimens available. 
A further 20% of patients felt that they were not informed and a 
minority of I % felt that they were informed only after commencing 
treatment. Five patients did not respond to the question (table 4 .5). 
The larger portion (61 %) of patients chose their treatment, whereas 
a smaller portion of patients felt they did not choose their treatment 
(table 4.5) . 
The majority of patients (93%) are satisfied with their treatment, 
whereas 7% of patients are not satisfied with their treatment. Six 
patients did not respond to the question (table 4.5). 
The majority of patients (55%), is awaiting a transplant and are on 
the transplant list. A smaller portion of patients (44.19%), are not 
on the transplant list, and a further 1.15% of patients do not know , 
or are not sure. Nine patients did not respond to this question (Table 
4.5). 
Although the majority of patients were informed regarding the 
treatment modalities, not all patients were, and not all patients 
chose their treatment option. 
Surely a treatment on which life is dependent which impacts the life 
of a patient in such a way as RRT should be discussed with patient? 
Even if the patient is not able to be treated by a specific treatment, 
should the patient not be informed and have the reason why slhe is 
not able to make use of it, explained? The patient should be 
provided with the opportunity, if not to decide the type of 
treatment, at least to participate in the decision and be made to feel 
like slhe infact chose the treatment with the doctors' guidance. 
The majority of individuals are awaiting transplant, which indicate 
the shortage of available donors. 
4.2.4. LABORATORY RESULTS 
(Group B patients; n = 95) 
The table below (table 4.6) indicates the means of the blood taken 
from the 95 patients taking part In the study a month prior to 
commencement (where available); at commencement of therapy; a 
month after, and 3 months after . 
The highlighted areas indicate abnormal results. 
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Table 4.6: Blood results of CRF patients 
Prior to At After 1 After 3 
Normal RRT' Commencement month months 
Value 
Males/Fe Mean S.D Mean S.D Mean S . D Mean S.D 
males 
GFR 120-125 9 .62 5 6 .7 3.42 
mllmin/l . 
73m ' 
Sodium (Na) 135-150 137 . 11 4 .65 138 4 .54 138 .34 3 . 19 138 .6 4 . 57 
mmol/L 
Potassium 3 .5-5 4 .31 0.98 4 .91 0 .92 4 . 39 1 4 .72 0.94 
K) mmoliL 
Chloride (CI) 98-108 104 .67 6.73 105 7.26 102.91 5 1 103 . 14 10 . 86 
mmoliL 
Carbon 23- 19.31 3 .67 20.15 5.4 22 .24 4 .46 21 .54 4 .15 
dioxide (CO,) 27mmoliL 
S--Urea 3 .4-7 .4 30.78 14 . 7 31 .62 14 .76 22.12 9 .51 25 .89 25 .1 4 
mmoliL 
S--Creatinine 80-1151 743 313.76 984.2 468.48 775 .87 299.45 861 .07 325 .34 
53-
97umoliL 
Magnesium 0 .75-1 .15 0 .89 0 .09 0 .95 0 .2 0.94 0 . 17 1 0 .26 
Mg) mmoliL 
Phosphate 0 .8-1.4 1 .91 0.7 1.85 0 .78 1.51 0 . 51 1 .66 0 .65 
mmoliL 
Albumin 35-52 giL 32 .64 4 .7 30 .7 7.15 33.87 5 .42 34 .88 4 .55 
Calcium 2 .15-2.5 2 . 16 0 .27 2.28 0 .36 2 .37 0 . 32 2 .39 0 .3 
mmoliL 
Cholesterol 3-5 .2 5 .57 4 .8 1 .73 4 .49 1 . 32 4 .32 1 . 11 
mmoliL 
S--Iron 9- 22 .73 31 .66 10 .52 5 .92 12 .56 5 .99 11 .05 5 .53 
30umoliL 
S-Transferrin 2 .00- 1.75 0 .29 4 .63 9 .75 8 .01 28 .84 1.72 0.36 
3 .6g/L 
S-Ferritin 15- 331 .25 291.22 527.7 583 . 1 457 .5 3 494.89 431.98 439 .1 8 
200ng/ml 
% Saturation 15-50% 23 .17 6 .96 27 .93 17 .01 31 .78 18 29 . 19 19 .31 
Hemoglobin 14-181 9 .38 2 .11 8.93 2 .23 9 .1 7 2 .03 9.44 2 . 15 
IIHb) 12-16g/dL 
Hematocrit 42-521 0 .29 
IIHCT) 37-46% 
Parathyroid 15-65ng/L 511 327 .62 832 .6 1291.39 320.28 246.15 423 .65 486 .38 
hormone 
IIPTH) 
, RR T - R ena l Replacement T herap y 
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4.2.4.1. Prior to renal replacement therapy - Laboratory results 
(All data discussed in 4.2.4.1. is indicated in table 4.6) 
The results obtained from the 'prior to RRT' column were obtained 
from 16 patients; these were the only patients for whom blood 
results were available one month prior to commencement of RRT 
(table 4.6). The mean glomerular filtration rate (GFR) in this group 
was 9.62 mLlminll.73m 2 • With reference to the various guidelines 
(2.5.2), dialysis should have been implemented immediately in this 
group, yet it was postponed for another month. It must, however, be 
acknowledged that there was a standard deviation of 
5mLlminll.73m 2 • 
This postponement may adversely affect the patient. 
As indicated the mean CO 2 is 19.3ImmoIlL, which is low and, as 
discussed below, may be due to several reasons, including the use of 
diuretics, or from vomiting (table 4.6). 
The mean urea IS 30.78mmo1lL and the mean creatinine IS 
743f1moIlL, which are both high and is characterized by the uremic 
syndrome, and a severe decline in renal function. Both these values 
had increased at commencement, but declined after commencement 
as result of the implementation of renal replacement therapy (table 
4.6). 
The elevation of phosphates (mean 1.9lmmollL) predisposes the 
patient to the risk of developing extraosseous deposits of calcium 
(table 4.6). 
The mean albumin was below normal (32.64mmoIlL) and indicates 
that deterioration of nutritional status often begins early in the 
course of chronic renal insufficiency. However, when serum albumin 
stores started to fail, the diet should have been adjusted (table 4.6). 
According to the CARl, CSN and NIH, dialysis should have been 
commenced in this group when malnutrition resulted from a failure 
to respond to dietary intervention. 
Both the transferrin and ferritin are abnormal: the transferrin is low 
and the ferritin is high. Alterations in iron and total iron binding 
capacity levels are indicative of a wide range of dysfunctions, 
including anemias and nephrosis (table 4.6). 
The mean hemoglobin in this group was below normal (9.38g/dL, 
with a standard deviation of2.llg/dL) (table 4.6). 
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Despite the known benefits of treatment, anemia still remains 
common among CRF patients. Due to lack of awareness of the 
prevalence of anemia in the CRF population, there is a lack of 
screening for anemia and hence a lack of early intervention. 
Complete prevention of anemia may minimize the development of 
LVH and/or other manifestations of CVD, and reduce the mortality 
rate in this population in the long term . 
The mean PTH was high (511 ng/L), with a standard deviation of 
327.62ng/dL (table 4.6). 
Effective management of secondary hyperparathyroidism in the early 
stages of CRF is important to prev ent the development of renal 
osteodystrophy, which is a mutlifactorial disorder characterized by 
abnormal bone remodeling. If excess PTH secretion is not treated , it 
leads to full-blown secondary hyperparathyroidism, which is 
associated with many deterious effects on CRF patients. One report 
suggest that immediate pre-dialysis (CCr <IOml/minll .73m 2 ) PTH 
levels should be maintained at higher level of 300-500pg/ml to 
prevent renal osteodystrophy (Avram, 2001). However the ideal 
level of PTH in pre -dialysis patients has not been clearly defined. 
Th is constellation of physiochemical changes that occurs with renal 
failure is referred to as uremia or the uremic syndrome 
4.2.4.2. At commencement - Laboratory results 
(All data discussed in 4.2.4.2. is indicated in table 4.6) 
Survival of end-stage renal disease patients on dialysis depends , to 
a large extent, on their condition at the time dialysis was first 
initiated. 
The mean GFR at commencement was 6.7ml/minlI .73m 2 , which 
according to the majority of guidelines already discussed, means 
that dialysis should have already been commenced (table 4.6). 
The DOQI guidelines suggest that dialysis should be commenced 
when the GFR is between 9-14ml/min/1.73m2, irrespective of 
diabetic status. Whereas the NIH suggest commencing dialysis when 
the GFR is less than I Occ/min or 15cc/min in diabetics ( table 4.6). 
This delay in ini tiation of dialysis may have an adverse effect on 
the patient's long term survival (Daugirdas el 01., 200 I). 
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Carbon dioxide (C02) measurements are used in the diagnosis and 
treatment of numerous potentially serious disorders associated with 
changes in body acid - base balance. The majority of patients' C02 
was low, with a mean of 20 . 15mmollL. Alkalosis resulting from a 
decrease in CO 2 can be due to numerous reasons, including the 
administration of diuretics, except the carbonic anhydrase 
inhibitiors, excess aldosterone , and ingestion of alkaline drugs and 
vomiting, which can be associated with the uremic syndrome. 
However, usually in CRF there is a build-up of the anions of weak 
acids in the body fluids that are not being excreted by the kidneys . 
In addition , the decreased GFR reduces the excretion of NH 4 + , 
which reduces the amount of bicarbonate added back into the body 
fluids. Thus, CRF can be associated with severe metabolic acidosis 
(table 4.6). 
Furthermore , metabolic acidosis is an indication for commencing 
chronic renal replacement therapy. 
The mean urea was 31.62mmo1lL with a standard deviation of 
14.76mmo1lL and the creatinine mean was 984.21!mo1/L with a 
standard deviation of 468.481!mo1/L (table 4 .6). 
As previously discussed the systemic effects of uremia are 
numerous , affecting all systems .. 
The CSN guidelines suggest that dialysis should be commenced in 
patients with clinical evidence of uremia. 
The mean phosphate was elevated, 1. 85mmo1/L with a standard 
deviation of O.78mmoI/L. Patients suffering from 
hyperphosphatemia are at risk of developing extraosseous deposits 
of calcium (table 4.6). 
The serum albumin is one of the most powerful measures of visceral 
protein and was therefore used in the study. 
The serum albumin is low , as the mean for the 95 patients was only 
30.7g/l. The symptoms the patients experience may interfere with 
appetite and dietary intake. It has been proven that malnutrition is a 
strong predictor of poor clinical outcome and mortality. A low 
serum albumin is also a risk factor for cardiac disease in dialysis 
patients (table 4.6). 
According to the DOQI guidelines the ultimate survival on dialysis 
depends greatly on nutritional status and albumin status at the time 
dialysis is initiated. The CARl guidelines suggest that dialysis 
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should be commenced at the first sign of malnutrition when it is 
suspected to be due to uremia a nd unresponsiveness to dieta ry 
intervention or correction of other reversible causes . T his correlates 
with the CSN guidelines , which suggest that dialysis be commenced 
in patients with clinical evidence of malnutrition. The NIH suggests 
that dia lysis be commenced earlier than IOcc/m in if a lbumin is less 
than 4 . 
The mean ferritin was 527 . 7ng/ ml , with a standard deviation of 
583 . lng/ml. An elevated ferritin, up to IOOOng / ml , indicatives an 
acute phase reaction and non-specific tissue damage , e .g. lung 
infection; osteomyelit is ; urinary tract infection , or SLE (table 4 .6) . 
The mean hemoglobin at commencement was 8 .93g /dL with a 
standard deviation of 2 .23g/ dL , which was further decreased when 
compared to the PESRD group (table 4.6). 
Anemia is characterized by a state of low hemoglobin lev e ls , 
resulting In deficient transport and release of oxygen throughout the 
body. 
Anem ia remains the leading cause of morbidity and mortality among 
patients with chronic kidney disease . In particular anemia 
contributes to cardiac complications via LVH , and ha s been shown 
to be a major contributory factor in the development of CVD . In 
addition , failure to treat anemia results in an increase in RBC 
transfusions , and a decrease in quality of life , a decrease in exerc ise 
tolerance and impaired cognitive functioning . F urthermore , an 
increase in blood transfusions can adversely affect graft survival 
and holds further dangers of transmission of diseases and reactions . 
The mean PTH was greatly increased (832 .6ng/ L , with a standard 
deviation of 1291 .36ng/ L) when compared to the normal va lues. 
Elevated PTH hormone is ubiquitous i n patients with chronic renal 
failure. As renal function decreases , serum calcium levels and 
vitamin D hormone levels tend to decrease , while the serum 
phosphorus levels tend to increase (table 4 .6). 
4 .2.4.3. One month and three months after commencement 
(All data discussed in 4.2.4 .3. is indicated in table 4.6) 
The C02 has remained low, w ith a mean of 22 .24mmo 1/L and 
21.54mmo1 / L after 3 months. It has , however , increased since the 
commencement of RRT. 
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Urea and creatinine have remained high, which indicates chronic 
renal failure, but have declined with the implementation of dialysis. 
The phosphates are still above normal but have declined since 
commencement. 
Albumin is also still below normal but has continued to rise, since 
commencing RRT, showing an improvement in nutritional status. 
It is not only the symptoms experienced by patients that interfere 
with appetite and dietary intake, but the severe dietary restrictions 
also contribute to their nutritional status. 
The transferrin after one month is elevated above normal and after 
three months has declined to below normal. The ferritin remains 
high but has also declined from 527.7ng/ml at commencement to 
431.98ng/ml after 3 months of treatment. 
The hemoglobin has also risen since commencement, when it was 
8.93g/dL, and after 3 months has gone up to 9.44g/dL . However this 
is still low in comparison to the normal values. 
The PTH has remained high during the first three months of 
treatment. 
All these changes are related to fluid and electrolyte abnormalities, 
disordered regulatory functions (anemia, hypertension, renal 
osteodystrophy, and metastatic calcification) and the accumulation 
of uremic toxins, which causes physiological changes and alter the 
functions of various organ systems. 
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4.2.5. SUBJECTIVE GLOBAL ASSESSMENT 
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Figure 4.13: Graphic representation of subjective global 
assessment 
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The subjective global assessment is a clinical technique used for 
assessing the nutritional status of a patient based on features of the 
patient's history and physical examination. 
As described in the graph (Fig. 4.13) 49.47% of patients fall into 
the B category, 32.63% fall into the C category and the remainder 
17.90% fall into the A category of the SGA. 
As indicated above (Fig 4.13.) , the majority of patients commencing 
renal replacement therapy fall into Category B, which suggests that 
patients are moderately or suspected to be malnourished. The second 
largest percentage of patients fall within category C, which implies 
that they a re severely malnourished, and only a minority, fall within 
category A, which suggests that the patient is well nourished. 
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4. 2.6. TREATM ENT 
Renal Replacement Therapy 
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Figure 4.14 : Graphic representation of treatment regimens over 
a three month period, from date of commencement. 
As demonstrated in the graph (Fig.4 . 14), the majority of patients 
(95%) commencing renal replacement therapy had acute 
hemodialysis (AHO) as their first treatment modality . A further 3% 
of patients had chronic hemodialysis (CHO), and I % had continuo u s 
ambulatory peritoneal dialysis (CAPO). An addit ional 1% had 
continuous veno - venous hemodialysis (CVVH / O) as the first 
dialysis treatment. 
After I month of treatment , 94% of patients were on CHD. A further 
5% were on CAPO and an additional 1% was on APO (Fig 4 . 14) . 
After 3 months of treatment, 97 % of patients were on CHO and 3% 
of patients were on CAPO (Fig 4.14). 
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4.2.7. ACCESS FOR RENAL REPLACEMENT THERAPY 
Table 4.7: Total number of access placed during the first 3 
months of treatment. 
Number of Frequency Percentage 
access 
I 19 20 .00 
2 46 48.42 
3 24 25.26 
4 5 5.26 
5 0 0 
6 0 0 
7 I 1.05 
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With regard to the access during the first three months of treatment 
it was found that the majority of individuals (48%) had two access 
p lacements , a further 25.26% of patients had 3 , 20% had I access , 
5.26% had 4 and an additional 1.05 had 7 access placements (tab le 
4 . 7). 
4.3. EVALUATION OF CRF PATIENTS SUBDIVIDED 
INTO CATEGORIES . 
(GROUP B; N = 95) 
Once the 95 patients were assessed and evaluated as a group , they 
were subdivided into three categories (I , 2 and 3) based on their 
development of renal failure , fo r comparative measures . 
These three categor ies cons isted of the follow ing: 
Category 1: Acute renal failure pat ients, who were not diagno sed o r 
educated prior to the development of acute renal 
failure. 
Category 2: Chron ic renal failure patients who were aware of their 
renal insufficiency pr io r to the commencement of 
treatment but were not managed by PESRD program . 
Category 3: Chronic renal failure patients who were informed a n d 
educated regarding their renal insufficiency and 
participated in a PESRD program . 
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Figure 4.15: Graphic representation of the number of patients 
in various category subdivisions . 
As indicated in the graph (Fig. 4.15),56 patients (59%) fell into 
category 1, 22 patients (23%) fell into category 2 and the 
remainding 17 patients (18%) fell into category 3. 
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4.3.1. LABORATORY RESULTS 
4.3.1.1. One montb prior to commencement of RRT. 
Table 4.8: Laboratory results, prior to commencement of RRT 
subdivided into the various categories 
15-65 ng/L 
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According to Duncan's multiple range test, there is a significant 
difference in category I (5.32 mllmin/1.73m2), when compared to 
both category 2 (12.69 ml/min/1.73m2) and category 3 
(IO.85ml/min/1.73m 2), with regard to GFR. Furthermore there is a 
sign ificant difference in creatinine in category 1 (I 040.5~moI/L), 
when compared to category 2 (581.67~moI/L) and category 3 
(608.I~moI/L), when Duncan's multiple range test is used (table 
4.8). 
As indicated in table 4.8, all three groups have a severe decline in 
renal function , indicated by their above normal urea and creatinine 
values. 
Category I's GFR (5.32 ml/min.I .73m 2), according to the various 
guidelines, should have in fact started dialysis. With reference to 
the US DOQI guidelines (2003), which suggest dialysis be 
commenced at a GFR of between 9-14 ml/minll.73m2, both category 
2 and 3 should be commencing dialysis and not be postponed for yet 
another month (Table 4 .8). 
All three categories are suffering from hyperphosphatemia, while 
category I has the greatest elevation: 2.09 mmol/L (Table 4.8) . 
Both category I and 2 show decreased albumin levels (Table 4.8), 
and possible malnutrition, as albumin is a strong indicator of 
nutritional status. However, category 3's albumin (35.25 giL) is 
still within normal limits . 
With regard to the iron profile, the serum iron in category I is 
above normal (35.33 ~moI/L), the transferrin has declined in both 
category I (1.79 giL) and 2 (1.67 giL) and ferritin levels has begun 
to increase in both category I (382.90 ng/ml) and 2 (280.30 ng/ml). 
The hemoglobin in all three categories has declined (Table 4.8), 
while category I has the lowest Hb of 8.41 g/dL. 
PTH is elevated in both category I (70 I ng/L) and 2 (321 ng/L). 
Category 3 did not have a PTH value taken a month prior to 
commencement of RRT (Table 4.8). 
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4.3.1.2 . At commencement of RRT 
Table 4 .9: Laboratory results at commencement of RRT, 
according to categories 
Normal Value 
GFR 
\34 
Category 3 patients were the earliest group to commence RRT with a 
GFR of 8.85mllminll.73m 2 and a standard deviation of 
5 .27mllminlI.73m 2. Following category 3 is category 2 with a GFR 
of 6.96mllminlI.73m 2 and a standard deviation of 
2.07mllminlI.73m2 . Category I,s on the other hand, commenced 
RRT the latest when the mean GFR was 3.12mllminlI.73m 2, with a 
standard deviation of 2.97mllminll .73m 2 (Table 4.9). 
According to Duncan ' multiple range test the GFR is significantly 
different in category I and 3. Category I commenced dialysis at a 
lower GFR than both category 2 and 3 . 
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All 3 categories commenced dialysis later than recommended by 
various guidelines, and as previously discussed, the time at which 
dialysis is commenced can greatly influence the outcome of the 
patient. 
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All patients throughout the various categories presented showed a 
decreased CO 2 level (Table 4.9). Category 3 ( 19.7Ig/L) showed the 
greatest decrease, followed by category I (20.14g/L) and then 
category 2 (20.61 giL). 
Category 3 (34.95mmoI/L) presented showed the highest urea, 
followed by category (32 .5SmmoI/L) and then category 2 
(27.35mmoIlL). Category I, displayed the highest creatInine 
(I 061 .34J.1moI/L), followed by category 3 (959.S2J.1moI/L) and then 
category 2 (SI7.14J.1moI/L). 
Category 3 (1.95mmoI/L) showed the highest phosphate, followed by 
category 2 (1.93mmoI/L) and then category I (1.75mmoI/L). 
Category I (29 .05g/L) displayed the lowest albumin value, followed 
by category 3 (30.5g/L) and then category 2 (32 .75g/L). According 
to Duncan's multiple range test for albumin, there is a significant 
difference between category I and 2. However, all albumin results 
throughout the 3 selected categories had a below-normal albumin 
(Table 4 .9) . 
Transferrin was higher than normal in both category I (5.20g/L) and 
3 (5.66g/L), yet lower than normal in category 2 (1.76g/L). 
All categories displayed an elevated ferritin result: category the 
highest (616.69ng/ml), followed by category 2 (595ng/ml) and 
thereafter category 3 (369.5Sng/L). 
Category I and category 3 showed the same mean hemoglobin 
(S.7Ig/dl). Both were lower than category 2 (9.75g/dl), yet all three 
were below normal values. 
The PTH was elevated in all 3 categories, yet category 2 (IS07ng/L) 
showed the highest value, followed by category 3 (459ng/L) and 
then 2 (230.95ng/L). 
With respect to anemia and nutritional status, which are two strong 
predictors of patient outcome, category 2 displays the best chance, 
followed by category 3, and thereafter category I, which shows the 
poorest outcome. The nutritional status was based on the albumin 
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level , which is a strong nutritional marker and the anemia was based 
on the hemoglobin level within the three categories (Table 4.9) . 
4.3.1.3. One month after commencement of RRT 
Table 4 . 10: Laboratory results I month after commencement 
according to categories. 
The OFR was no longer calculated after implementation of renal 
replacement therapy, as it may be influenced by dialysis. Dialysis 
removes the creatinine and therefore creatinine cannot be used in 
the determination of the OFR to determine the kidney function 
accurately. 
After a month from date of commencement of RRT, category 2 ' s 
C02 level has normalized (24.47mmoI / L), yet category 1 
(21.65mmoI/L) and 3 (21.56mmoI/L) still show below normal 
results. According to Duncan's multiple range test for C02 , there is 
a significant difference in category 2 when compared to categories I 
and 3 (Table 4 . 10). 
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According to Duncan ' s multiple range test for creatinine, there was 
a significant difference between category I (844.93/1mo I/L) when 
compared to category 2 (630.68/1moI/L) and category 3 
(738.13/1moI/L) . Furthermore, urea and creatin ine remained above 
normal in all groups indicating CRF , but have, however, declined 
from date of commencement as a res u lt of dialysis (Table 4.10). 
All phosphates have remained above normal. Category 2 
(I.S8mmoIlL) has the greatest elevation, which could resu l t from 
diet or insufficient use of phosphate-binding medication (Table 
4.10). 
Album ins have increased in category I (33.91 giL) and category 3 
(34.12g/L) but have declined in category 2 (33.S3g/L). 
Transferrin has remained elevated in both category I (14 .27g/L) and 
3 (8.1 Og/L) and remained declined in category 2 (1.80g/L). Ferritin 
has declined in both category I (403.41 ng/ml) and category 3 
(238.3ng.ml) and remains elevated in category 2 (728.6ng/m l ). 
However all categories remain above normal (Table 4.10). 
The hemoglobin has increased in both category I (9.2Sg/dl) and 
category 3 (9 .0 I g/dl) and has declined in category 2 (9.09g/dl), 
however all results are st i ll helow normal (Tahle 4. 10). 
The PTH decreased In category 3 (32Sng.dl) and elevated In 
category I (3IS.3ng/dl) . 
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4.3.1.4. Three months after commencement of RRT 
Table 4.11: Laboratory results 3 months after commencement 
according to categories 
STAGE4 
Normal Value Cat. 1 Cat. 2 . Cat 3. 
Males/Females Mean S.D Mean S .D Mean 
GFR 120-
125ml/min/1 .73 m 2 
Na 135 150 mmol/l 138.1 3 . 52 140 .6 5 .75 138 
K 3.5-5 mmolll 4.65 0.81 4 .96 1.12 4.64 
CI 98-108 mmollL 104.9 4 . 55 103 . 9 7 .54 98.8 
CO, 23 27 mmolll 21.42 4.18 22.13 4 .17 21.25 
S-Urea 3.4-7 . 4 mmol/L 27 . 59 31.36 24.88 13.16 23.27 
s- 80 11 5153 97 989.2 344.3 810 . 3 201.1 783 . 1 
Creatinine j./m oi/L 
Mg 0 . 75 1 . 15 mmollL 1.02 0.31 1 0 .1 6 0 . 94 
Phosphate 0 .8 1 .4 mmolll 1.65 0 .59 1.93 0 .83 1 . 37 
Albumin 35-52 g/l 34.48 4.49 35 .62 3.33 35.46 
Calcium 2 . 15 2 . 5 mmolJL 2.35 0 .24 2.42 0.41 2.45 
Cholesterol 3-5.2 mmol/l 4 .2 1 .34 4 .35 0 .71 5 
S-Iron 9-30 ~mollL 9 .85 3.52 13.53 10.52 11.85 
s 2 . 00 3 . 6 91L 1.74 0 .3 8 1.67 0 .33 1 . 73 
Transferrin 
S Ferritin 15 200nglml 306 .2 325 672 .3 659.7 316 .7 
% 15-50% 24.28 11.89 36 .95 34 .5 25.83 
Saturation 
Hb 14 18112-16gldl 9.39 2 .14 9.39 2.17 9.63 
PTH 15-65ng1L 201.5 89.13 789 514.8 281 
138 
S.D 
4.56 
1 . 01 
21.97 
4.31 
6.73 
333.9 
0 .21 
0.49 
5.83 
0 . 32 
4.13 
0.47 
235.4 
3.39 
2 .3 
118.6 
C02 has remained low in 
commencement of treatment, 
(21.25 gIL), when compared to 
(22.13g/L) (table 4.11). 
all three groups 3 months after 
category 3,s CO 2 was the lowest 
category I (21.42g/L) and category 2 
Urea and creatinine remained above normal. However this expected 
as patients have diplayed chronic renal failure (tab le 4.11). 
According to Duncan's multiple range test there is a significant 
difference in the phosphates of category 3, when compared to 
category I. The phosphates remained elevated in both category 1 
(1 .65mmoIlL) and 2 (1.93mmoIlL), and normalized in category 3 
(1 .37mmoIlL). 
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The transferrin was found to be below normal in all three groups , 
and ferritin has remained high in all three groups (Table 4.11). 
All the Hb have remained low , (Table 4.11) , although it has risen 
over the last two months. 
All PTH has remained elevated above normal values , although it has 
declined from prior data (Table 4 . 11). 
4.3.2. FIRST TREATMENT OF RENAL REPLACEMENT 
THERAPY, WITH RESPECT TO THE SUBDIVIDED 
CATEGORIES. 
% of patle nts 
In = 96) 
1 
AHD CWHD CHD CAPD 
Renal replace nnt therapy 
~ Category 1 (n = 56) 
• Category 2 (n = 22) 
o Category 3 (n = 17) 
Figure 4.16: Grapbic representation of tbe first treatment 
according to tbe subdivided categories. 
As demonstrated in the figure above (Fig.4.16), 98% of patients in 
category I commenced dialysis with acute hemodialysis (AHO) and 
a further 2% of patients commenced dialysis with continuous veno-
venous hemodialysis (CVVHO). 
In category 2 95% of patients had acute hemodialysis as their first 
treatment and 5% of patients had continuous ambulatory peritoneal 
dialysis (CAPO) as their first treatment. 
In category 3 88% of patients underwent acute hemodialysis as their 
first treatment and the remainder 12% of patients underwent chronic 
hemodialysis (CHO) as the first treatment. 
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4.3.3. NUMBER OF ACCESSES PLACED DURING THE FIRST 
THREE MONTHS OF RRT, ACCORDING TO THE 
SUBDIVIDED CATEGORIES. 
140 
From the results obtained it was determined that category 1 had the 
most accesses placed (2.32). Category 2 had the second most number 
of accesses placed (2.23) and was followed by category 3, which 
had the smallest number of accesses placed (1.82). 
4.4. EVALUATION OF CRF PATIENTS SUBDIVIDED 
ACCORDING TO GFR RATE INTO VARIOUS 
STAGES. 
(GROUP B; N = 95) 
The 95 CRF patient's GFR at commencement of RRT was noted and 
used to subdivide the patients into four stages of GFR. The patients 
were placed into one of the stages , dependent on their GFR at 
commencement of RRT. 
These four stages consisted of the following: 
Stage I: Chronic renal failure patients, who commenced RRT at a 
GFR of between 0-5ml/minll.73m2 . 
Stage 2: Chronic renal failure patients who commenced RRT at a 
GFR of between 6-IOml/minll.73m2. 
Stage 3: Chronic renal failure patients who commenced RRT at a 
GFR of between 11-15ml/minll.73m2. 
Stage 4: Chronic renal failure patients who commenced RRT at a 
GFR of between 16-20ml/minll.73m2 • 
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Percentage 
('!o) 
of patients 
STAGE 1 STAGE 2 STAGE 3 STAGE 4 
(0-5) (6-10) (11-15) (16-20) 
Stage based on GFR (ml/mIn/1.73m 2) 
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1 ~(n=95) 
Figure 4.17 : Grapbical represeutation of tbe number of patieuts 
in various GFR stages 
From the total 95 patients taking part in the study, 44 patients 
(46%) fell into stage I, 39 patients (41 %) fell into stage 2, 11 
patients (12%) fell into stage 3 Only I (I %) patient fell into stage 
4 (figure 4.17). 
4.4.1. LABORATORY RESULTS 
All blood results from the patients subdivided into the various 
stages of GFR were considered. Stage 4 consisted of only one 
patient, and will, therefore not be discussed as the results are 
limited to only one person , and may not represent the general renal 
population in that stage . 
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Table 4.12: Laboratory results oftbe various subdivided G"~R Stll~C8 over it" ",ont.h pcr\od ,,~ 
Prior to commencement At commencement After 1 month After 3 months \ 
Normal Value 
Sta.e1 Stage 2 Sta.e 3 SI@lLe1 Stage 2 Stage 3 Stage 1 Stage 2 Slage 3 Slage 1 Slage 2 Stage 3 
Males I Females 
In = 441 In = 391 In = 111 In= 441 In = 391 In = 111 In = 441 In = 391 In -111 In= 441 In = 391 In = 111 
GFR 120-
125mllmin/1 .73m2 
6.02 11.92 12.92 3.9 7.83 12.29 
Na 135 150 mmoVL 
132.44 135.33 136.67 137.33 138.76 137.82 138.44 138.49 137.27 139.13 138.38 137.18 
K 3.5 -5 mmolll 
3.93 4.44 3.53 5.11 4.73 4.66 4.12 4.52 4.59 4.78 4.71 4.65 
CI 98 - 108 mmoi/L 
107.38 102.25 105.67 106.97 102.83 104.91 102.09 103.47 103.8 102.67 103.48 103.8 
CO, 23 -27 mmoVL 
17.63 21.5 24 17.33 21.84 22.6 21 .14 22.5 23.1 20.38 23.04 21 .6 
5 Urea 3.4 - 7.4 mmoi/L 
35.89 27.11 24 39.12 26.64 19.6 24.08 21.32 16.95 26.19 27.24 20.99 
5 80 115/53-97 
Creatinine ~moUL 
928.89 615.14 483.67 1327.3 784 496.73 946.12 681.76 465.45 1012.3 726.61 635 
Mg 0.75-1.15mmoi/L 
0.9 0.85 0.96 0.91 0.65 0.98 0.94 0.82 0.96 1.12 0.73 
Phosphate 0.8 1.4 mmoi/L 
1.98 3.45 1.84 2.09 1.61 1.28 1.54 1.34 1.29 1.75 1.61 1.58 
Albumin 35 - 52 giL 32.84 31 36 29.47 31 .55 33.44 33.33 34.13 35.11 36.36 33.08 34.44 
Calcium 2.15-2.5 mmoUL 
2.14 2.21 2.18 2.21 2.24 2.36 2.34 2.39 2.43 2.4 2.43 2.27 
Cholesterol 3-5.2 mmoi/L 
4.41 5 .5 5.37 5.45 4.28 3.4 5.17 3.66 4.23 4.42 4 .46 3.65 
S -Iron 9- 30 ~moVL 
37.87 7.6 10.47 10.35 6.1 12.82 12.35 7.73 11 .53 10.84 9.35 
5- 2.00 - 3.6 giL 
Transferrin 1.86 1.64 6.93 2.53 2 8.86 1.73 1.14 1.79 1.57 2.02 
5 Ferritin 15 - 200nglml 
168.5 494 544.89 573.99 156.85 344.7 667.83 168.13 311.68 713.85 121.4 
% 15 - 50% 
Saturation 27.6 18.73 30.88 25.99 12 31 .26 36.19 19.33 25.48 36.84 21 
Hb 14 18 112 16g/dl 9.53 9.19 11.7 8.77 8.64 10.48 8.93 9.14 10.58 9.41 9.29 10.29 
PTH 15 - 65ng/L 815 359 435.53 1454 159.8 414.05 181.67 353.37 360.52 985.95 153.5 
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4.4.1.1. One month prior to commencement of RRT . 
When considering of the blood results a month prior to 
commencement of RRT , all three stages (I, 2, and 3) should already 
have commenced treatment with respect to the various guidelines 
(Table 4.12) . 
Stage I presented with a below normal (132.44mmoIlL) sodium , a 
month prior to commencement of RRT. Stage I and 2 presented with 
a below normal carbon dioxide level (Table 4.12) . 
The elevation of urea and creatinine in all three stages (1 , 2 , and 3) 
a month prior to commencement clearly indicates the declined renal 
function (Table 4 . 12). 
All three 
phosphates 
stage 2 has 
stages (I, 2 , and 3) have above normal levels of 
a month prior to commencement (Table 4 . 12) , while 
the greatest elevation (3.45mmoI/L). 
Furthermore, stage 1 and 2 are characterized by poor nutrition , as 
albumin levels are below normal and albumin is a strong indicator 
of nutritional status (Table 4.12) . 
Stage 
whereas 
levels. 
has a slightly decreased calcium level (2.14mmoI /L ) , 
both stage 2 and stage 3 present with normal calcium 
Cholesterol is above normal in stage 2 (5.5mmoI / L) and stage 3 
(5.37mmoI / L), yet normal in stage I (4.4lmmoI/L). 
With regard to the iron profile the serum iron is below normal in 
stage 2 (7.6IlmoI/L) and above normal in stage 1 (37 .S7IlmoI/L) . The 
transferrin is below normal in both stage 1 (I.S6g/L) and stage 2 
(1.64g/L) and yet above normal in stage 3 (I0 .47g/L). The ferritin is 
elevated in both stage 2 (494ng/ml) and stage 3 (544.S9ng/ml) . The 
percentage saturation for all three groups is within normal limits 
(Table 4.12). 
The hemoglobin in all three stages (I, 2 , and 3) is below normal 
while stage 2 (9 . 19g/dl) has the lowest hemoglobin (Table 4.12). 
The parathyroid hormone is above normal in both stages I (SI5ng / L) 
and 2 (359ng / L). No parathyroid hormone result was available for 
stage 3 a month prior to commencement of RRT (Table 4.12). 
© Central University of Technology, Free State
144 
4.4.1.2 . At commencement of RRT 
With regard to the laboratory results at the commencement of RRT, 
it can be seen ~Table 4.12) that the mean GFR for sta~e 1 was 
3.9ml f minll.73m : for stage 2 it was 7 .83 ml f minfl .73m and for 
stage 3 it was 12.29 ml f min f I.73m 2. 
Duncan ' s multiple range test for GFR clearly displayed the various 
subdivisions made, indicating that each group is significantly 
different from each other based on the GFR at commencement. 
The potassium in stage was above normal (5.llmmoIfL) , 
predisposing the patients to the risks associated with hyperkalemia . 
All three stages (I , 2, and 3) still have a below normal carbon 
dioxide level (Table 4 . 12). 
Both urea and creat inine are above normal in all three stages (1 , 2 , 
and 3) , which is evidence of the severely declined renal function . 
T he creatinine has increased in all three stages when compared to 
the laboratory results obtained a month prior to commencement 
(Table 4.12). 
Stage 3 showed with a below normal magnesium level , as opposed to 
both stage 1 and stage 2, which showed a normal magnesium level 
(Table 4.12) . 
All three stages (I , 2 , and 3) showed hyperphosphatemia (Table 
4 . 12) , while stage 1 presenting with the highest value (2.09mmol f L) . 
All three stages (I , 2, and 3) showed a below normal albumin level 
(Table 4 . 12) , with stage I showed the lowest albumin (29.47gf l). 
Stage I's cholesterol elevated from 1 month prior to commencement 
to 5.45mmolfL at commencement. Both stage 2 and 3 ' s cholesterol 
decreased from a month prior to commencem e nt to commencement 
of therapy ( T able 4.12) . 
With regard to the iron profile, stage 3 ' s serum iron is below normal 
(6 . lflmol fL) , and stage 1 and 2 ' s have normalized . Stage I ' s serum 
transferrin is above normal value s, whereas stage 2 and 3's are 
normal. The ferritin is above normal in stage I (544.89ngfml) and 
stage 2 (573.99ng f ml) and normal in stage 3 (156.85ngfml). The 
percentage saturation is below normal in stage 3 (12%) . 
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The hemoglobin level has remained below normal in all three stages 
(Table 4.12). 
Furthermore the parathyroid hormone is above normal in all three 
stages (Table 4.12). 
With the above in mind it must be remembered that the survival of 
an end - stage renal disease patient on dialysis depends, to a large 
extent , on their condition at the time dialysis was first initiated. 
4.4.1.3. One month after commencement 
With regard to the laboratory results one month after commencement 
of treatment , the urea and creatinine remain elevated , which is 
common in chronic renal failure patients (Table 4.12). 
After I month the carbon dioxide levels in stage I (21.14mmoIlL) 
and stage 2 (22 . 5mmoIlL) were below normal, whereas the level in 
stage 3 was normal (23.1 mmoIlL) . 
Phosphate levels decreased , but remained above normal in stage I 
(1.54mmoIlL). Stage 2 and stage 3 ' s phosphates normalized (Table 
4.12) . 
The albumin increased from commencement , but remained below 
normal in both stage I (33 .33g / L) and stage 2 (34.13g/L), and 
normalized in stage 3 (35 . llg/L). 
With regard to the iron profile, the serum iron has increased in both 
stage I (12.S2I1moI / L) and stage 2 (12.35I1moI /L ) and remained 
below normal in stage 3 (7.73I1moI /L ) . The serum transferrin was 
above normal in stage I (S.S6g / L) and below normal in stage 2 
(1,73g / L) and stage 3 (1 . 14g/L). The ferr i tin was above normal in 
stage 1 (344 .7ng/L) and stage 2 (667 .S3ng/L). 
The hemoglobin has remained below normal in all three stages (1,2 , 
and 3) , and the parathyroid hormone has remained a bove normal in 
all three stages (Table 4.12). 
4.4.1.4. Three months after commencement of RRT 
Three months after the date of commencement the carbon dioxide 
levels were found to be below no rmal in both stage 1 (20.3SmmoI / L) 
and 3 (21.6mmoI / L) . 
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The urea and creatinine remain above normal in all three stages , 
representing chron ic renal fa i lure (Table 4 . 12) . 
The magnesium decreased in stage 3 (O .73mmoIlL) and was below 
norma l, yet remained normal in stage I and stage 2 (Table 4 . 12). 
T he phosphates were found to be above normal in all three stages 
(Table 4.12). 
The albumin normalized in stage 1 (36.36g/L) , yet declined below 
normal in stage 2 (33.08g/ LO and stage 3 (34 .33g / L) . 
With regard to the iron profile the serum iron normalized in all 
three groups, and the serum trans ferrin decreased and was found to 
be below normal in both stage I (1.79g/L) and stage 2 (1 .57g/L ). 
However , the transferrin normalized in stage 3 (2 .02g /L). T he 
ferritin remained abov e normal in stage I (311 .68ng/ L) and stage 2 
(713.85ng / L) . Furthermore Duncan's Multiple Range Test for 
ferritin has shown a s ignificant d i fference between GFR stages 2 
and 3, three months after commencement of treatment. 
The hemoglobin remained below normal in all three stages (1,2, and 
3) and the parathyroid hormone remained above normal levels in all 
thre e stages (T able 4 . 12) . 
As demonstrated above, the patient with rena l failure display a 
multitude of problems. 
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4 .4.2. TREATMENT ACCOR DI NG TO T HE SUBD I VIDED 
STAGES OF GFR 
Stage 1'5 bectllElit Stage 2's treatment 
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Figure 4 . 18 : Grap h ic representation of treatme n t over tbree 
m ont hs, according to the s u bdiv id ed sta ges . 
As ind icated in fig.4 .1 8 , 100% (44) of patients commencing d ialys is 
in stage I had AHD . After I month 90 .91 % (40) had C HD, 6.82% (3) 
had CAPD and 2 .27% (I) had APD. After 3 months 97.73% (43) had 
CHD , and 2 .27% (1) had CAPD . More pat ients moved into CHD 
after 3 months (fig .4.18) . 
In stage 2 94 .87% (37) of patients were on A HD, 2.56% (1) on 
CVVH/D , and 2 .56% (1) on CAPD at the commencement of 
t reatment. After I month 100% (37) of pat ients we re on CHD and 
afte r 3 months 97.44% (38) were on CHD and 2 .56% (1) on CAPD 
(F ig . 4.18). 
I n stage 3 patients at commencement of treatment 72.73% ( 8) 
underwe nt AHD and 27.27% (3) underwent C HD . After I month 
90 .9 1% (10) underwent CHD and 9 .09% (I) underwent CAPD. Afte r 
~ 
-c 
-c 
-P" 
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3 months the statist ics remained the sa me: 90.9 1% (10) on C H D and 
9 .09% (1) on CAPO (Fig. 4 . 18). 
There was on ly I patient out of the 95 who commenced dialys i s in 
the GFR stage 4 s / he therefore acts as a limitat ion and doesn ' t 
provide a result resembling the general population. However the 
patient commenced RRT with AHD, then changed to CAPO and then 
to CHD (Fig . 4.18) . 
4.4 .3 . ACCESSES PLACED ACCORDING TO THE VARIOUS 
GFR SUBDIVISIONS 
From the study, it was determined that stage 1 had a greater number 
of accesses placed (2 .5) in comparison to stage 2 (1 .97). However , 
stage 2 had a greater number of access placed than stage 3 (1 .82), 
which has the least number of accesses placed . Stage 4 had the 
greatest (3 .00). However , this result is limited as only a patient fell 
within the subd iv ision. 
4. 5. FINANCIAL ASPECTS OF RENAL REPLACEMENT 
THERAPY AND RELATED COSTS 
CRF patients' med ical expenses are extremely high for both the 
paticnt and the funder . Maintenance costs become extremely high, 
which places a heavy burden on national resources . 
Several bas ic costs in the pr ivate healthcare system and the 
government healthcare system were considered . This included: 
Hospital fees 
Theatre and s urgery costs 
Renal replacement therapy costs 
Cost of access and placement 
Transplantation costs 
Cost of medication 
The cost of standard blood tests. 
T he cost of doctor's visits . 
It was determ ined that the cos t s involved in RRT are extremely 
h igh. Costs associated with renal replacement therapy can be 
reduced, thereby allowing mo re patients to be treated for the same 
amount of money. Furthermore the reduct ion of costs, would enable 
mo re patients to benefit from th is life - saving treatment , especially 
within the government healthcare sector . 
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5 . 1. An investigation of the indications for renal replacement 
therapy and the optimal time to commence therapy 
According to Baillod & Moorhead (1974) treatment can be optimized 
by examIDIDg areas of failure. 
In reference to the 95 patients taking part in the study their 
glomerular filtration rate was initially compared to all stated 
guidelines for the indications for commencing renal replacement 
therapy. 
As acknowledged in the literature review, there were discrepancies 
among the guidelines as to the optimal GFR at which dialysis should 
be commenced. 
The US DOQl guidelines (2003) sug¥ested commencing dialysis at a 
GFR of between 9- 14mllminll .13m , irrespective of their diabetic 
status, whereas the NIH (2003) suggests commencing dialysis at a 
GFR of I Omllminll. 73m' and 15mllminll. 73m' for diabetics. The 
CARl guidelines (2003) and the CSN guidelines (2003) do not have 
a GFR at which dialysis should be commenced, however they feel 
dialysis should be implemented at the first sig n of malnutrition that 
is not responding to treatment or when there is evidence of uremia. 
The CARl guidelines (2003) state that the use of "absolute 
indicators" results in delayed initiation of dialysis and patients with 
comorbid conditions; dialysis can be implemented at a GFR greater 
than IOmllmin / 1.73m'. 
By looking at the 95 
commencement (where 
afterwards and three 
acknowledged: 
patients as a whole, at a month prIor to 
applicable), at commencement , a month 
months thereafter, the following was 
A month prior to commencement (table 4.6), patients had a mean 
GFR of 9.62mllminll.13m', which according to the DOQI guidelines 
(2003), means that dialysis should have commenced. However, in 
the in context of the CARl guidelines (2003), "absolute indicators" 
should not only be used., Looking at the patients nutritional status, 
the albumin (which is a strong indicator of nutritional status) 
showed a decreased value of 32 .64g / L, which means that this group 
should have had some form of dietary intervention. If still no 
improvement, dialysis should have been commenced. However , it 
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was observed that, at commencement, the albumin (table 4.6) , had 
declined further. In reference to the SOA, which is a clinical 
technique used for assessing the nutritional status of a patient based 
on features of the patient's history and physical examination, it was 
found that the majority of patients were possibly malnourished . The 
second greatest percentage of patients was found to be severely 
malnourished and only the minority was found to be well nourished 
(figure 4.13). 
It has been proven that malnutrition is a strong predictor of poor 
clinical outcome. A low serum albumin is also a risk factor for 
cardiac disease in dialysis patients. In addition, In a study 
conducted by Acchiardo & Smith (2000), malnourished patients in 
both cohorts had more hospitalizations per year per patient. The 
length of hospitali zations was longer and their mortality rate higher. 
However, the reasons for their decline in nutritional status could be 
due to symptoms they were experiencing which interfered with their 
appetite , and therefore also interfered with the dietary intake and 
the dietary restrictions placed on indi v iduals with renal 
insufficiency. 
This brings to mind the second part of the CARl (2003) and CSN 
guidelines (2003), which suggest dialysis should commence with 
clinical evidence of uremia. The patients , a month prIor to 
commencement, already began to display signs of uremia. The mean 
urea (table 4.6) was 30.78mmollL, the creatinine 7431lmollL , the 
phosphate was 1.91 mmollL, the Hb was 9.38g / dL , the ferritin was 
331.25ng/mL, transferrin 1.75g/ dL, and PTH 511ng / L. Anemia , 
hyperparathyroidism, fatigue and electrolyte imbalances were some 
of the factors present (table 4.6). 
Anemia is characterized by a low Hb, the mean of which was 
9.38g / dL in this group. Anemia is a leading cause of morbidity and 
mortality among patients with chronic kidney disease. Furthermore, 
anemia has been shown to be a major contributory factor in the 
development of cardiovascular disease (CVD) and left ventricle 
hypertrophy (LVH). In addition, anemia results in an increase in red 
blood cell transfusions , which in turn can affect graft survival. It 
also results in impaired cognitive functioning and decreased 
exercise tolerance , which can explain the lack of participation in 
activities of CRF patients (figure 4.8) , and is discussed further on. 
Most importantly it results in a decrease in quality of life. 
Despite consideration of the above , treatment was postponed for a 
month, which adversely affected the patients. 
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At the commencement of treatment (Table 4.6) , the mean GFR had 
decreased to 6.7ml / min ll.7 3m 2 , the mean urea had increased to 
31.62mmoIlL , the mean creatinine had elevated to 984.2/LmoIlL, the 
mean phosphate had decreased to 1.85mmol / L, although still 
elevated above normal values. The mean albumin declined further to 
30 .7g /L, the mean ferritin increased to 527.7ng/ mL , the mean Hb 
decreased further to 8.93g/ dL and the PTH rose to 832.6ng / L. 
As di s played by the above results , it is apparent that there was a 
further deterioration in the patients ' health, which already a month 
prior to commencement displayed a poor clinical outcome and a high 
risk for mortality. 
It must be acknowledged that the survival of end s tage renal disease 
patient s on dialy s is depends to a large extent on their condition at 
the time dialysis was first initiated. 
There were however , some overall improvement s In th e pati en t s 
once dialysis had been commenced. The nutritional sta tus improved , 
as the albumin (table 4.6) increased to 33 .87g /L after I month and 
further increased to 34.88g/ L , after 3 months, although these are 
still below normal values. The Hb increased to 9 . 17g/ dL after 1 
month, and to 9.44g/ dL after 3 months. Yet here again , despite the 
improv e ment , Hb is s t i ll below recommended values (Ta ble 4.6). 
Urea, creatInIne and phosphate levels all decr ease d, which IS 
expected with the implementation of RRT. There wa s also a decline 
In the PTH after comm e nc e ment of dialysis (Table 4 .6). 
It has been concluded that the initiation of dialy s is s hould b e 
patient-specific , and not withheld up until their creatinine clearance 
falls into a mandated range, as thi s may affect his / her surv ival. 
When considering the various treatment modalities of the 
commencing dialysis , the following was acknowled ge d 
4.14) : 
patient s 
(Figure 
From the 95 patient s 95% of patients had AHD, 1 % had CVVH / D, 
3% h ad CH D and 1 % had CA PD (Figure 4.14). 
Aft e r 1 month of treatment 94% of patients were o n C HD, a further 
5% o n CA PD and an ad ditional 1 % was on APD. After 3 month of 
tr eat m e nt 9 7% of patients were on CHD and 3% were o n CA PD. Thi s 
cl ea rl y indi ca tes that the majorit y of patients are o n CH D (F igur e 
4.14) . 
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With regard to access during the first three months of treatment 
(Table 4.7), it was found that the majority of individuals (48,42%) 
had two access placements , a further 25 ,26% of patients had 3 , and 
20% had 1 access. 5,26% had 4 and an additional 1,0 5% had 7 
access placements. It must however be acknowledged that the 
accesses placed refer both to temporary catheters and permanent 
catheters, as well as AV fistulas and AV grafts, and after 3 months 
not all patients had permanent access. 
With better patient preparation and perhaps early detection of C R F, 
could the number of AHD sessions not be declined and the number 
of accesses that are placed decreased? This is discussed further on 
(5.8) . 
This lead us to another part of the study in which the 95 patients 
were subdivided according to various stages of GFR. From the total 
95 patients taking part in the study, 44 patients (46%) fell into 
stage 1,39 patients (41%) fell into stage 2, 11 patients (12%) fell 
into stage 3 and only 1 (1 %) patient fell into stage 4 (figure 4.15). 
In consideration of the blood re s ults a month prIor to the 
commencement of RRT, all three stages (1, 2, and 3) should have 
commenced treatment with respect to the various guidelines (Table 
4 . 12) . 
Stage I showed a below normal (132.44mmoIlL) sodium , a month 
prior to commencement of RRT. Stage 1 and 2 showed a below 
normal carbon dioxide level (Table 4.12) . The elevation of urea and 
creatinine in all three stages (I, 2 , and 3) a month prior to 
commencement clearly indicates the declined renal function (Table 
4 . 12) . 
All three stages (1, 2 , and 3) have above normal level s of 
phosphate s a month prior to commencement (Table 4 . 12) , while 
stage 2 has the greatest elevation (3.4SmmoIlL). Furthermore st age 
I and 2 are characterized by poor nutrition, as albumin levels are 
b e low normal and albumin is a strong indicator of nutritional status 
(Table 4.12). Stage 1 has a slightly decreased calcium level 
( 2 . 14mmoI / L) and the cholesterol is above normal in stage 2 
(5.5mmoI / L) and stage 3 (5.37mmoI/L) . 
With regard to the iron profile the serum iron is below normal in 
stage 2 (7.6/LmoI / L) and above normal in stage 1 (37.87/LmoI / L). The 
transferrin i s below norma l in both stage I (1.86g / L) and stage 2 
(1.64g/ L) and yet above normal in stage 3 (IO.47g / L). The ferritin is 
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elevated in both stage 2 (494ng / ml) and stage 3 (544. 8 9ng / ml). The 
percentage saturation for all three groups is within normal l imits 
(Tab l e 4.12). The hemoglobin in all three stages (I , 2 , and 3) is 
below normal while stage 2 (9 . 19g / dl) has the lowest hemoglobin 
(Table 4.12). 
The parathyroid hormone is above normal In both stage s I (815ng/ L) 
and 2 (359ng / L) (Table 4.12). 
With regard to the laboratory results at commencement at RRT , it 
can be seen (Table 4.12) that the mean GFR for: stage I was 
3.9mllminll.73m 2 ; stage 2 was 7 .83 mllminll.73m 2 , and s tage 3 was 
12.2 9 mllminll .73m 2 The potassium in stage I was above normal 
(5.11 mmoIlL), predisposing the patients to the risks a s sociated with 
hyperkalemia. All three stages (I, 2, and 3) st ill have a below 
normal carbo n dioxide level (Table 4.12). Both urea and creatinine 
are above normal in all three stages ( I , 2, and 3) , which is evidence 
of the severe l y declined renal function . The creatinine increased in 
all three stages when compared to the laboratory results obtained a 
month prior to commencement (Table 4.12). Stage 3 s howed a below 
normal magnesium level, as opposed to both stage I and stage 2 , 
which didplayed a normal magnesium level (Table 4.12). All three 
stages (I , 2, and 3) displayed hyperphosphatemia (Tab le 4 . 12) , 
whi le stage I showed the highest value (2 .09mmoIlL). All three 
stages (1, 2 , and 3) showed a below normal albumin l e v e l (Table 
4.12), while stage I showed the lowest albumin (29.47gl1 ). Stage I ' s 
cholesterol elevated from commencement to 5.45mmo ll L at 
commencement. Both s tage 2 and 3's choleste r o l decreased from a 
month prior to commencement, to commencement of therapy (Table 
4.12) . This may , however , be a negative and not nece ss ariliy a 
positive result , as it may be a reflection of poor nutrition. 
In reference to the iron profile, stage 3's serum iron is below 
normal (6.I/lmoIlL) , and stage I and 2's has normali z ed . Stage I's 
serum transferrin is above normal values , whereas stage 2 and 3 
have normal serum transferrib. The ferritin is above normal in stage 
I (544.89ng / ml) and stage 2 (573 .99ng / ml) and normal in s tage 3 
(156 .85ng / ml). The percentage saturation is below normal in stage 3 
(12%). T h e hemoglobin level has remained below normal in all three 
stages (Table 4.12). 
Furthermore , the parathyroid hormone IS above normal In all three 
stages (Tab le 4.12) . 
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With the above in mind it must be remembered that the s urvival of 
an end stage renal disease patient on dialysis depends, to a large 
extent, on their condition at the time dialysis was first initiated. 
In reference 
commencement 
elevated, which 
4 . 12) . 
to the laboratory results one month after 
of treatment, the urea and creatInIne remain 
is common in chronic renal failure patients (Table 
After I month the carbon dioxide levels in stage 1 (21.14mmoI / L) 
and stage 2 (22.5mmoIlL) were below normal , whereas s tag e 3 was 
normal (23.lmmoI / L). Phosphate levels decreased , but remained 
above normal in stage I (1.54mmoIlL). Stage 2 and stage 3 ' s 
phosphates normali z ed (Tab l e 4.12). The albumin increased from 
commencement, but remained below normal in bot h stage I 
(33 .33g / L) and stage 2 (34.13g/ L), and normalized in s tag e 3 
(35.llg/L). 
With regard to the iron profile , the se rum ir o n increased in both 
stage 1 (12.S2J.1moIlL) and stage 2 (12.35J.1moI / L), and remained 
below normal in s tage 3 (7.73J.1moIlL) . The serum tran s ferrin was 
abov e normal in stage I (S.S6g/ L) and below normal in stage 2 
(1,73g/ L) and stage 3 (1.14g/ L). The ferritin was above normal in 
stage I (344.7ng/L) and stage 2 (667.S3ng/L). The hemoglobin 
remained below nor mal in all three stages (I , 2 , and 3) and the 
parath yroid horm o n e ha s remained above normal in all three stages 
(Table 4.12). 
After 3 months from the date of commencement the carbon dioxide 
l evels were found to be below normal in both stage I (20.3SmmoI / L) 
and 3 (21 .6 mmoI /L) . The urea and creatinine remain above normal 
in a ll thr ee stages , repre se n t ing chronic renal fa ilure (Tab le 4.12). 
The magn esi um decreased in stage 3 (O .7 3mmoI / L) and was below 
normal, yet remained normal in stage I and stage 2 (Ta ble 4.12). 
Th e phosphates were found to b e above normal in all three s tage s 
(Tab le 4.12 ). The albumin normali ze d in stage I (36.36g / L) , ye t 
declined below normal in stage 2 (33.0Sg / LO and stage 3 (34.33g / L). 
In reference to the iron profile the serum iron normali z ed in all 
thre e groups. The se rum transferr in de crease d and was found to be 
below normal in both s tage I (I.79g / L) and stage 2 (1.57g/L). 
Ho weve r , the tran sferrin normalized in stage 3 (2 .02g / L). The 
ferritin remained a bove normal in s tage I (311 .6Sng/ L) and s tage 2 
(713.S5ng / L). Furthermore, Duncan's MUltiple Range Test for 
ferritin has shown a significant difference betw ee n GFR 2 and 3 , 
thr ee months after commencement of treatment. Th e hemo g l obin 
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remained below normal in all three stages (I, 2, and 3) and the 
parathyroid hormone remained above normal levels in all three 
stages (Table 4.12). 
As demonstrated above patients with renal failure display a 
multitude of problems. 
In cons.ideration of the treatment (Fig. 4.18), it was found that 100% 
of stage 1 (GFR - 0- 5 mllmin / l.73m2) patients underwent AHD. 
Stage 2 (GFR - 6- 10 mllminll.73m2) patients showed a decrease to 
94.9%, and stage 3 (GFR - 11 - 15 mllminll.73m2) patients had a 
further reduction to only 72% using AHD as their first treatment. 
Stage 4 was left out as it consists of one patient and is therefore not 
a true reflection of that specific population. 
There were less patients requiring AHD in the group that started 
dialysis earlier. Therefore the earlier the dialysis commenced, the 
smaller the need for emergency dialysis. 
After 1 month of treatment stage 1 had 91 % of patients on CHD, 7% 
were on CAPD and 2% were on APD. However after 3 months 98% 
of patients were on CHD, and 2% 
increase in CHD patients. and 
treatment (Fig. 4.18). 
were on CAPD , indicating a 7% 
14% of patients who changed 
Stage 2 had 100% of patients on CHD after 1 month and after 3 
months had 97% of patients on CHD and 3% on CAPD, thereby 
indicating a mere 3% change in patients' treatment (Fig. 4.18) . 
Stage 3, 1 month after of commencement , had 91 % of patients on 
CHD and 9% on CAPD. After 3 months it had the same treatment 
regImens. This indicates no change in the patients' treatment (Fig. 
4. 18). 
Furthermore, when the number of accesses that were placed was 
considered, it became apparent that stage 1 patients had the greatest 
number, followed by stage 2 and thereafter stage 3, which had the 
least number of accesses placed during the 3 months from the date 
of commencement (4.4.3). 
Judging from the above results it becomes apparent that stage 3 
patients were better managed and prepared for RRT. Patients in 
stage 3 underwent fewer changes in treatment, and a reduced number 
of accesses placed , when compared to the other stages. This can 
only benefit the patient. Besides benefiting the patient, there is 
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great cost reduction for the funders, thereby benefiting the funders. 
This will be discussed in greater detail further in the chapter (5.8). 
In evaluating the 95 patients taking part in the study, the patients 
were once again subdivided into 3 categories. 60% of the patients 
fell into category I who were acute renal failure patients who were 
not diagnosed or educated prior to the development of acute renal 
failure. 23.16% of patients fell into category 2, who were chronic 
renal failure patients who were aware of their renal insufficiency 
but were not managed by a PESRD program. The remaining 16.84% 
of patients were placed in category 3 , who were chronic renal 
failure patients who were informed and educated regarding their 
renal insufficiency and participated in a PESRD program (fig. 4.15). 
As previously indicated in the discussion following the results at a 
month prior to commencement of RRT, a significant difference was 
found in creatinine in category 1 when compared to category 2 and 
3, however all three groups showed a severe decline in renal 
function. All three categories suffered from hyperphosphatemia. 
Malnutrition was present in category I and 2 and anemia was 
present in all three groups, however category 1 had the lowest 
hemoglobin. The low hemoglobin could be a result of 
mismanagement and failure to implement EPO treatment, or it could 
be a result of severe uremia, as in category l(table 4.8). 
Furthermore, at commencement category 3 commenced RRT at a 
higher GFR than both categories 1 and 2 . Category I commenced 
dialysis with the lowest GFR, and a significant difference in GFR 
was found between category 1 and 3. However all three categories 
commenced dialysis later than prescribed by several guidelines, and 
all had a decreased C02 value, elevated urea and creatinine, 
increased phosphate values, decreased albumin and hemoglobin 
levels and increased ferritin and PTH values (table 4.9). 
From an anemia and nutritional perspective category I displayed the 
lowest values. Category 2 had the higher Hb and albumin value 
when compared to category 3 (table 4.9). 
After I month of treatment category 2's C02 normalized, but their 
albumin decreased. The albumin in both category I and 3 increased, 
but still remain below normal values. Phosphates remained elevated 
in all three categories. Ferritin is also still elevated and Hb is still 
below normal values (table 4.10). 
After 3 months the albumin in category 2 and 3 normalized. The Hb 
remained decreased and the ferritin remained elevated. Transferrin 
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values were low in all three categories. Phosphates normalized in 
category 3, yet remained above normal in both category 1 and 2 
(table 4.11). 
From the subdivisions and the above information , it can be 
concluded that patients in category I, who were patients who 
developed acute renal failure without awareness of their condition, 
had the greatest potential for a poor clinical outcome. Furthermore, 
after 3 month s patients still suffered from anemia, malnutrition , 
hyperphosphatemia and hyperparathyroidism. In addition, the 
ferritin values r e mained high , which, as previou sly discussed, are 
indicative of acute phase reaction, and non - specific tissue damage 
such as infection (table 4.11) . 
Category 2, consisted of patients who were aware of their chronic 
renal insufficiency prior to commencement but were not managed by 
a PESRD program, displayed similar results to those seen In 
category I: anemia; malnutrition ; hyperphosphatemia, and 
hyperparathyroidi s m. However, unlike category I, after 3 months of 
treatment category 2 's nutritional status improved (table 4 .11 ). 
Category 3 consisted of patients who, like category 2, were aware of 
their chronic renal disease prior to commencement of RRT, but 
differ in the fact that they participated in a PESRD program. 
However ca t egory 3 displayed similar results to both of the above 
categories , the only difference is that the phosphate s were better 
managed after 3 months and, like category 2, nutritional status 
improved (table 4.11). 
In conclusion, management of patients prior to commencement is of 
v ital importance and can playa role in determining their outcome 
and well - being. Participation in a PESRD program a benefiting 
factor will b e discussed further on. 
In continuing our attempt to establish the optimal time to commence 
RRT, the patients' perspective on their lives and treatment were 
taken into consideration, as it is the p atie nt who is affected by our 
decision, and who relies on us for th e best possible decision and 
treatment. 
As discussed by Karger and Basel (1975) optimization of dialysis 
can no longer have the gratifying significance of length en ing life 
and r ei nserting a patient into the restricted environment of the 
family, but rather must guarantee the full time restitution to soc iet y 
of a totall y rehabilitated individual. 
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With respect to the patient psychosocial assessment the majority of 
patients (76.84%) do not take part in activities (figure 4.8). Could 
this not be improved with an early starting time , which will thus 
increase well - being. Baillod and Moorhead (1975) have determ in ed 
that optimal dialysis requires adaptation or tailoring of the 
treatment to the particular needs of each patient. Their experience 
defines optimi za tion of dialysis as willingness on the part of the 
center to adapt to the patients' needs, using as much technical 
ingenuity as necessary to motivate the patient to demand of us and 
him / herself the ability to lead a normal life, so that s / he can be 
success full y reinserted into his community. 
Fo urty-seven point three seven percent (47.37%) of patients 
displayed hypertension and 24.21% of patients suffered from 
diabetes (table 4.2). These are the two leading causes of renal 
failure. A further 67.37% (fig, 4.8) of patients were in hospital for a 
variety of reasons , not necessarily renal related. As discussed, the 
screening consideration of the patients' medical historie s is of vital 
importance as this is what causes them to have a predisposition to 
renal failure. Furthermore, despite the fact that 47.37% (table 4.2) 
of patients suffered from hypertension , their renal failure may not 
be secondary to the hypertension , and patients may di splay some 
missed cause as a r es ult of their hypertension. 
If these patients had been screened prior to commencement, and 
continually monitored, there renal failure could have been detected, 
and perhaps postponed. If not at leas t the patient would have been 
better prepared , with an improvement in well - being , and a better 
chance of survival. 
However, only 18.09% of patients felt that they were prepared for 
rena l replacem ent therapy (table 4.3). A fU'rther 36.17% of patients 
felt that they were not informed prior to commencement of RRT 
(table 4.3). An additional 24.47% of patients felt that their renal 
impairment was managed prior to commencement of RRT (table 4.3). 
Only 6.32% of the patients participated in a support group (table 
4.3) and a minority of 24.47% of patients felt that they were 
educated regarding kidney disease pflor to commencement of 
therapy (table 4 . 3) . 
As indicated by the results obtained above, the majority of 
individuals never had the advantage of a PESRD program , nor did 
they have the benefit of cardioprotective and reno protective 
strategies, which form part of the optimal therapy for chronic renal 
insufficiency . In addition to this, the optimal treatment in c ludes the 
prevention of m e tabolic disorders, the prevention of malnutrition, 
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and the preservation of the quality of life and adequate preparation 
for RRT, as discussed within the literature review. 
The CARl guidelines (2003) suggest that patients with a GFR of 
30ml/min / 1.73m 2 should be referred to a nephrology service, and 
patients with a higher GFR should be considered as patients with 
declining renal function, or clinical features suggesting that renal 
function may decline rapidly. The BRA guidelines (2003) suggest 
that patients should be referred with a creatinine of > 150umo1 / L, 
and the CSN guidelines (2003) correlate with the CAR l guidelines 
(2003), and suggest referral at a GFR of 30ml / minll .73 m 2 . The NIH 
(2003) suggests referral when the serum creatinine has increased to 
1.5mg/ dL in women and 2.0 mg/dL in men. Despite these guidelines, 
few had the benefit of a nephrology services at the specified stages. 
The majority (92.05%) of patients participating in the study stated 
that they would have liked to have participated in a PESRD program 
(table 4.3), and yet only the minority had the benefit of one. The 
question that arises is: why were patients not offered this option? [s 
it perhaps due to insufficient awareness of renal disease , or perhaps 
because of the fact that kidney disease for the most part is 
asymptomatic? According to Baillod and Moorhead (1975) failure to 
start treatment early, is due not only an inability to recogni ze 
problems associated with renal disease and inadequate facilities , but 
also to delayed referral by medical colleagues. 
The majority (67.74%) of patients who have commenced dialysis 
feel that their renal failure is a serious and life - threatening 
condition (fig. 4.10) and a further 55.53% of patients feel that their 
kidney disease restricts their life (fig. 4 . 11). As described by 
Cameron (1996) renal failure can be a frightening and bewildering 
time . Having patients who are better prepared can reduce the stress 
placed on patients and their families , making RRT more adaptable. 
In addition, the majority (55 . 17%) of patients were in a phase of 
denial at commencement of therapy, and 1.15% of patients were in a 
bargaining phase . 43.68% of patients had accepted their renal 
failure at commencement of therapy (fig. 4.12). Better preparation 
and education of patients could have increased th e number of 
patients in a phase of acceptance. 
The majority (93.26%) of patients is satisfied with their treatment 
(table 4 .27), even though 38.89% of patients did not choose their 
treatment (table 4.5) and 20% of patients were not even informed 
regarding the various treatment options (table 4.5) . 
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Almost 55% of patients are awalttng a transplant (table 4.5). 
Everywhere in the world there is a relative shortage of donor 
kidneys from the recently dead, and walttng li sts for kidney 
transplantation become longer and longer every year (C ameron , 
1996). 
Almost 39% of patients who have commenced dialysis are still 
unaware of the cause of their renal failure (table 4.3). 3.33% of 
patients are unaware of how to manage their fluid int ake (table 4.3) , 
and 4.55 % of patients are unaware of how to manage their dietary 
intake (table 4.3). 34.44 % are unaware of anemia and th e treatment 
thereof (4.3), 30% are unaware of the complications involved in 
renal failure (table 4.3) and 37.78% of patients did know how their 
complications associated with renal failure are managed (table 4.3). 
Patients at this stage of renal failure should be aware of how to 
manage their renal failure and even though the majority do know 
how, a minority still don 't and therefore educating the patient 
should be part of the RRT, since educating the patient has a direct 
impact on the compliance of the patient to treatment , and can 
influence patient well being and decrease mortality . In addition, 
according to Robinson (2001), educating the patient reduces the 
stress rate for the patient and the family. 
The study aimed at providing a comparative investigation of the 
indications for renal replacement therapy and the optimal time to 
commence the therapy. 
From the study, it was determined that the need to commence 
dialysis should be based not only on the glomerular filtration rate, 
but on the patient 's well - being , and the factors affecting the renal 
patient, while ensuTIng nutrition and implementation of 
renoprotective and cardioprotective strategies and discerning 
whether implementation of renal replacement therapy wi II in fact 
benefit the patient. The indications for commencing renal 
replacement therapy should be patient specific, and s hould aim at 
providing the patient with the best possible quality of life and 
s urvival. 
The optimal time to commence renal replacement therapy wou ld be 
at the first clinical evidence of deterioration despite medical 
intervention. However optimizing renal replacement therapy 
incorporates the management and treatment of the factors affecting 
renal failure patients, in order to completely rehabilitate the 
patient. 
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5.2. Screening of high-risk patients is important in the detection 
and management of kidney disease. 
Through conducting a simple survey targeting individuals at risk for 
the development of CKD, it has become apparent that the screening 
of high-risk individuals IS important in the detection and 
management of kidney disease. Furthermore, screening should 
become part of a routine for these high risk individuals, especially 
considering the fact that, for most part, CKD is asymptomatic, and 
the patient displays a variety of non- specific signs and symptoms. 
S/ he may therefore be misdiagnosed up until advanced renal failure. 
As emphasized in the literature study, this is too late for 
cardioprotective and renoprotection strategies to be implemented, 
which in turn impacts morbidity and mortality in dialysis patients. 
It has also become apparent that more education needs to be focused 
on kidney disease, not only for individuals in the health profession , 
but also the patients , especially those at risk . 
Besides, is it not worth screening for kidney disease if one is at risk 
for a minimal cost, enabling the possibility of postponing or 
preventing CKD, and improving health in an area that is dominated 
by poor clinical outcome? For the health professionals whose aim is 
to care for, manage and treat patients, is not our responsibility to 
provide our patients with the best possible care and treatment, and 
so to provide them with the best possible chance of survival and 
quality of life? 
5.3. It is beneficial to manage factors affecting renal function in 
order to prolong the pre-treatment phase. 
Various studies have indicated that ESRD can be prevented or at 
least be slowed in its progression to chronic renal failure. 
According to the CARl guidelines (2003), correction of any 
superimposed reversible factors that contribute to a decreased GFR, 
which can restore a level of renal function compatible with a more 
conservative approach to care and delay the need for dialysis . 
Progression to ESRD is therefore delayed to the extent that 
initiation of RRT may also be delayed. 
As previously discussed, slowing the progress of renal disease can 
be acieved by ensuring tight blood pressure control; by the use of 
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angiotensin II inhibitory drugs; statins; calcium and iron 
supp lement s and phosphate binders; vitamin supplementation ; tim ely 
use of recombinant erythropoietin; dietary counseling; preservation 
of nutritional status assessed by serum albumin levels, and in- time 
creation of access. These are parts of the integrated therapeutic 
strategy to be offered to predialysis CRI patients. 
There is also some experimental evidence that superimposed renal 
injury may cont ribut e to the accelerated progression of chronic 
renal disease, through nephron loss and fibrosis (CARl guidelines). 
According to the CARl guidelines (2003): 
a) Early efforts should be made to identify and where possible, to 
correc t , pre - renal and post- renal insults, in order to prevent 
irreversible injury and delay the need for dialysis 
b) Exposure to nephrotoxic agents should be avoided (where 
possible) in patients with renal disease 
c) Where contrast exposure cannot be avoided , the risk of renal 
injury can be reduced by: 
• Pre - hydration, 
• Acetylcysteine, 
• Using lower doses of contrast and 
• Using non - ionizing contrast. 
5.4. A PESRD educational program is an effective component in 
the management of kidney disease. 
As indicated by the results obtained above , the majority of 
individuals never had the advantage of a PESRD program , nor did 
they have the benefit of cardioprotective and reno protective 
strategies , which form part of the optimal therapy of chronic renal 
in sufficiency. In addition to this, the optimal treatment includes the 
prevention of metabolic disorders, the prevention of malnutrition , 
and the preservation of the quality of life and adequate preparation 
for RRT, as discussed within the literature review. 
However, the minority of patients whose renal imp airment was 
managed prior to commencement of RRT did better on dialysis, as 
indicated in the subdivision of the patients into the vaTlOUS 
categories (4.3). 
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With regard to a PESRD educational program, the patients were 
consulted as to their perspective , as it is the patients themselves 
who would take part in this component. 
The minority (24.47%) (table 4.3) of patients felt that they were 
educated regarding kidney disease prior to commencement of 
therapy. 
With regard to dialysis patients' level of knowledge regarding their 
kidney disease , the study indicated that 38.95% of patients (table 
4.3) who have commenced dialysis were not aware of the cause of 
their renal failure. 3.33% of patients (table 4.3) were unaware of 
how to manage their fluid intake , 4.55% of patients (table 4.3) were 
unaware of how to manage their dietary intake. 34.44 % (table 4.3) 
were unaware of anemia and the treatment thereof, 30% (table 4.3), 
were unaware of the complications involved in renal failure and 
37.78% of patients (table 4.3) did know how their complications 
associated with renal failure are managed. 
Patients at this stage of renal failure should be aware of how to 
manage their renal failure, and even though the majority doe s know , 
the minority still does not and therefore focus need s to place on 
educating patients. This is essential because educating the patient 
has a direct impact on the comp lian ce of the patient , and can 
influence patients' well being and decrease mortality. In addition , 
according to Robinson (2001), educating the patient reduces the 
stress rate of the patient and the family. 
The Department of Health's policy on organ transplantation and 
chronic renal dialysis (draft document: 2003) state that education 
programs should be encouraged so as to put more emphasis on the 
management of some of the diseases that cause renal failure, such as 
diabetes. 
In conclusion the study revealed that the majority (92.05%) of 
patients participating in the study would have liked to have 
participated in a PESRD program , and yet on ly the minority had th e 
benefit (table 4.3). Therefore patients should be given the 
opportunity to participate in a PESRD educational program. 
5.5 . Initiating a PESRD program early in the course of kidney 
disease is advantageous to the patient 
The CARl guidelines (2003) suggest that patients with a GFR of 
30ml /min/l.73m2 be referred to a nephrology service, and those with 
a higher GFR, should be considered as patients with declining renal 
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function or with clinical features suggesting that renal function may 
decline rapidly. The BRA guidelines (2003) suggest patients be 
referred with a creatinine of > 150umol /L and the CSN guidelines 
(2003) correlate with the CARl guidelines and suggest referral at a 
GFR of 30ml / minll.73m 2 • The NIH (2003) suggests referral when 
the serum creatinine has increased to 1.5mg/ dL in women and 2.0 
mg/dL in men. Despite these guidelines few patients had the benefit 
of a nephrology services. 
It was found from the survey that 9% (fig. 4.4) of patients screened 
could have benefited from a PESRD program, and yet were not 
referred . 
According to Legrain el al. (1975) the prospective treatment of end 
stage renal failure should actually start at the earliest possible stage 
of renal disease. 
To slow the progressIOn of kidney failure, to prevent the 
consequences of chronic kidney disease and to decrease 
cardiovascular mortality associated with CKD, it is crucial to detect 
patients with CKD early and to optimize their care (Rossert & 
Wauters , 2002). 
According to Jungers (2002) renoprotection and cardioprotection are 
only effective if implemented from the early stage of renal failure. 
Renoprotection includes the use of dietary and pharmacological 
measures aimed at halting or at least slowing the progression of 
renal failure and it is currently considered a fundamental goal in the 
treatment of CRI patients. Cardioprotection has only recently 
emerged as another fundamental goal of the treatment of chronic 
renal failure in the predialysis stage. Risk factors for accelerated 
atherosclerosis , left ventricular hypertrophy and myocardial fibrosis 
are the main causes of cardiovascular disease in uremic patients. It 
develops from an early stage in CRI and therefore cardioprotective 
therapy should be implemented as early as possible in the course of 
renal failure to effectively prevent the development of 
cardiovascular disease and reduce the excess cardiovascular 
morbid- mortality that affects uremic patients. 
Only early, regular management by a dedicated nephrological team , 
in close cooperation with other involved physicians, may give the 
patient his / her best chance at avoiding or at least substantially 
delaying end - stage renal disease and preventing or at least 
attenuating uremic complication. Late-referred patients are unfairly 
deprived of such benefits . 
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5.6. Early commencement of dialysis is beneficial to the patient 
from various perspectives 
The quality of life depends on the efficiency of treatment. 
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As determined in the above study, in which 95 patients were 
subdivided into the various GFR stages, early commencement of 
dialysis is beneficial for numerous reasons. 
From a management perspective , it has been concluded that patients 
in stage 3 were better managed and more prepared for RRT than 
patients commencing dialysis in the other stages (table 4.3). 
Patients in stage 3 underwent fewer changes in treatment (Fig. 
4.18), and a r educed number of accesses were placed (4.4 .3) when 
compared to the other stages. This can only benefit th e patient. 
Besides benefiting the patient , there is great cost reduction for the 
funders, which benefits the funders also 
A 100% of stage I patients , who were patients who commenced 
dial ys is at a lower GFR, hence later underwent AHD (Fig. 4.18) and 
had more complications such as an increased number of accesses 
(4.4.3) when compared to the other two stages. 
Furthermore, as discussed In the literature review and seen 
throughout the study, 'failure to thrive' is difficult to reverse when 
patients have been kept in their low clearance phase for long 
periods , during which time calorie intake gradually decreases, blood 
pressure control becomes increasingly difficult and anemia becomes 
more profound. The time taken to replace body weight and mu sc le 
mass closely approximates the duration of patient's inability to 
work and commencement of effective dialy s is. 
Baillod and Moorhead (1975) state that failure to s tart treatment 
early is due not only to an inability to recognize problems 
associated with renal disease and inadequate facilities, but also to 
delayed referral by medical colleagues. 
Delay in treatment and poor counseling affect rehabilitation both 
directly and as a result of medical complications. Mental and 
ph ysica l r e habilitation are independent. The three major factors 
influencing mental rehabilitation are physical health , loss of 
creditability at work and within the family, and the lowering of 
standards and expectations of life. A negative approach by medical 
staff reduces the patient's hope and initiative. 
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In conclusion early commencement of dialysis is beneficial to the 
patient for various reasons, as the survival of end stage renal 
disease patients on dialysis depends , to a large extent, on their 
condition at the time dialysis was commenced. 
5.7. There is an improvement in the outcome of patients who are 
managed prior to the commencement of RRT . 
According to Legrain et al. (1975) , having nephrological advice as 
soon as any sIgn of renal disease IS detected enables the 
establishment of an accurate diagnosis and thereby allows for 
preventative intervention at a stage when renal disease may respond 
to aetiologic therapy . 
In reference to the study, 24.47% of patients (table 4.3) felt that 
their renal impairment was managed prior to commencement of RRT. 
Furthermore, it was concluded from the results that were obtained 
from the patients who were subdivided into the various categories 
that patients in category I, who were patients who developed acute 
renal failure without awareness of their condition, had the greatest 
potential of a poor clinical outcome . Furthermore, after 3 months of 
treatment patients still suffered from anemia, malnutrition, 
hyperphosphatemia and hyperparathyroidism (table 4.1 1). In 
addition, the ferritin values remained high, which as previously 
discussed, is indicative of an acute phase reaction , and non - specific 
tissue damage such as infection (table 4.11) . 
Category 2, who were patients who were aware of their chronic 
renal insufficiency prior to commencement, but were not managed 
by a PESRD program, displayed similar results to those seen in 
category 1: anemia; malnutrition; hyperphosphatemia; and 
hyperparathyroidism. However unlike category I after 3 months of 
treatment, category 2's nutritional status did improve (table 4 . 11). 
Ca tegory 3, were patients who like category 2, were aware of their 
chronic renal disease prior to commencement of RRT , but differ in 
the fact that they participated in a PESRD program. However 
category 3 displayed similar results to both of the above categories, 
the only difference is that their phosphates were better managed 
after 3 months and, like category 2, nutritional status improved. 
In conclusion management of patients prior to commencement is of 
vital importance and can playa role in determining their outcome 
and well-being. 
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168 
According to Kgosi Letlape (2002), the chairperson of the national 
council of the South African Medical Association , general 
healthcare in South Africa is in a crisis (personal finance 2002). 
Maintenance costs for RRT become very high, which places a heavy 
burden on national resources . 
An observation of the current situation suggests that the c ost that is 
incurred per patient through dialysis could be dramatically reduced 
if more donor organs could become available. Furthermore , the cost 
per patient treated for end stage renal failure could drop , allowing 
for more patients to be treated better with the same amount of 
money. 
Through early detection and management of renal in s ufficiency , 
costs to the funders could be dramatically reduced . 
As previously di s cussed diagnosis is the key to the prevention of 
renal failure , and ultimately , from a financial perspective , there is 
no greater cost r eduction than complete prevention of a disease that 
has a high con s umption of national resources. However , s ince renal 
failure can not always be completely prevented , offering both 
disease specific and non - specific intervention to s low the 
progressIOn can in fact postpone the need for these high financial 
demands. 
When dialysis becomes inevitable, costs can still be reduced by 
looking at the following statistics obtained from the study: 
From the 95 patients , 95 % had AHD , I % had C VVH / D , 3 % had C HD 
and I % had CAPO (Figure 4.14) . 
AHD is approximately double the price to conventional dialysis per 
session in the private sector when compared to CHD. Also the 
majority of AHD takes place in the IC U setting, or in a high care or 
even a normal medical ward , all of which cost extra. In addition 
patients who develop ARF predominantly are characterized by more 
complications, which in turn require more medical intervention and 
therefore the co s ts involved increase dramaticall y. 
AHD for CRF patients can be prevented through early detection of 
renal insufficiency , improved patient management and early 
implementation of renal replacement therapy, which will prevent 
further complications and further costs. 
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According to Robinson (2001) kidney disease education can lower 
the cost of care for the patient, facility and government. Therefore 
educating the patients to assist in managing themselves IS an 
essential component. 
Not only can cost be reduced at the commencement of therapy, but 
on an continuous basis. 
Continuous management and treatment of the factors affecting renal 
failure patients is essential, and effective management and treatment 
can further reduce the costs. 
In a study conducted by Acchiardo & Smith (2000), malnourished 
patients in both cohorts have more hospitalizations per year per 
patient. The length of hospitalizations is longer and their mortality 
rate higher, and therefore treatment of factors such as nutrition and 
anemia are essential components in preventing an elevation in an 
area that is already dominated by high cost and depletion of 
resources . 
The costs of CHD and CAPD are similar for the patients, although 
the cost of running a CHD unit is far more, as it requires staff, 
hemodialysis machines and maintenance, and therefore, where 
resources are limited, patients are encouraged to undergo peritoneal 
dialysis. 
Costs can also be reduced through maintenance and preservation of 
vascular access. With regard to the study it was found that, during 
the first three months of treatment , the majority of individuals 
(48.42%) had two access placements, a further 25.26% of patients 
had 3 access placements, 20% had I access, 5.26% had 4 and an 
additional 1.05% had 7 access placements (table 4.7). Furthermore, 
this number of accesses refers to both temporary and permanent 
accesses and not all patients had permanent access after 3 months . 
Furthermore permanent access may not last forever and therefore 
maintaining access is important not only from a financial point of 
view, but also because the number of accesses available for this life 
saving treatment is limited. 
With greater cost reduction, more patients can be treated with the 
same amount of money, thereby allowing more patients with a 
chance for this life saving treatment. 
The costs and labour-intensive therapeutic programs to alleviate the 
long term personal suffering of patients suffering from renal failure 
can be justified on humanitarian grounds alone. 
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The challenge therefore is to maximize health gain per unit of 
expenditure w i thin acceptable ethical and moral criteria. 
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APPENDIX A: 
EXPERIMENTAL CONSENT FORM/EKSPERIMENT 
MAGTIGINGS VORM 
184 
A COMPARATIVE INVESTIGATION OF THE INDICATIONS 
FOR RENAL REPLACEMENT THERAPY AND THE OPTIMAL 
TIMING FOR COMMENCING THE THERAPY 
Rearcher: Chevon Lee Becker 
Conuwtnumb~ : 0828241883 
Date/DatumlLetsatsi: _____ _ 
A Patient informationIPasient inligtinglHlahiso lesedi ya monkakarolo 
SumarneNanlSefane: ________________ _ 
First narneNolle namelLebitso : _____________ _ 
MalelManliklMonna: -,,-_______ _ 
FemaleNrouliklMosadi: _______ _ 
Date ofbirth/Geboorte datumILetsatsi la tswalo: ___________ _ 
J.D. numberll.D. nommerlNomoro ya J.D.: _____________ _ 
B. Patient's Consent 
Indicates that I understand that all subjects in the project are volunteers, that I can withdraw at 
any time from the experiment, that I have been or will be informed as to the nature of the 
experiment (information sheet), that the data I provide and my blood results, will be anonymous 
and my identity will not be revealed without my permission, and that my performanoe in this 
experiment may be used for additional approved projects. Finally, I shall be given an opportunity 
to ask questions prior to the start of the experiment and after my participation is complete. 
B. Pasient Toestemming 
Verwys daarna dat ek verstaan dat almal in die projek vrywilligers is, dat ek ter eruge tyd van die 
experiment kan onttrek, dat ek ingelig is of gaan word oor die natuur van die eksperirnent 
(inligtingstuk), dat die inligting wat ek verskaf en my bloed uitslae vertroulik gehanteer sal word 
en dat my identiteit nie sonder my toestemming bekend gemaak sal word nie, en dat my 
vordering in die eksperiment dalk gebruik sal word vir addisionele projekte. Laastens, dat ek 'n 
geleentheid gebied sal word om vrae te vra voor die eksperiment en na die projek verily is. 
B. Tumallano ya monk. karolo 
Ngiyaqonda ukuthi lenhlolo ayiphoqelelwe, futhi nginelungelo lokwenquaha ukulungenela 
loluhlelo. Ngiwkwaziswa ngendlela whlelo oluzohamba ngalo, (kanye noshiolelo Iwesaziso) futhi 
nemiphumela yegazi lami ayisoze idalulwe ngaphandle kwemvume yami. Ekungeneleni kwami 
loluhlelo ngiyaqonda ukuthi lokhu kuwsetshenziicwa ezinhlelweni ezizayo. 
Okokugeing ngiwnikezwa ithuba lokubuza imibuw ngaphambi kokuba igale lenhlolo, emva 
kokuba sekuphothuliwe ngayo. 
Patient's signature/Pasient handtekening/ 
Tshaeno ya monka karolo 
Da Ie/ Da tum/ Lesta tsi 
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C. Information sheet 
The optimal timing for commencing renal replacement therapy is imperative and can pose a strong 
influence on the outcome and well-being of a patient commencing treatment. 
185 
However in South Africa and many other countries. late referral remains a serious problem, thereby 
distinguishing the indications and optimal timing for commencing treatment can only be beneficial to the 
patient and their funders. 
The aims of the study is to provide a guideline to the indications and optimal timing of commencing renal 
replacement therapy derived from comparative investigations incorporating factors affecting renal 
patients. In addition it will supply guidelines to manage patients in prCHlOd stage renal failure to ensure 
improved outcomes of patients, with an increase in patient well-being, and a decline in morbidity and 
mortality. It will in turn provide the patient with best chance of survival and an improved quality of life, 
in a area that is predominantly characterized by poor clinical outcome. 
In addition there is no associated risks Of complications for the individuals participating in the study and 
their treatment will not be influenced in any marmer. 
C. Inligtingstuk 
Die optima Ie tyd vir die begin van nier behandeIing is baie belangrik en kan n' baie sterk invloed he op 
die uitslae en die welsyn van n' pasient wat begin met behandeling. 
Maar in Suid-Afrika en baie ander lande, pasiente word verwys laat en dit is n' baie emstig problem, en 
dit is hoekom die bepaling van die indikasies en optimale tyd vir behandeling sal voordelig wees, vir die 
pasient en vir die fmansiele implikasies. 
Die doel van die studie is om n' leidraad te gee oor die indikasies en die optimale tyd vir die begin van 
nier behandeling (dialise) wat afgelei is van vergeIykend narvorsing en inkorporeer die faktore wat n' 
nier patient voorgee. Dit sal ook leidrade gee vir die behandling van n' patient wat voor nierversaking, 
om beter uitslae te lay en beter patient welsyn en n' afneem van sieklikheid en dodelik. Dit sal n' pasient 
die beste kans gee vir oorlewing en n' beter kwaliteit van lewe, in n' gebied wat die vemaamste deel 
uitmaak van beboeftig klinies uitslag. 
Daar is ook nie gevaar ofingewikkeJdheid vir die pasient wat in die studie deelneem en die studie sal nie 
n' invloed he op hull. behandeling. 
C. Kanye noshioteIo lwesaziso 
Kodwa lapha e South Africa nakwamanye amazwe, kuba nezinkinga eziningi uma isiguli sithunyeIwa 
kwabanye odokotela emua kwesikhathi Iokho kubarnbezeIa uk'll<jaIa kokwelashwa kwesiguli, futhi nalabo 
abazokhoka lezo zindleko bayabambezeIeka. 
Injongo yaIesisifundo ukunika umhlahlanollela nasekuboneheni isikhathi sokuhlinzwa kulezo ziguIi 
ezifaneIe ukuthi zithole usizo dunjalo, futhi kuzokwenja ukuthi ekugeineni kube nomhlahIandlela 
wokusiza lezo ziguli ezinalenkinga ukuze sibe nempwnelelo engeono kulezoziguli. 
Ukunezelela azikho izinkinga ezingaze zibokhona urna urnuntu ethatha igalelo ngokuzobe kufunowa. 
Kanjalo futhi nokunyangwa kinabo angoke kuphoqeleko. 
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APPENDIX B: 
RISK FACTORS FOR RENAL FAILURE 
• Hereditary renal disease 
• Haematuria / pro t einuria 
• Arterial hypertension or cardiovascular disease 
• D ia betes 
• Reccurent urinary tract infections 
• Age >60 yrs 
• Unexp lained anemia 
• Exposure to certain drugs (e . g. NSAIDs , antibiotics) or chemicals 
• " Psych" patient 
The " Psych " pat ient , includes patients suffering f rom th e following ; 
• Constipation 
• Sleep disturbances 
• Personality changes 
• Memory - " dementia " 
• Icthing 
• Lethargy 
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APPENDIX C: 
STAGES OF CHRONIC KIDNEY DISEASE 
Table AI: Stages of chronic kidney disease 
Stage Descript ion GFR 
(ml/min/1.73m2) 
1 Kidney damage >90 
With normal 
GFR 
2 Mild decrease i n GFR 60-89 
3 Moderate decrease in GFR 30-59 
4 Severe decrease in GFR 15-29 
5 Kidney Failure < 15 o r dialysis 
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APPENDIX D: 
PATIENT PSYCHOSOICIAL ASSESSMENT 
Patient Details 
Name: ____________________________________________ __ 
Age : __________________________________________ _ 
Sex: 
-------------------------------------------
Race: ______________________________________________ __ 
Occupation: ________________________________________ _ 
Employment status: Full-timefPart time/Selfemployed/Unemployed 
Do you participate in any activities: yes/no 
If yes, please specify -----------------------
(sports, hobbies, community activities) 
Do you have any habits, such as smoking, drinking: yes/no 
If yes, please specify 
Spiritual 
Religion :. ______________________________ _ 
How would you describe your relationship with your God? 
188 
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Family medical history 
Your role in the family : father, mother, sister, brother, other. 
Has any immediate family member (father, mother, brother, sister) suffered from; 
Hypertension: 
Heart conditions: 
Diabetes: 
Renal conditions: 
Previous medical history 
yes/no 
yes/no 
yes/no 
yes/no 
Do you have any other medical conditions (e.g. hypertension, diabetes etc.) : 
Have you been hospitalised before: yes/no 
If yes, specifY reasons and length of time in hospital: 
Development of renal impairment 
Were you informed prior to developing renal failure? 
189 
If yes, where you aware of how to manage your renal impairment to slow the progression 
leading to renal disease and to reduce and manage associated complications? 
I 
I, 
I II 
Ii , 
I 
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Did you participate in any support groups offered? 
If yes, did you feel that these meeting were beneficial? yes/no 
If yes, please specifY, in what respect? 
Do you feel that educating a person about renal failure is beneficial prior to development 
of renal failure? [fyes, please state why? 
Treatment of renal failure 
a) Your perspective of your disease 
When did your illness start? 
What do you think is the cause of your disease? 
How serious is your disease to you? 
Do you feel you are in control of your situation, or do you feel restricted by it? 
Do you have support and assistance from your family and friends? 
What effect does your illness have on your family? 
I 
'I 
II 
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Were you in a phase of acceptance of your disease, at commencement of dialysis? ifno 
please state your phase or your emotions at commencement oftreatment. 
b) Your perspective of your treatment 
Were you presented and informed about all your treatment options? 
Do you feel that you participated in the choice of treatment? 
Are you satisfied with the treatment you have chosen? yes/no 
Would you have preferred an alternative treatment? 
[fyes, please state the alternative treatment, 
Are you on the transplant list? 
lfnot please state reasons why? 
Management of your disease 
Are you aware of how to manage your renal failure, with regard to : 
Fluid intake 
Anemia management 
Dietary allowances 
Medications 
yes/no 
yes/no 
yes/no 
yes/no 
yes/no 
Do you know what medications you take and the reasons for taking the med ications? 
yes/no 
Are you aware of the complications associated with renal failure? yes/no 
Do you know how to prevent and manage such complications? yes/no 
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APPENDIX E : 
Patient Clinical and Biochemical Assessment 
(To be completed by doctor, renal nurse, or clinical technologist) 
Primary diagnosis of patient: 
Date of first diagnosis of renal impairment: 
Additional diagnosis/or complications experienced by patient: 
Was the patient referred to a nephrologist: yes/no 
Date of referral, ifreferred:, __________ _ 
Did the patient participate in a pre - end stage renal disease program: yes/no 
Date patient started, if yes: __________ _ 
Length of time in program:, __________ _ 
Number ofyisits: 
0-5 times 
6-10 times 
11-15 times 
16-20 times 
20 or more times 
192 
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• To be taken one month prior to commencement of treatment. 
Patient Clinical and Biochemical Assessment 
Date 
Blood pressure 
Weight 
GFR 
Blood results 
S -Sodium 
S - Potassium 
S - Chloride 
S-C02 
S - Urea 
S - Creatinine 
S - Magnesium 
S - Phosphate 
S -Albumin 
S - Calcium (total) 
Cholesterol 
S - Iron 
S - Transferrin 
S - Ferritin 
% Saturation 
Hemoglobin 
Hematocrit 
Parathyroid hormone 
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Aspects of clinical assessment 
(A) Always, (S) Sometimes, (N) Never. 
AJS/N AJS/N 
Cardiovascular Integument 
Edema Itchirlg 
High Blood Dryness 
pressure 
Low Blood pressure 
Chest pain Neurological 
Pulmonary_ Headaches 
Listlessness 
Dypsnea Decreased concentration 
Coughing Confusion 
Sputum Dizziness 
Restless legs 
Urinary 
HaematoloQY 
Output 
Anehpric Anemia 
" Fatigue 
Musculo I Skelet 
Emotional 
Weakness 
Pain Anxious 
Cramps Depressed 
Aggressive 
Talkative 
Introvert 
© Central University of Technology, Free State
195 
Treatment 
Reason for renal failure: 
Date of commencement of treatment: 
Time in hospital and reason for stay: 
First treatment/After 1 month of treatment/After 3 months of treatment 
Treatment modality: 
Access and date of placement: 
Complications or associated problems at commencement oftreatmentlafter I month/after 
3 months. 
;1 
'I 
I 
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• With reference to first treatment/treatment after I month/treatment after 3 months 
Patient Clinica l and Biocbemical Assessment 
Date 
Blood pressure 
Weight 
GFR 
Blood results 
S -Sodium 
S - Potassium 
S - Chloride 
S -CO2 
S - Urea 'I 
S - Creatinine 
!I 
S - Magnesium 
S - Phosphate ,I , 
S -Albumin 
S - Calcium (total) 
Cholesterol 
S - Iron 
S - Transferrin 
S - Ferrit in 
% Saturation 
Hemoglobin 
Hematocrit 
Parathyroid hormone 
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Aspects of assessment 
(A) Always, (S) Sometimes, (N) Never. 
AlS/N AlSIN 
Cardiovascular Integument 
Edema itching 
High Blood Dryness 
pressure 
Low Blood pressure 
Chest pain Neurological 
Pulmonary Headaches 
Listlessness 
DYQSnea Decreased concentration 
Coughing Confusion 
Sputum Dizziness 
Restless leQs 
Urinary 
Haematology 
Output 
Anehpric Anemia 
Fatigue 
Muscu 10 I Skelet 
Emotional 
Weakness 
Pain Anxious 
Cramps Depressed 
Aggressive 
Talkative 
Introvert 
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APPENDIX F: 
SUBJECTIVE GLOBAL ASSESSMENT 
PATIENTS NAME:______ AGE: 
MALE I FEMALE DlAGNOSIS, ________ _ 
Indicate the appropriate category with a tick or fill in a numerical value were applicable 
HISTORY 
I) 
2) 
Weight Change 
Maximum body weight 
Wei ght 6 months ago 
Current weight 
Overall weight loss in pa~1 6 months 
% weight loss in past 6 months 
Change in past 2 weeks 
Increase 
Decrease 
No change 
Dietary Intake (rebtive to normal) 
No change 
C hange Duration 
Type 
3) Gaslro - intestinal symptoms (lasting > 2 weeks) 
None 
Nausea 
4) Functional Capacity 
No dysfunction 
Dysfuncti on 
PHYSICAL EXAM INA TlON 
Vomiting 
% Weight change :: WI 6 months ago· current wt • 
100 
wl6 month s ago 
Wee ks 
Increased intake 
Suboptimal solid diet 
-----Fuliliquid diet 
IV or hypo!,;aloric liquids 
-----Slarvation 
Diarrhea 
---
Duration: Weeks 
---
Anorexia_ 
Type: Works suboptimall y 
---Ambulatory 
-----Sedridden 
(For each trait specify: 0 = normal ; 1 + = mild; 2+ = moderate; 3+ = severe) 
Loss of subcutaneous fat (shoulders, tri ceps, chest, hand s) 
--------Muscle wasting (quadriceps, deltoid s) 
Ankle edema 
Ascites 
SURJECTiVE GLOBAL ASSESSMENT RA TlNG 
A = well nourished 
---- B = moderately (or susoected of being) malnourished 
----C = severely malnourished 
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APPENDIX G: 
GLOMERULAR FILTRATION RATE FORMULA 
Healthy Start MDRD GFR Calculator 
How To Use This Calculator 
Simply fill in the Serum Creatinine in MmollL as well as the age of the patient in the appropriate block. 
Your result is automatically calculated 
Do NOT save over this file when you exit! 
It is important to note the sex and race of the patien~ 
Male (Other) 
Female (Other) 
African Male 
African Female 
Do Not Type In 
This Row! 
ResuHs 
GFR Serum Creatinine (MmoIIL) 
a 
Age 
a #CIVlO! mllmin per 
1.73 m2 
# =1 86*+POWER (SERUM CREATININE,-1 .154)* + POWER(AGE, -0.203) 10.00566575 
Serum Creatinine (MmoIlL) 
a 
Age 
a 
GFR 
#CIVla! mllmin per 
1,73 m2 
# =186*+POWER (SERUM CREATININE,-1.I54)* + POWER(AGE, -0.203) 10.00763619158 
Serum Creatinine (MmoIIL) Age GFR 
a a #DIVIOI mllmin per 
1 7~ m? 
# =186*+POWER (SERUM CREATININE,-1.I54)* + POWER(AGE, -0.203) 10.004674634 
Serum Creatinine (MmoIIL) 
a 
Age 
o 
GFR 
#DIVIO! mllmin per 
1,73 m2 
# =186*+POWER (SERUM CREATININE,-1.154)* + POWER(AGE, -0.203) I 0.00630009345 
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